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Summary
1 Summary 
Coronaviruses are large positive-stranded RNA viruses that are able to infect a 
broad range of vertebrates and are mainly associated with respiratory, enteric, and 
sometimes, systemic diseases. Human coronaviruses are known to generally cause 
mild upper-respiratory tract disease including common cold, and occasional enteric 
infections. The emergence of a novel coronavirus causing severe acute respiratory 
syndrome (SARS) highlighted the potential of coronaviruses to seriously impact on 
human health.
The functions of a large number of coronavirus-encoded proteins and cis-acting
RNA elements are poorly understood or unknown. The major aim of this thesis was 
to investigate the role of replicase-encoded gene products in the context of both viral 
RNA replication and host interactions. We mainly focused on the replicase-encoded 
non-structural proteins (nsps) nsp1, nsp8 and nsp9. In addition to the 
characterization of viral functions we also studied coronavirus-host interactions in the 
context of host innate immune responses. 
 Nsp8 and nsp9 have been recently described to bind RNA molecules but the 
exact function(s) and RNA substrate specificities remained elusive. The analysis of 
an MHV mutant (Alb391) that carries a 6 nucleotide insertion in an essential 3’ cis-
acting RNA element allowed us to provide conclusive genetic evidence that this 3’ 
cis-acting element interacts with nsp8 and nsp9. Our data furthermore indicate that 
the extreme 3’-end of the MHV genomic RNA is involved in this interaction and that a 
large portion of the 3’ untranslated region of MHV is dispensable for viral RNA 
replication. Collectively, our studies led us to propose a substantially refined model 
for the initiation of coronavirus negative strand RNA synthesis. 
There is accumulating evidence that a number of coronavirus gene products are 
involved in virus-host interactions. Our studies on the impact of host innate immune 
responses revealed that coronaviruses are very poor inducers of type I interferons 
(IFNs). However, the infection of type I IFN receptor-deficient mice with mouse 
hepatitis virus (MHV) revealed that a swift induction of type I IFNs is essential to 
combat coronavirus infections. We could demonstrate that plasmacytoid dendritic 
cells (pDCs) are able to sense coronavirus infections through toll-like receptor 7 
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(TLR7) and that pDCs are in fact the main producers of protective type I IFNs early 
after infection.  The impact of pDC-derived type I IFNs was demonstrated by 
antibody-mediated depletion of pDCs in mice which results in increased virus 
replication, spread and severity of disease. 
Finally, we have generated and characterized an MHV mutant bearing a deletion 
in the C-terminal region of nsp1. We showed that this nsp1 mutant can grow to high 
viral titers in tissue culture, but is strongly attenuated in mice. Attenuation was 
abolished in mice lacking the type I IFN receptor, suggesting a pivotal role of nsp1 in 
modulating host innate immune responses. Additionally we demonstrated that this 
virus retained the ability to replicate in professional antigen presenting cells and, 
consequently, was found to be highly immunogenic. Immunization with this nsp1 
mutant virus elicited potent cytotoxic T cell responses and protected mice against 
homologous and heterologous virus challenge. Taken together, the presented 
attenuation strategy has implications for the rational design of live attenuated 
coronavirus vaccines aimed at preventing coronavirus-induced diseases of veterinary 
and medical importance, including the potentially lethal SARS. 
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2 Zusammenfassung 
Cornaviren sind grosse positiv-strängige RNS Viren, die ein breites Spektrum von 
Wirbeltieren infizieren und hauptsächlich Atmungs-, Magen-Darm- und manchmal 
Systemische Krankheiten verursachen. Humane Coronaviren sind dafür bekannt, 
meist milde Infektionen der oberen Atemwege zu verursachen, können aber 
gelegentlich auch Krankheiten des Verdauungstrakts hervorrufen. Das Auftauchen 
eines neuen Coronavirus, das das schwere akute respiratorische Syndrom (SARS), 
eine schwere Form der Lungenentzündung, verursacht, legte das Potential dieser 
Viren, ernsthaft die menschliche Gesundheit zu gefährden, an den Tag.  
Die Funktionen vieler Coronavirus-kodierter Proteine und cis-wirkende RNS 
Elemente sind kaum verstanden oder gar unbekannt. Das wichtigste Ziel dieser 
Thesis war es, die Rolle der Replikase-kodierten Genprodukte sowohl im Kontext der 
viralen Replikation, als auch deren Interaktionen mit dem Wirt zu untersuchen. Wir 
schenkten unsere Aufmerksamkeit hauptsächlich den Replikase-kodierten nicht-
strukturellen Proteinen (nsps) nsp1, nsp8 und nsp9. Nebst der Charakterisierung der 
viralen Funktionen haben wir uns auch zum Ziel gesetzt, Coronavirus-Wirt-
Interaktionen im Rahmen der angeborenen Immunantwort zu untersuchen. 
Nsp8 und nsp9 wurden kürzlich als RNS-bindende Moleküle beschrieben, aber 
ihre exakte(n) Funktion(en) und RNS Substratspezifitäten sind unbekannt. Die 
Analyse einer MHV Mutante (Alb391), die eine Insertion von 6 Nukleotiden in einem 
essentiellen 3‘ cis-wirkenden RNS Element hat, hat aufgezeigt, dass dieses 3‘ cis-
wirkende RNS Element mit nsp8 und nsp9 interagiert. Des weiteren weisen unsere 
Daten darauf hin, dass das extreme 3‘ Ende der genomischen MHV RNS an dieser 
Interaktion beteiligt ist, und dass grosse Teile der 3‘ nicht-translatierten viralen RNS 
für die virale Replikation entbehrlich sind. Unsere Studien erlauben uns ein 
substanziell verfeinertes Modell der Initiierung der negativ-strang RNS Synthese der 
Coronaviren vorzuschlagen. 
Die Anzeichen, dass etliche Coronavirale Gene in Virus-Wirt Interaktionen beteiligt 
sind, häufen sich. Unsere Studien über die Bedeutung der angeborenen 
Immunantwort des Wirts zeigten auf, dass Coronaviren sehr wenig Typ I Interferone 
(IFN) induzieren. Dennoch zeigt die Infektion von Mäusen, die den Typ I IFN 
Rezeptor nicht haben, dass eine rasche IFN Antwort essentiell für das Überleben des 
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Wirts und die Bekämpfung des Virus‘ ist. Wir konnten auch aufzeigen, dass 
plasmacytoide dendritische Zellen (pDCs) eine Cornavirusinfektion durch den Toll-
like Rezeptor 7 (TLR7) erkennen, und dass diese pDCs die hauptsächliche Quelle für 
das protektive IFN sind. Der Einfluss des durch pDCs produzierten IFNs konnte 
durch die Depletion der pDCs mittels Antikörper demonstriert werden. MHV infizierte 
pDC-depletierte Mäuse erholten sich langsamer von der Krankheit und das Virus 
konnte besser replizieren und sich in verschiede Organe ausbreiten.
Schliesslich generierten und charakterisierten wir eine MHV Mutante, deren C-
terminale Region des nsp1 deletiert wurde. Wir zeigten, dass diese Nsp1-Mutante zu 
hohen Titern in Zellkultur wachsen kann, aber in der Maus stark abgeschwächt ist. 
Diese Schwächung ist in Mäusen, die den Typ I IFN-Rezeptor nicht haben, wieder 
aufgehoben, wodurch eine zentrale Rolle von nsp1 in der Regulierung der 
angeborenen Immunantwort des Wirts verdeutlicht wird. Desweiteren konnten wir 
zeigen, dass das Virus immer noch in professionellen Antigen-präsentierenden
Zellen wachsen konnte und infolgedessen hoch immunogen ist. Immunisierung von 
Mäusen mit der nsp1 Mutante rief eine starke zytotoxische T-Zell Antwort hervor, und 
konnte die Mäuse sowohl vor einer homologen als auch einer heterologen viralen 
Infektion schützen. Zusammenfassend hat die beschriebene Attenuationsstrategie 
Einfluss auf die zukünftige rationale Entwicklung von attenuierten coronaviralen 
Lebendimpfstoffen und könnte helfen, medizinisch und veterinärmedizinisch 
bedeutsame Coronaviren, einschliesslch des SARS-Coronavirus, wirksam zu 
bekämpfen.
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3 Abbreviations 
°C  Degree celsius 
3CL Poliovirus 3C like proteinase 
A  Adenine 
aa  Amino acid 
ACE2 Angiotensin converting enzyme 2 
ALT Alanine 2-oxoglutarate-aminotransferase 
BAC Bacterial artificial chromosome 
BCoV  Bovine coronavirus 
BHK Baby hamster kidney  
Bp  Base pair 
BSA Bovine serum albumin 
BtCoV  Bat coronavirus 
C   Cytosine 
cDC Conventional dendritic cells 
cDNA  Complementary (copy) DNA 
CEACAM  Carcinoembryonic antigen-related cell adhesion molecule 
CoV Coronavirus 
CPE  Cytopathogenic effect 
C-terminus Carboxyl-terminus 
CTL Cytotoxic T lymphocyte 
CV1 African green monkey cells 
d  Day 
DMEM  Dulbecco´s Modified Eagles Medium 
DMSO Dimethylsulfoxid 
DMV Double membrane vesicles 
DNA  Desoxyribonucleicacid 
dNTP Desoxynucleoside triphosphate 
DTT  Dithiothreitol 
E protein  Envelope protein 
E. coli  Escherichia coli 
e.g. Exempli gratia (for example) 
EDTA Ethylendiamine tetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
ER  Endoplasmatic reticulum 
ERGIC Endoplasmatic reticulum-Golgi intermediate compartment  
FACS Fluorescent activated cell sorter 
FCS Fetal calf serum 
FeCoV Feline Coronavirus 
Fig. Figure 
FIPV Feline infectious peritonitis virus 
G Guanine 
g  Gram 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
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GFP Green fluorescent protein 
gmRNA Genomic mRNA 
gpt Guanine phosphoribosyltransferase
h Hour
hAPN human aminopeptidase N 
HCoV Human coronavirus 
HCoV-229E Human coronavirus 229E 
HCoV-HKU1  Human coronavirus HKU1 
HCoV-NL63  Human coronavirus NL63 
HCoV-OC43 Human coronavirus OC43 
HE Hemagglutinin esterase 
Hel Helicase
His Histidine 
HVR Hypervariable region
i.c. Intra cranially
i.e. Id est (that is)
i.p. Intraperitoneally
IBV Infectious Bronchitis Virus 
IFN Interferon
IRF7 Interferon regulatory factor 7 
ISRE Interferon stimulated response element 
kb Kilo base 
kDa Kilo Dalton 
L Liter
L929 Mouse fibroblast cells 
LB Luria Bertani Medium 
LCMV Lymphocytic choriomeningitis virus 
M Molar
M protein Membrane protein 
mAb Monoclonal antibody 
MEM Minimal essential medium 
MHV Murine hepatitis virus 
min Minute
mL Milliliter
mM Millimolar 
MOI Multiplicity of infection 
Mpro Main proteinase
mRNA Messenger RNA
N protein Nucleocapsid protein 
NendoU Nidoviral uridylate-specific enoribonuclease 
Nsp Non-structural protein
nt Nucleotide
N-terminus Amino-terminus
ORF Open reading frame 
p.i. Post infection
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pAPC Professional antigen presenting cell 
PBMC  Peripheral blood mononuclear cells 
PBS  Phophate buffered saline 
PCR  Polymerase chain reaction 
pDC plasmacytoid dendritic cells 
PEDV  Porcine epidemic diarrhea virus 
PFU  Plaque forming units 
pp Polyprotein 
PLP Papain like proteinase 
RL Renilla luciferase 
RNA Ribonucleic acid 
rnp Ribonucleprotein 
rpm  Revolutions per minute 
RPMI 1640  Roswell Park Memorial Institute (cell culture medium) 
RT  Reverse transcriptase 
s  Second 
S protein  Spike protein 
SARS  Severe acute respiratory syndrome 
SARS-CoV  SARS coronavirus 
SD  Standard deviation 
SDS  Sodium dodecylsulfate 
sg Subgenomic 
sg mRNA  Subgenomic mRNA 
SL-CoV  SARS-like coronavirus 
SV40  Simian Virus 40 
T  Thymine 
TBE buffer  Tris borate EDTA buffer 
TGEV  Transmissible gastroenteritis virus 
TLR Toll-like receptor 
TRS  Transcription regulating sequence 
ts Temperature sensitive 
U  Uracil 
UTR  Untranslated region 
V  Volts 
vlp Virus like particle 
w/v Weight per volume 
µg  Microgram 
µL Microliter 
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4.1 Coronavirus classification 
The Coronaviridae family (genus Coronavirus (CoV) and genus Torovirus) belongs 
together with the families Arteriviridae and Roniviridae to the order Nidovirales (39, 
48) (Table 1). Coronaviruses are positive stranded RNA viruses with a genome size 
of 27 to 31 kilobases (kb). They can infect numerous mammalian and avian species 
and mainly cause respiratory and enteric diseases. They have long been recognized 
as important pathogens of livestock and companion animals. In humans, 
coronaviruses are usually associated with upper respiratory tract infections and can 
cause the common cold.   
In 2003, during the outbreak of the severe acute respiratory syndrome (SARS) in 
China, the causative agent of this disease was identified as a formerly unknown 
coronavirus (SARS-CoV). This virus was responsible for more than 8,000 
documented cases, with a fatality rate of 10%, and spread to more than 30 countries. 
The resulting renewed interest in coronavirus research subsequently led to the 
discovery of two additional human coronaviruses HCoV-NL63 and HCoV-HKU1 (87, 
154, 263, 278). 
Initially, coronaviruses have been classified into three groups based on serological 
cross reactivity that were, more recently, supported by phylogenetic analyses. These 
analyses and the availability of an increasing number of coronavirus genome 
sequences, led to the concept to divide coronavirus groups I and II to subgroups Ia/Ib 
and IIa/IIb, respectively (94, 96, 215, 232). However, it should be noted that the 
recent detection of numerous group I and II and yet unclassified coronaviruses in 
bats most likely will lead to a further revision of the current coronavirus classification 
(49, 69, 89, 185). 
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Order Family Genus Species
Equine arteritis virus (EAV) 
Lactate dehydrogenase- elevating virus (LDV) 
Porcine respiratory and reproductive 
syndrome virus (PRRSV) 
Arteriviridae Arterivirus 
Simian hemorrhagic fever virus (SHFV) 
Gill-associated virus (GAV) 
Roniviridae Okavirus
Yellow head virus (YHV) 
Equine torovirus (ETV) 
Bovine torovirus (BTV) 
Porcine torovirus (BTV) 
Torovirus
Human torovirus (HTV) 
Transmissible gastroenteritis virus (TGEV) 
Feline infectious peritonitis virus (FIPV) a
Canine coronavirus (CCV) 
Human coronavirus NL63 (HCoV-NL63) 
Human coronavirus 229 E (HCoV-229E) 
Porcine diarrhea virus (PEDV) 
Group 
I
b
Bat coronavirus (BtCoV)* 
Human coronavirus OC43 (HCoV-OC43) 
Bovine coronavirus (BCoV) 
Murine coronavirus (MHV) 
a
Human coronavirus HKU1 (HCoV-HKU1) 
SARS coronavirus (SARS-CoV) 
Group 
II
b
SARS-like bat coronavirus (BtCoV) * 
Infectious bronchitis virus (IBV) 
Nidovirales 
Coronaviridae 
Coronavirus
Group III 
Turkey coronavirus (TCoV) 
Table 1: Overview of Nidovirales families, genera and species.  
* Recently, numerous bat coronaviruses have been identified that are not yet classified or 
grouped according to their RNA-dependent RNA polymerase sequence into group Ib or 
group IIb.
Group I coronaviruses include the long-known human coronavirus 229E (HCoV-
229E) as well as the porcine transmissible gastroenteritis virus (TGEV), feline 
coronaviruses (FeCoVs), and porcine diarrhea virus (PEDV). New group I 
coronaviruses include the human coronavirus NL63 (HCoV-NL63) (83, 87, 263) and 
several bat coronaviruses detected in China, Africa, Europe and America (69, 89, 
185, 247, 274). HCoV-NL63 was isolated from a 7-month-old child suffering from 
bronchiolitis and conjunctivitis. HCoV-NL63 is distributed worldwide and can be 
responsible for up to 20% of human respiratory tract infections (common cold) during 
13
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winter time. Occasionally, HCoV-NL63 infections can also cause more severe clinical 
signs of disease especially in children, in adults with underlying disease or in elderly 
(reviewed in (262)).
The most extensively studied members of group II coronaviruses are murine 
hepatitis virus (MHV), bovine coronavirus (BCoV), and SARS-CoV. MHV (group IIa) 
can cause enteritis, pneumonia, hepatitis, and demyelinating encephalomyelitis in 
mice and is widely used as animal model for a number of diseases of medical 
importance, such as acute viral hepatitis or multiple sclerosis (17, 179). BCoV (group 
IIa) causes diarrhea in calves and cattles and mixed infection with other pathogens 
results in serious disease. The involvement of BCoV in respiratory tract diseases has 
also been reported (105, 106, 244). Interestingly, BCoV and HCoV-OC43 are highly 
homologous suggesting a relatively recent zoonotic transmission event about 100 
years ago (271).
SARS-CoV, a group IIb member, mainly infects the lower respiratory tract and 
causes fever, dry cough, headache, hypoxemia and dyspnoea (51, 72, 199, 200, 
215). The search of a reservoir for SARS-CoV has led to the discovery of a similar 
virus in bats, termed SARS-like bat coronavirus. Taking in consideration the diversity 
of species and the habitats bats occupy, large population sizes and densities, and 
the ability to migrate, bats appear to be ideal candidates for the natural reservoirs of 
many coronaviruses (74).
Group III coronaviruses include the avian coronavirus infectious bronchitis virus 
(IBV) that was the first coronavirus to be discovered in the 1930s. IBV is responsible 
for considerable economic losses in poultry and causes severe bronchiolitis and 
nephritis (38, 129). Although, IBV infections are usually not lethal, secondary 
microbial infections can increase disease severity and fatality. Other group III 
coronaviruses, that are genetically and antigenically related to IBV, cause enteric 
disease in turkeys (Turkey coronavirus), and respiratory and kidney disease in 
pheasants (Pheasant coronavirus). Recently IBV-like viruses have also been 
reported in several other Gallinaceous (avian fowl-like species) (reviewed in (40, 
252).
14
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4.2 Coronavirus morphology
The coronavirus RNA genome associates with the nucleocapsid protein (N) to 
form a helical ribonucleocapsid, which is surrounded by a membrane envelope. The 
size of the pleiomorphic coronavirus virion is 80 to 150 nm. Embedded within the 
envelope, there are three structural proteins expressed by all coronaviruses, i.e. the 
membrane (M) protein, the envelope (E) protein and the spike (S) protein. Some 
group IIa coronaviruses additionally encode a hemagglutininesterase (HE) which is
also embedded into the viral envelope (174, 230). In electron microscopical images
coronaviruses display a crown-like structure that gave rise to the name 
“Coronaviruses” (corona; latin: crown) and are formed by about 17 – 20 nm 
projections of S protein homotrimers (Fig. 1). 
Fig1. Electron micrograph and schematic representation of a coronavirus.
Figures from Holmes and Enjuanes (79) and Stadler et al. (240).
4.3 Coronavirus genome organization and replication 
4.3.1 The coronavirus genome 
The coronavirus RNA genome is a linear, non-segmented, single stranded 
positive-sense RNA. The 5’ end is capped and the 3’ end is polyadenylated (150, 
151). With a genome size of 27 kb to more than 31 kb, coronaviruses possess the 
largest known RNA genome among all RNA viruses. 
15
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Furthermore, all coronaviruses encode: 
1. A 5’ untranslated region (UTR) of 209 nts (MHV-A59) to 528 nts (IBV-
Beaudette) containing a so-called “leader sequence” of 65-98 nts at the 
extreme 5’ terminus and a short open reading frame (ORF) downstream the 
leader sequence that potentially encodes short peptides of 3-11 amino 
acids (aa) of unknown function.
2. A 3’ UTRs of 279 nts (TGEV) to 506 nts (IBV-Beaudette) followed by a 
poly(A) tail. 
3. A replicase gene comprised of two overlapping ORFs, ORF1a and ORF1b 
spanning about two thirds of the coronavirus genome (approx. 20 kb). 
Coronavirus replicase gene expression is complex and involves a ribosomal 
frameshift mechanism to express ORF1b and extensive proteolytic 
processing of large replicase polyproteins (see below).  
4. Four structural genes within the 3’-proximal one-third of the genome in the 
order (5’->3’) S-E-M-N. 
5. One to seven accessory genes (formerly called group-specific genes) 
interspersed between the structural genes.
16
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Fig. 2: Organization and expression of MHV-A59 genome 
Structural relationship of the MHV-A59 genome and subgenomic RNAs are shown. The virus 
ORFs are depicted in red (replicase), white (accessory proteins) and blue (structural 
proteins). The black box represents the common 5’ capped leader sequence, An indicates 
the poly(A)-tail. The ribosomal frameshift is indicated with an arrow. The autoproteolytic 
processing of ORF1a/ORF1ab polyprotein into the 16 nsps is shown. Nsp1-3 are processed 
by PL1/PL2 (green triangles), whereas nsp4-16 are processed by 3CL (red triangle). Known 
or putative protein functions are written above or below the corresponding box. Ac, acidic 
domain; L, leader; Y, Y domain, containing several transmembrane regions. 
 
4.3.2 Coronavirus replication cycle 
Replication of coronavirus begins with the association of the spike protein to its 
appropriate receptor and subsequent fusion of the lipid bilayer of the viral envelope 
with the host cell membrane and entry into the cell. Group IIa coronavirus MHV uses 
murine carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), 
members of the immunoglobulin superfamily of receptors, whereas a number of 
group I coronaviruses, for example HCoV-229E, TGEV and FIPV require the zinc 
metalloprotease aminopeptidase N (APN, CD13) for entry into their target cells. 
17
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Human angiotensin-converting enzyme 2 (ACE2) has been identified as the receptor 
for SARS-CoV, a group IIb member and for HCoV-NL63, a group I member. For the 
most studied group III member, IBV, no specific and required host receptor has been 
identified, but preferential binding to sialic acid moieties could be demonstrated. (65, 
73, 113, 163, 260, 277, 282).  
After infection, the first ORF in the genome is translated as two large polyproteins 
pp1a and pp1ab of 495- or 803-kDa of size (for MHV), respectively (158). The distal 
positioned ORF 1b is expressed as a fusion protein with ORF 1a as a result from a -1 
pseudoknot-induced ribosomal frameshift at a slippery sequence (25, 27-30, 66, 78, 
109, 233). These large polyproteins are proteolytically processed by two or three 
functional proteinases into 15 (for group III coronaviruses) or 16 nonstructural 
proteins, nsp1-nsp16 (for group I and II coronaviruses) (Fig. 2). Coronaviruses 
usually posses 2 papain-like proteinases (PL1pro and PL2pro; encoded in nsp3) and 
one poliovirus 3C-like proteinase (3CLpro; encoded in nsp5). Exceptions are group III 
coronaviruses (e.g. IBV expresses an inactive form of PL1pro) and group IIb 
coronaviruses (e.g. SARS-CoV and SARS-like CoV do not encode a PL1pro domain). 
The released processing products form the viral replicase/transcriptase complex that 
is engaged in the synthesis of the genomic and subgenomic RNAs.  
Coronavirus RNA synthesis takes place in double membrane vesicles (DMV) most 
likely generated by the association of coronavirus non-structural proteins with host 
intracellular membranes (97, 104, 204, 228, 234). Shortly after 
replicase/transcriptase complex assembly, genomic and sg minus-strand RNAs are 
synthesized that serve as templates for the production of positive-strand genomic 
and sg mRNAs. Initially, it had been suggested, that the coronaviral 
replicase/transcriptase synthesizes only one minus-strand template of genome length 
that serves as template for all (genomic and sg) positive strand mRNAs. (149). 
However, the fact that coronavirus replicative intermediates of sg length function in 
RNA synthesis (220) and the discovery of minus-strand sg mRNA containing an anti-
leader sequence at their 3’-end in TGEV infected cells (225, 226), led Sawicki and 
colleagues to propose a model termed “discontinuous extension of minus-strand 
RNA” (221). In this model the genomic RNA is the template for the synthesis of a set 
of genomic and sg minus strand RNAs. During minus strand synthesis, the viral 
replicase/transcriptase complex is suggested to pause at a transcription regulatory 
18
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sequence (TRS) and then relocate to the 5’ end and re-initiate minus strand 
synthesis to add the anti-leader sequence to the nascent RNA chain. TRSs appear 
repeatedly in the genomic RNA, near the 5’ end of the genome (downstream the 
leader sequence; “leader TRS”) and at various positions downstream the replicase 
gene (“body TRSs”). Therefore, the discontinuous extension of minus strand RNAs 
results in a set of sg minus strand RNAs that differ in length according to the position 
of TRS elements within the genomic RNA template. Each minus strand sg RNA can 
serve a template for the production of a particular sg positive strand mRNA. As a 
result of this transcription mechanism a characteristic nested set of 3’-coterminal sg 
mRNAs with a common structure (a leader sequence of ~60-90 nts at the 5’ end, 
followed by a TRS and a so-called “body” sequence at the 3’ end) is produced. The 
model of discontinuous extension of minus-strand RNA has received support from a 
number of studies on Arteriviruses and Coronaviruses that demonstrated that the 
TRSs found in sg mRNAs of arteri- and coronaviruses are derived from the 
corresponding body TRSs (266, 267, 298). It is believed that only the 5’-terminal 
ORFs of coronavirus mRNAs are translated. Thus, although coronavirus mRNAs are 
structurally polycistronic (except the smallest sg mRNA), they most likely function as 
monocistronic mRNAs with only the 5’-ORF being translated (35, 128, 159).  
Coronavirus sg mRNAs encode for accessory proteins that are usually 
dispensable for virus replication in tissue culture and for structural proteins that are 
needed to assemble progeny virus particles. Coronaviruses particle assembly and 
budding takes place at the cis-Golgi network also known as Endoplasmatic-
Reticulum-Golgi-Intermediate-Compartment (ERGIC) (218, 258, 259). The E and M 
proteins play an important role during virus budding and have been proposed to 
induce virus envelope curvature during MHV and SARS-CoV infection (7, 47, 169, 
208). Co-expression of E and M from MHV, TGEV, IBV, and SARS-CoV in 
mammalian expression systems results in formation of virus-like particles (VLP) (16, 
47, 145, 183, 268). Furthermore it has been shown, that both MHV and IBV E are 
sufficient for the generation of VLPs (47, 169) suggesting that neither N nor S are 
needed for viral budding. In contrast Huang et al. described that M and N are 
sufficient for the formation of SARS-CoV pseudoparticles (118) suggesting a minor 
role of E in viral release. Notably, the dependence of E for virus particle formation 
may vary amongst coronaviruses, or coronavirus groups, since MHV and SARS-CoV 
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mutants lacking the entire E gene are viable, but at variance E gene-deleted TGEV 
mutants were not viable (64, 147, 197).
In order to produce infectious particles the genomic RNA has to be incorporated 
into the virions. This is assisted by the formation of a complex of N and viral genomic  
RNA called ribonucleoprotein (RNP) complex. The nucleocapsid protein condenses 
the large RNA molecule so that it fits into the relatively small virus particle. It has 
been reported that the MHV N protein specifically recognizes a packaging signal 
encoded within ORF1b of MHV. However, N protein was also reported to bind to TRS 
elements, leader RNA and even unspecifically to any RNA (46, 54, 173, 182, 194, 
214, 243, 293). Alternatively, it has been proposed that, at least for MHV, the M 
protein might interact with the packaging signal. The specificity is granted by the 
finding that M coimmunoprecipitates only N bound to genomic RNA but not N bound 
to sg mRNA (191-193). Recent work demonstrated that M and E proteins from MHV 
can incorporate a heterologous RNA molecule only if it contained the packaging 
signal. The direct selection of packaging signal RNA has been attributed to M, 
making this protein to the key player in viral assembly (189).  
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Fig. 3: The coronavirus replication cycle
After adsorption of viral particles the positive-stranded RNA genome is uncoated and 
replication starts in the cytosol. A nested set of subgenomic mRNA is produced in double 
membrane vesicles by discontinuous transcription during minus-strand synthesis resulting in
structural (spike (S), envelope (E), membrane (M), nucleocapsid (N)) and non-structural 
proteins (nsps). Viral proteins assemble and bud at the ER Golgi intermediate compartment
(ERGIC) and are processed in the Golgi apparatus. Newly produced viral particles are
incorporated in vesicles and released by exocytosis. Picture adapted from (257). 
4.4 Coronavirus genes
4.4.1 Coronavirus structural genes 
Conservation of the N protein among coronaviruses is relatively poor, but 
sequence comparison revealed three domains of which the middle one possesses 
RNA binding capacity (152, 176, 194, 299). After reverse genetic systems have been 
established, it has been reported, that the recovery of recombinant coronaviruses is 
critically facilitated by N protein expression (3, 13, 37, 45, 223, 253-256, 285-287). 
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This effect may be related to the finding that N protein is required for efficient genome 
RNA replication (3, 223). Thus, in addition to the function as a structural protein, N is 
also involved in coronavirus RNA synthesis. 
The M protein is a key player of virus assembly and budding and is able to interact 
with S, E, and N (61, 107, 119, 273). It is a triple spanning membrane protein and 
has a short glycosylated ectodomain and a large C-terminus endodomain. MHV M 
gene mutants encoding an M protein that lacks two aa at the carboxyterminus have 
been generated. These mutants formed initially tiny plaques but after several 
passages in tissue culture gained fitness. Isolated clones contained compensatory 
mutations in N indicating a direct protein-protein interaction between M and N (146). 
This interaction has been further corroborated: clustered charged-to-alanine N gene 
mutants have been constructed, and indeed, some second-site revertants contained 
mutations within the M gene (119).
Another membrane protein is E which has low abundance in infected cells. 
Nonetheless it plays a pivotal role in coronavirus assembly (23, 268). Reverse 
genetic studies of TGEV revealed an indispensable role of E in TGEV propagation 
(50, 197). However, recombinant and viable MHV and SARS-CoV mutants lacking E 
have been reported, although the mutant MHV virus displayed a small plaque 
phenotype and grew to greatly reduced titers (64, 147). Notably, the MHV E gene 
could functionally be replaced by BCoV, SARS-CoV (group II coronaviruses) or IBV 
(group III coronavirus) E genes, but not by the TGEV (group I coronavirus) E gene 
(145). Whether the requirement of E in particle formation differs amongst coronavirus 
groups remain to be elucidated. 
The most intensively studied coronavirus structural protein is the heavily 
glycosylated S protein with a molecular weight of 150-200 kDa. It is responsible for 
the corona-like shape of the virion as perceived by electron microscopy. It plays an 
important role in receptor binding, membrane fusion, tropism and pathogenesis. A 
seminal experiment performed by Kuo et al. showed that S determines the tropism. 
They fused the carboxyterminal 64 residues of MHV S protein (representing the 
endo- and tansmembrane-domains) to the FIPV spike ectodomain. This virus termed 
feline MHV (fMHV) lost the ability to infect murine cells but could now infect feline 
cells (144). The fMHV virus is now used in a modified protocol of the targeted 
recombination-based reverse genetic system (177).  
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4.4.2 Coronavirus accessory genes 
A variety of genes encoding accessory proteins are interspersed between the 
structural genes. Their number and location varies within coronavirus genomes and 
their functions are largely unknown. Some concordance, also regarding the positions 
where these genes are encoded within the genome, can be observed within groups 
or subgroups of coronaviruses. For one accessory protein, namely the NS2 protein 
encoded in mRNA2 of MHV and some other group IIa coronaviruses, a cyclic 
phosphodiesterase (CPD) activity has been predicted (232). This activity may rather 
play a role in vivo than in vitro, since a single aa substitution (Leu94Pro) resulted in 
attenuation in mice, whereas no significant difference in tissue culture could be 
observed (237).  Even the deletion of NS2 in MHV-JHM led to no significant 
differences in growth in cell lines (224). In general it can be stated, that accessory 
proteins are not required for viral replication in vitro but may support growth in the 
respective host (36, 60, 86, 102, 110, 112, 174, 198, 288).
4.4.3 Coronavirus replicase gene 
The replicase gene is encoded at the 5’-end of the genomic RNA and is comprised 
of two large ORFs, ORF1a and ORF1b. As mentioned above, coronavirus replicase 
gene expression is complex and involves the expression of two large polyproteins, 
pp1a and pp1ab that are extensively processed by viral proteinases. Here, functional 
details of the resulting 16 polyprotein processing end products are summarized. 
However, it should be noted that in addition to the final processing products (i.e. 
nsp1-16), intermediate processing products may also have significant impact on viral 
replication. This idea is supported by analyses of a large panel of temperature 
sensitive (ts) MHV mutants that are defective in RNA synthesis. Complementation 
analyses indicated that a large portion of ORF1a-encoded replicase gene products 
encompassing nsp4 to nsp10 may constitute a single complementation group (cistron 
I), whereas ORF1b-encoded gene products could be complemented in trans and 
therefore form individual cistrons (222). 
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4.4.3.1 Nonstructural protein 1 (nsp1) 
Nsp1 is encoded at the 5' end of the replicase gene and is, thus, the first mature 
viral protein expressed in the host cell cytoplasm (294). Therefore an important role 
in coronavirus replication has been suggested. It is encoded by all mammalian 
coronaviruses known to date (coronavirus group Ia, Ib, IIa, and IIb), but has not been 
identified in avian coronaviruses (coronavirus group III). nsp1 is processed by the 
papain-like proteinases (98) and can be detected in SARS-CoV- and MHV-infected 
cells as early as 6h post infection (p.i.) Immunofluorescence experiments revealed 
that MHV and SARS-CoV nsp1 molecules co-localize with other replicase proteins 
into discrete cytoplasmic foci that were both perinuclear and dispersed throughout 
the cytoplasm. These cytoplasmic foci likely represent coronavirus replication 
complexes, where viral RNA synthesis occurs (104, 205). It has been shown, that the 
carboxy-terminal half of MHV nsp1 is dispensable for virus replication in tissue 
culture, whereas deletion of residues amino-terminal to amino acid (aa) 123 failed to 
produce infectious virus (32). It remains to be determined, whether the amino-
terminal half of nsp1 is required for MHV replication, or if essential 5’-cis-acting 
elements located within the nsp1-coding sequence (34) have been deleted. A recent 
in vitro study suggested that SARS-CoV nsp1 may be associated with host cell 
mRNA degradation and may counteract innate immune responses (133, 190). Nsp1 
was shown to be a major pathogenicity factor (see chapter 6) and it has been 
suggested that partial deletion of nsp1 may be an efficient and secure system for the 
rational design of attenuated coronavirus vaccines (275, 300).   
4.4.3.2 Nonstructural protein 2 (nsp2) 
For coronavirus nsp2 there has yet no function been proposed. Deletions using 
reverse genetic systems indicate that nsp2 is dispensable in both SARS-CoV and 
MHV (99, 100). Noteworthy, the entire nps2-encoding region could be deleted with 
only moderate changes in growth and RNA synthesis. It has also been shown, that 
nsp2 of MHV co-localizes with replicase complexes, but similar studies on nsp2 from 
other coronaviruses are required to determine whether these cleavage products 
display the same cellular localization pattern (24, 31, 33, 97, 204, 228, 264).  
4.4.3.3 Nonstructural protein 3 (nsp3) 
Based on sequence comparisons a multidomain organization with five conserved 
domains (listed in the order N- to C-terminal bellow) has been revealed: Ac (acidic 
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domain), PL1pro, ADRP (ADP-ribose-1”-monophosphatase, also called X-domain), 
PL2pro, and Y (containing several trans-membrane regions) (255, 297). The Ac, 
ADRP, PL2pro, and Y domains are conserved in all coronaviruses, but PL1pro is in 
some coronaviruses either not active (IBV) or is lacking completely (SARS-CoV and 
SARS-like CoVs) (207, 232). PLpros are responsible for the proteolytic release of 
nsp1, nsp2, nsp3 and the aminoterminus of nsp4. It has been shown that coronavirus 
PLpros have slightly different substrate specificities that are best illustrated by their 
ability to release nsp1 from replicase polyproteins. Four different patterns of nsp1 
processing have been identified: (i) no nsp1 and a single active PL2pro (IBV; group III 
coronaviruses), (ii) a group IIa-specific processing pattern where nsp1 is processed 
by PL1pro but not by PL2pro (MHV), (iii) a group IIb-specific processing pattern, where 
no PL1pro is present and hence nsp1 is processed by PL2pro (SARS-CoV), and (iv) a 
group I-specific processing pattern where nsp1 is released by PL1pro but is assisted 
by PL2pro (HCoV-229E) (21, 22, 56, 67, 135, 250, 295, 297). These patterns 
represent the four major phylogenetic lineages of coronaviruses. Besides the 
proteolytic activity a deubiquitinating activity could be demonstrated for SARS-CoV 
and HCoV-NL63 PL2pro (14, 15, 56, 211). Another role for SARS-CoV PL2pro may be 
the inhibition of IFN response independently of the protease activity via interaction 
with IRF3 (68). Recently the crystal structure of SARS-CoV ADRP has been resolved 
and the SARS-CoV and HCoV-229E ADRP domains were shown to indeed display a 
ADP-ribose-1”-monophosphatase processing activity (77, 207, 211, 217). 
Interestingly, the ADRP-domain of HCoV-229E was demonstrated to be dispensable 
for virus RNA synthesis (207), suggesting a possible role in vivo. Indeed we could 
demonstrate that an MHV ADRP mutant grows to slightly reduced titers in the liver 
but, strikingly, did not induce liver disease. Moreover, the mutant virus induced only 
low levels of inflammatory cytokines TNF-? and IL-6, but increased level of IFN-? in 
plasmacytoid dendritic cells (pDCs) (Eriksson et al, in revision). Recently it has been 
reported, that MHV nsp3 has 4 membrane-spanning regions, allowing the protein to 
insert into the ER membranes co-translationally. It has been shown, that the 
transmembrane (TM) is important for membrane association of the replicase  and 
tethering the PL2pro domain for viral polyprotein processing (121, 135).  
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4.4.3.4 Nonstructural protein 4 (nsp4) 
Nsp4 is a very hydrophobic protein. Bioinformatic studies have shown, that nsp4 
and nsp6 have membrane spanning helices (296). Biochemical fractionation studies 
revealed that nsp4 is a integral membrane protein (97, 135, 196, 236). It has been 
shown that MHV nsp4 is required for virus replication, as the nsp4 coding region 
cannot be deleted from the ORF1a. Additionally, it has been demonstrated that the 
carboxy terminus of MHV nsp4 is dispensable for virus replication in culture, whereas 
deletions of regions within nsp4 containing residues amino terminal to P335 
prevented recovery of infectious virus (196, 236). Using an MHV ts mutant described 
by Sawicki et al. (222), Baker and colleagues suggested that nsp4 is involved in DMV 
formation (44). 
4.4.3.5 Nonstructural protein 5 (nsp5) 
Nsp5, the main proteinase is a cysteine proteinase with a serine proteinase-like 
structure (6). It is responsible for the processing of nsp4-nsp16 and is distantly 
related to picornaviral 3C proteinases (93, 296). Crystal structures of several 
coronavirus nsp5 have been resolved, and a high degree of substrate specificity and 
structure could be demonstrated (6, 108, 281). Since several inhibitors are available 
for related proteinases and due to the fact, that nsp5 is involved pivotally in virus 
replication and transcription it has become a key target in the search for antiviral 
agents (280).  
4.4.3.6 Nonstructural protein 6 (nsp6) 
Like nsp4, nsp6 is a highly hydrophobic protein and is predicted to be an integral 
membrane protein. Hence, it is, together with nsp3 and nsp4, likely to function in 
anchoring the replication complexes to the lipid bilayer (196). 
4.4.3.7 Nonstructural proteins 7-11 (nsps7-11) 
Biochemical and structural data on nsps 7-10 indicate, that these proteins are 
nucleic acid binding proteins (76, 120, 131, 178, 245, 246, 290). SARS-CoV nsp8 
has been demonstrated to possess an RNA-dependent RNA polymerase (RdRp) 
activity, enabling the synthesis of small RNAs in vitro (120). It has been proposed 
that nsp8 may act as a primase. The model suggests that nsp8 initiates viral RNA 
replication by producing small RNA primers utilized by the “main” RdRp (nsp12). It is 
not clear whether nsps7-10 recognize specific coronaviral RNA sequences, but 
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evidence from our work indicate that MHV nsp8 and nsp9 may interact with an 
essential 3’ cis-acting element at the 3’ UTR and with the extreme 3’ end of the MHV 
genome (see chapter 6) (301). The analysis of an MHV ts mutant encoding a 
mutation in nsp10 demonstrated that nsp10 is involved in viral RNA synthesis (222, 
229, 284). A further analysis of this ts mutant revealed that the defect in RNA 
synthesis at the restrictive temperature may be based on a potential function of 
nsp10 as a cofactor for 3CLpro activity and plays a critical role in negative-strand 
elongation (70, 71).  
4.4.3.8 Nonstructural protein 12 (nsp12) 
Nsp12 encodes the RNA-dependent RNA polymerase domain that differs 
substantially from its homologs in other positive-strand RNA viruses. RNA-dependent 
RNA polymerase activity could be demonstrated for in vitro expressed SARS-CoV 
nsp12 (57).  An MHV ts mutant, termed Alb ts22, was found to encode a mutation in 
nsp12 and to be defective in RNA synthesis at the restrictive temperature. This 
mutant carries a mutation (His868Arg) in a predicted thumb subdomain of MHV RNA-
dependent RNA polymerase, which has been implicated in other RNA polymerases 
with polymerase activity (222). Thus, upon a shift to the restrictive temperature both, 
plus- and minus-strand synthesis stopped immediately. Given the crucial role of 
RNA-dependent RNA polymerase in the virus life cycle and the success obtained 
with polymerase inhibitors in the treatment of other viral diseases, nsp12 is an 
attractive target for antiviral drugs (279).  
4.4.3.9 Nonstructural protein 13 (nsp13) 
By computational analysis nsp13 has been classified as belonging to superfamiliy 
1 (SF1) helicases (95). nsp13 has a zinc-binding domain at its N-terminus, which is 
known to be required for the enzymatic activity of the protein (227). Using 
recombinant HCoV-229E and SARS-CoV nsp13, it was demonstrated, that the 
helicase efficiently unwinds both partial-duplex RNA and DNA with 5’-to-3’ polarity 
and that the energy needed for this process may be provided through the NTPase 
activity encoded within the aminoproximal region in nsp13 (123, 124, 255). The 
NTPase activity of nsp13 might be involved in capping of viral RNAs (124). The 5’-to-
3’ polarity of the helicase activity argues against a role of nsp13 in separation of 
secondary RNA structures arising during RNA synthesis. By reverse genetics a 
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domain with undefined functions has been targeted, leading to a lethal IBV in cell 
culture (84).  
4.4.3.10 Nonstructural protein 14 (nsp14) 
Bioinformatics studies demonstrated a homology of nsp14 to known cellular RNA 
processing 3’-5’ exonucleases (ExoN) of the DEDD superfamily (232). The ExoN 
activity has been demonstrated for HCoV-229E and SARS-CoV nsp14 (55, 181). It 
has been shown that the coronavirus ExoN activity can efficiently process single-
stranded and double-stranded RNA to final products of 8-12 nucleotides, but not 
DNA or ribose-2’-O-methylated RNA (181). Recombinant HCoV-229E ExoN mutants 
showed drastically reduced RNA synthesis and the common molar ratio of individual 
sg mRNAs was altered. The findings were consistent with the failure to recover 
infectious HCoV-229E progenies (55, 181). However, Eckerle et al. demonstrated 
that MHV mutants encoding ExoN-inactivating mutations are viable but, remarkably, 
displayed decreased polymerase fidelity (75). This observation support the idea that 
coronaviruses may possess a mechanism of RNA proofreading to stably maintain 
their extraordinary large RNA genome (94). In addition to the ExoN domain, 
coronavirus nsp14 may encode an additional function. Support for this hypothesis 
was provided by the description of an MHV nsp14 mutant that grew like wild type 
MHV in tissue culture but was severely attenuated in mice (237). The responsive 
mutation is located in the carboxyterminal part of nsp14 that may constitute a second 
functional domain of nsp14. 
4.4.3.11 Nonstructural protein 15 (nsp15) 
Snijder and colleagues proposed that nsp15 encodes a domain that has 
similarities to the poly(U)-specific cellular endoribonuclease XendoU (232). This 
domain is encoded in all Nidoviruses and was designated NendoU. The NendoU 
activity has been confirmed by a study where SARS-CoV nsp15 has been expressed 
in E.coli and the manganese-dependent enzyme activity has been shown (19). 
Further studies revealed that MHV nsp15 forms a hexamer and can process both 
double and single-stranded RNA. Like for the ExoN activity of nsp14, 2’-O-ribose-
methylated RNA appeared to be resistant to cleavage by the NendoU enzyme. This 
observation supports a functional link of nsp14, nsp15 and the 2’-O 
methyltransferase (2’-O-MT) encoded in nsp16 (20, 122, 132, 213). Likewise, these 
activities, i.e. XendoU, ExoN and 2’-O-MT, are functionally linked in the cellular 
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snoRNA processing pathway (232). Notably, reverse genetic studies revealed that 
MHV mutants bearing alanine substitutions in the NendoU catalytic pocket were 
easily recovered, and showed little or no delay in virus growth kinetics, indicating that 
the NendoU activity may not be essential for viral RNA synthesis (134). 
4.4.3.12 Nonstructural protein 16 (nsp16) 
Nsp16 has been predicted to possess 2’-O-MT activity. Extensive attempts to 
demonstrate methyltransferase activity of recombinant expressed nsp16 initially 
failed to produce conclusive evidence (85, 232, 272). However, a recent report from 
Decroly et al. conclusively showed that recombinant expressed FIPV nsp16 
exclusively bound N7-methylated capped RNAs and mediated AdoMet-dependent 
methyl transfer from AdoMet to the 2’-O position of 7MeGpppAC3-6 RNAs resulting in a 
cap-1 formation (2’-O methylation at nucleotide position 1) (63). These results further 
corroborate the idea that nsp16 is (probably in conjunction with the NTPase activity of 
nsp13) involved in coronavirus cap structure formation and further indicate that 
coronavirus mRNAs may carry a cap-1 structure.  
 
4.5 Coronavirus cis-acting elements 
RNAs of positive strand RNA viruses are known to contain cis-acting elements that 
regulate viral replication, transcription, and gene expression. The term “cis-acting 
element” refers to the Latin word cis, which means "on the same side as". For 
coronaviruses various cis-acting elements are known. First, a ribosomal frameshift 
element comprised of a slippery sequence and a pseudoknot structure is known to be 
involved in a programmed -1 frameshift event during ORF1a/ORF1b translation. 
Second, coronaviruses harbor cis-acting elements at their 5’- and 3’-genomic termini 
that are specifically recognized by the viral replicase complex in order to replicate the 
genomic RNA. Finally, the process of coronavirus discontinuous transcription is 
regulated by TRS elements that direct the synthesis of sg minus strand RNAs.  
 
4.5.1 The coronavirus ribosomal frameshift element 
Coronavirus replicase gene expression is mediated by translation of ORF1a and 
ORF1b of the genomic RNA. This event is regulated co-translationally (ribosomal 
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frameshifting) and post-translationally (polyprotein processing). In order to translate 
the ORF1b region, a fraction of the ribosomes translating ORF1a from the genomic 
RNA must shift into the -1 reading frame to produce pp1ab. The coronavirus 
frameshift signal was first described for IBV and consists of a so-called slippery 
sequence, where the ribosomes can “slip” into the -1 frame, and a higher-order RNA 
structure, i.e. an RNA pseudoknot, downstream the slippery sequence. The 
coronavirus slippery sequence consists of seven nucleotides with the consensus 
sequence UUUAAAC (where UUU is the postslippage P-site and AAA the 
postslippage A-site) (26, 203). Coronavirus pseudoknot structures involved in 
ribosomal frameshifting have either been described as a classical pseudoknot, i.e. 
two stem loop structures where the two loop regions can form an additional stem 
region (also described as kissing loops), or as elaborated pseudoknots involving an 
additional loop and stem region (109). Most likely pseudoknots adapt a quasi-helical 
overall structure making them difficult to unwind during translation. Consequently the 
pseudoknot impedes the progress of the elongating ribosome. The delay required to 
melt down this secondary structure allows the simultaneous slippage of the P and A 
site tRNAs by one base in the -1 direction. In vitro studies revealed that up to 30% of 
translation products result from a ribosomal frameshift event at coronavirus frameshift 
elements. Both, modification of the slippery sequence and destabilizing mutations in 
pseudoknot stem regions have been shown to greatly reduce frameshifting efficacy 
(10, 28, 127, 188, 249).
4.5.2 Cis-acting elements regulating sg mRNA synthesis 
Coronaviruses have evolved an unusual process of discontinuous transcription to 
express the 3’-proximal third of their genomes. They produce a characteristic set of 
3’-coterminal sg mRNAs and each sg mRNA contains a 5’ leader sequence 
corresponding to the leader sequence at the 5’ end of the genome. Thus, during 
coronavirus sg mRNA synthesis sequences derived from the 5’ end of the genome 
(i.e. the leader sequence) and sequences derived from the 3’ third of the genome 
(i.e. the body sequence) are fused by a discontinuous step during minus strand sg 
RNA synthesis. TRS elements are known to be critically involved in this step as they 
determine the border of leader and body sequences. 
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 It is still not known, how the process is regulated in detail, but during negative-
strand synthesis a number of consecutive events have been proposed:
1. Recruitment of the replication-transcription complex (RTC) to the 3’ end of the 
genomic RNA and initiation of minus-strand synthesis. 
2. Elongation of minus-strand synthesis until the first functional TRS is found. A 
proportion of the RTC will ignore the TRS and continue to elongate the 
nascent RNA. Alternatively, the RTC will stop synthesis of the negative-strand 
RNA, relocate and bind to the leader TRS and reinitiate negative strand RNA 
synthesis by adding the anti-leader sequence to the nascent RNA strand. 
The relocation is believed to be guided by complementary base-pairing between 
the 3’end of the newly synthesized RNA (minus strand copy of the body TRS) and 
the leader TRS located at the 5’ end of the genome. This step necessarily implicates 
that 5’- and 3’-end derived sequences form a complex to bring the leader region and 
the newly synthesized minus RNA into proximity. Protein-RNA and protein-protein 
interactions probably mediate such an interaction. Heterogeneous nuclear 
ribonucleoprotein (hnRNP) A1, polypyrimidine tract-binding protein (PTB) and 
coronavirus N protein could help the formation and stabilization of such a complex, 
since they have been shown to bind MHV genomic RNA (117, 160, 161). However, 
many basic questions still remain unanswered. Which signal is responsible for the 
RTC to slow down or stop and which signal stimulates a strand transfer to the leader 
region? TRS-flanking regions have been proposed to be involved in this step (235), 
however comparative sequence analyses did so far not yield a common signature for 
such an RNA element. To which extend does the proposed stem loop structure (261) 
at the leader TRS impact on template strand transfer? Furthermore, are there 
particular nsps that act as “transcription factors” to guide coronavirus discontinuous 
minus strand synthesis? How, in structural terms, is the relocation of the 3’ end of the 
nascent minus strand RNA to the 5’ end of the genomic template being mediated? 
And finally, why did coronaviruses evolve such a complex mechanism of 
discontinuous extension of minus strand RNAs to produce their characteristic nested 
set of sg mRNAs? 
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4.5.3 Cis-acting elements regulating genome RNA replication 
Originally, systematic analysis of elements required for coronavirus genome 
replication was enabled by the discovery of defective interfering (DI) RNAs, which are 
remnants of viral genomic RNAs bearing multiple extensive deletions. These RNA 
constructs are not independently viable, but they can propagate by using the RNA 
synthesis machinery provided by a helper virus. Thus, DIs must have retained 
precisely those cis-acting elements required for replication. The first coronavirus DI to 
be discovered was from the JHM strain of MHV (170, 172) and subsequently DIs 
from other strains and species of coronaviruses have been described (53, 114, 180, 
201, 265). All coronavirus DI RNAs are comprised of sequences derived from the 5’ 
and 3’ genomic termini, and furthermore, often carry internal genome sequences that 
may harbor a packaging signal involved in selective packaging of an RNA into 
progeny virions (139). 
Studies carried out in various coronavirus species revealed that the first 467 – 649 
nts of the genomic 5’ end are indispensable for replication (53, 59, 82, 126, 140, 164, 
168). In most cases, probably with the only exception of IBV, the minimal 5’ cis-acting
elements extend into the coding region of the replicase gene product nsp1. The well 
described BCoV 5’ cis-acting element contains at least five stem-loop structures 
numbered I-V in 5’ to 3’ direction (26). The structure of stem loop I and II have been 
confirmed biochemically and were found to be essential (52). Stem loop III is well 
conserved amongst group II coronaviruses and has also been shown to be essential 
for DI RNA replication. A short intra-5? UTR open reading frame (ORF) of unknown 
function is associated with stem loop III. Integrity of the small ORF, but not the 
conservation of the peptide sequence seems to be critical (209). Stem loop IV and V 
extend into the ORF1a-coding region and both have been shown to be essential (34, 
210). Whether these described 5’ cis-acting elements are necessary only in the 
context of DI replication or also play a role in virus replication still remains to be 
elucidated. For MHV the secondary structure of the 5’-most 140 nts in the 5’ UTR has 
been predicted and structural support has been provided by NMR studies. 
Additionaly a mutational analysis revealed the essential role of stem loop 2 in MHV 
replication (162).
At the 3’ end of the coronavirus genome is a 3’ UTR, ranging in size from 273 nts-
505 nts followed by a polyA tail. The demarcation of essential regions at the 3’ end 
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began also with DI RNA studies.  As for the 5’ UTR, the required region not only 
encompassed the entire 3’ UTR, but also parts of the adjacent N ORF (140, 164, 
166, 168). However, this statement is only valid for group II coronaviruses. Mapping 
of group I and group III coronaviruses 3’ cis-acting replication signals showed that no 
fragment of N was implemented (59, 126). Controversially, mutations engineered in 
MHV genome support the notion that the 3’ genomic element required for viral RNA 
replication lies entirely within the 3’ UTR. Rearrangements of the MHV genome that 
translocated the N gene had no effect on viral replication (62). 
The secondary structure of the group II coronavirus 3’UTR is rather well 
characterized. Using recombinant MHV it has been shown that a functionally 
essential bulged stem-loop (BSL) followed by an essential pseudoknot reside at the 
upstream end of the 3’UTR (276). The basal part of the BSL can also bind with one 
strand of the first stem of the pseudoknot (PK) and thus, both structures cannot form 
simultaneously. Therefore it has been proposed that they constitute a molecular 
switch, with one component regulating the folding of the other, and possibly 
regulating different steps of viral replication (90). Downstream of the PK is a region 
which is less well conserved. This hypervariable region (HVR) can be mutated or 
entirely removed from the viral genome with little effect on virus replication in tissue 
culture (91). The nonessential nature of the HVR is surprising, since the region 
harbors the octanucleotide 5'-GGAAGAGC-3', which is almost universally conserved 
among coronaviruses and is always situated some 70 to 80 nt from the 3' end of the 
genome. The refinement of the complete structure of the MHV 3' UTR indicates that 
the minimal 3' cis-acting element required for MHV RNA synthesis is limited to no 
more than 160 nts of the 3' UTR. This means that nearly half of the 3' UTR, bases 30 
through 170, can be discarded without affecting the basic mechanism of viral RNA 
synthesis. The non-essential region encompasses in vitro binding sites for a number 
of host cell proteins, including PTB, hnRNP, a complex of mitochondrial aconitase, 
and the chaperones mtHSP70, HSP60, and HSP40. It follows that these binding sites 
cannot be strictly required for RNA synthesis, although they may play ancillary roles 
yet to be defined (see chapter 6) (301).
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4.6 Coronavirus reverse genetics 
The extreme large size of coronavirus genome and the instability of specific 
coronavirus sequences in conventional cloning vectors (e.g. plasmid DNAs) are 
regarded as major obstacles to the generation of recombinant viruses by traditional 
reverse genetic techniques. Therefore, reverse genetic systems for coronavirus are 
exclusively based on non-traditional approaches. First, Masters  and colleagues (141, 
175, 177) reported a method termed “targeted RNA recombination” that is based on 
recombination of MHV with a synthetic donor RNA. This approach is benefitting from 
the high rate of recombination in MHV (9, 12, 137, 138, 148) probably occurring via a 
template switching mechanism (171). Initially, a temperature-sensitive MHV mutant 
has been recombined with a synthetic donor RNA containing the mutation of choice 
in the N gene. Recombinant viruses have been selected at the restrictive temperature 
against the temperature sensitive parental virus. However, a more sophisticated and 
stringent method based on a switch of target-cell specificity has been reported 
recently (144, 177). Targeted RNA recombination has been successfully used for the 
manipulation of the 3’ third of coronavirus genomes including all structural genes, 
accessory proteins and 3’ UTR (177), and its application to two other coronaviruses 
has been reported (103, 219). However this technique is limited to the modification of 
the 3’-third of a coronavirus genome. Hence manipulation of the 5’ UTR and replicase 
genes had to await the development of systems based on the construction of full-
length cDNA coronavirus clones. In 2000 Enjuanes and collaborators reported the 
development of the first reverse genetic system based on full-length cDNA. They 
used a bacterial artificial chromosome (BAC) that harbors a full-length TGEV cDNA 
(4). Soon after, Baric and colleagues reported a system based on the systematic 
assembly of a full-length TGEV cDNA by in vitro ligation of six adjoining plasmid-
derived cDNA subclones spanning the entire TGEV genome (285). Finally, Siddell 
and colleagues showed an alternative to the cDNA cloning in bacterial systems. They 
used vaccinia virus as an eukaryotic cloning vector and stably inserted a full-length 
cDNA of HCoV-229E (253, 256). Regardless of the different cloning strategies and 
protocols established for recovery of the recombinant viruses, full-length cDNA-based 
systems enable the modification of all regions within coronavirus genomes. 
The number of coronaviruses which can be studied by reverse genetic systems is 
constantly increasing, and currently includes a number of human (HCoV-229E, 
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HCoV-OC43, SARS-CoV) and animal coronaviruses (MHV, TGEV, IBV, FIPV). (2, 4, 
13, 37, 45, 79, 92, 103, 144, 175, 177, 219, 239, 248, 253, 256, 285-287). Reverse 
genetic analyses have extended our knowledge on virtually all aspects of coronavirus 
infections, including tropism, pathogenesis, packaging and mechanisms and 
requirements for viral RNA synthesis. This knowledge together with the ability to 
modify in principle any base in the genome will help to develop novel coronavirus 
vaccines and vectors. 
4.7 Innate immunity and coronavirus 
Efficient and rapid antiviral host responses consist predominantly of the production 
of type I interferons (IFNs), an essential part of the innate immune system (251). 
Approximately 13 different IFN-?, and one IFN ? are known as type I IFNs. They can 
be secreted by all mammalian nucleated cells however the signaling molecules 
involved in viral recognition, the amounts of type I IFNs produced and secreted can 
differ among cell types. These soluble factors induce an array of intracellular 
effectors including protein kinase R (PKR), 2'-5'oligoadenylate synthetases (2’-5 
OAS) and Mx proteins which halt viral replication (241). Besides their direct antiviral 
role, IFNs also inhibit cell proliferation, regulate apoptosis and most importantly 
modulate the immune response, such as activation of the adaptive immune response 
via IFN? (111, 195).  
A hallmark of coronavirus infections is the strongly limited ability to induce type I 
IFN production. It has been shown that several cells lines, fibroblasts, or conventional 
dendritic cells are not able to produce type I IFN after infection with MHV. Also that 
neither macrophages nor monocyte-derived DC are able to produce type I IFN after 
SARS-CoV infection (130, 212, 289). Nevertheless, coronavirus replication can be 
reduced in vitro and in vivo by treatment with IFN-?. For example type I IFN 
treatment is able to diminish severity of SARS-like symptoms in SARS-CoV infected 
macaques and can reduce replication of MHV in mice (43, 101, 291). Strikingly, mice 
lacking the type I IFN-receptor (IFNAR-/-) rapidly succumb to MHV infection (42). 
These findings reflect the importance of type I IFNs in the defense against 
coronaviral infections. Plasmacytoid dendritic cells (pDC) have been identified as a 
major source of type I IFNs in human and mice (8, 41, 187, 231). In particular during 
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MHV infection they play an important role in producing IFN? to protect mice from 
lethal liver disease (42). 
Although coronaviruses are sensitive to IFN, the early production of these 
cytokines is highly restricted to pDCs which have been shown to recognize MHV 
infection through TLR7 (42). This strongly suggests that coronaviruses have evolved 
strategies to evade antiviral innate host responses either by avoiding or inhibiting the 
production of IFN. One possible mechanism may be the replication of coronaviruses 
in a double membrane vesicle, probably protecting viral RNA and replication 
intermediates from the recognition by pathogen recognition receptors (97, 204, 234, 
242, 257). It has been proposed that MHV can inhibit IFN? production, at the level of 
translation, since IFN? mRNA can be found in MHV infected cells, but almost no 
IFN? protein can be detected in supernatants from these cells (216). Furthermore 
various SARS-CoV and MHV gene products have been proposed to either directly 
inhibit IFN production or interfere with downstream signaling events (88, 133, 142, 
143, 300). For example, IRF3 signaling is affected during SARS-CoV infection (238). 
However, the mechanisms by which coronaviral proteins could inhibit type I IFN 
production, participate in the avoidance of coronavirus recognition, or block 
downstream events of host cell innate immune responses (e.g. IFN signaling, 
antiviral effector molecules) remain to be further characterized.
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5 Aim of the thesis 
Coronaviruses are positive stranded RNA viruses mainly associated with 
respiratory and enteric diseases. They can cause severe diseases in livestock and 
companion animals. In humans, coronavirus infections manifest usually as mild 
respiratory tract disease (common cold). However, the severe acute respiratory 
syndrome (SARS), caused by a formerly unknown coronavirus (SARS-CoV), 
exemplified the potential of coronaviruses to also seriously impact on human health.  
The major aim of this thesis was to investigate the role of replicase-encoded gene 
products in the context of viral RNA replication and host interactions. Furthermore, 
we aimed to define the importance of host innate immune responses to combat 
coronavirus infections.  
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“Genetic Interactions between an Essential 3’ cis-Acting RNA Pseudoknot, 
Replicase Gene Products, and the Extreme 3’ End of the Mouse Coronavirus 
Genome” 
Roland Züst, Timothy B. Miller, Scott J. Goebel, Volker Thiel, and Paul S. Masters 
Own contribution to this article: Recombinant MHV viruses containing either a 6 nt 
insertion alone or in combination with suppressor mutations in nsp8 or nsp9 or 
supressor mutations in nsp8/nsp9 alone have been generated and analyzed by 
plaque size, growth kinetics and sequencing. 
38
JOURNAL OF VIROLOGY, Feb. 2008, p. 1214–1228 Vol. 82, No. 3
0022-538X/08/$08.000 doi:10.1128/JVI.01690-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
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The upstream end of the 3 untranslated region (UTR) of the mouse hepatitis virus genome contains two
essential and overlapping RNA secondary structures, a bulged stem-loop and a pseudoknot, which have been
proposed to be elements of a molecular switch that is critical for viral RNA synthesis. It has previously been
shown that a particular six-base insertion in loop 1 of the pseudoknot is extremely deleterious to the virus. We
have now isolated multiple independent second-site revertants of the loop 1 insertion mutant, and we used
reverse-genetics methods to conﬁrm the identities of suppressor mutations that could compensate for the
original insertion. The suppressors were localized to two separate regions of the genome. Members of one class
of suppressor were mapped to the portions of gene 1 that encode nsp8 and nsp9, thereby providing the ﬁrst
evidence for speciﬁc interactions between coronavirus replicase gene products and a cis-acting genomic RNA
element. The second class of suppressor was mapped to the extreme 3 end of the genome, a result which
pointed to the existence of a direct base-pairing interaction between loop 1 of the pseudoknot and the genomic
terminus. The latter ﬁnding was strongly supported by phylogenetic evidence and by the construction of a
deletion mutant that reduced the 3 UTR to its minimal essential elements. Taken together, the interactions
revealed by the two classes of suppressors suggest a model for the initiation of coronavirus negative-strand
RNA synthesis.
RNA virus genomes contain cis-acting sequences and struc-
tures that interact with viral and cellular components to initiate
a variety of essential functions. Such interactions can mediate
RNA replication and transcription, the selective translation
of viral transcripts, and the speciﬁc packaging of progeny
genomic RNA (gRNA) into assembling virions. Initiation of
RNA virus genome replication occurs at the extreme 3 end of
gRNA in order to produce a strand of complementary polarity.
For positive-strand RNA viruses, the initiation of negative-
strand RNA synthesis requires the speciﬁc recognition of the
viral gRNA template and the juxtaposition of replicative pro-
teins and the 3 genomic terminus. cis-acting sequences are
believed to play pivotal roles in these processes. An intriguing
example of how cis-acting sequences can coordinate the assem-
bly and targeting of a replication complex to the initiation site
of negative-strand RNA synthesis has been provided by studies
of poliovirus replication (4, 23, 57). A crucial initial event in
this system is the formation of a ribonucleoprotein complex
around a cloverleaf RNA structure at the 5 end of the polio-
virus genome. This complex consists of the poliovirus protease-
polymerase precursor 3CD and the cellular poly(rC) binding
protein, both of which bind to the 5 cloverleaf (1, 2, 7, 17). In
order to target poliovirus 3CD to the initiation site of negative-
strand RNA synthesis, another cellular protein, poly(A) bind-
ing protein, becomes involved. Poly(A) binding protein is as-
sociated with the poly(A) tail of the poliovirus genomic RNA
(which also serves as a cis-acting replication element) and
bridges the 5 and 3 genomic termini by binding to the
poly(rC) binding protein and 3CD (4, 23). Thus, in this exam-
ple, cis-acting elements provide not only the basis for the
discrimination between viral and cellular RNA but also a plat-
form for the assembly of a negative-strand replication initia-
tion complex.
Coronaviruses are a family of positive-strand RNA viruses
possessing a complex, multicomponent RNA synthetic machin-
ery and a sophisticated program of gene expression that is
characterized by the transcription of a 3-nested set of sub-
genomic RNAs (sgRNAs), in addition to gRNA replication
(41). These features are shared with other members of the
nidovirus order, which also includes arteriviruses, toroviruses,
and roniviruses. For these viruses, the synthesis of both gRNA
and sgRNA begins with the initiation of negative-strand RNA
at the 3 end of the genome (49). A prerequisite for this event
is the translation of the replicase gene from the positive-strand
RNA genome, resulting in two large polyproteins. Extensive
self-processing by viral proteinases residing within the polypro-
teins eventually generates a number of processing intermedi-
ates and 15 to 16 mature end products, termed nonstructural
proteins (nsp’s) 1 to 16 (nsp1 to nsp16) (67). Many nsp’s
colocalize, together with the structural nucleocapsid (N) pro-
tein, at double-membrane vesicles to form the membrane-
associated replication complex (8, 10, 14, 22, 53). Although this
complex is believed to interact with cis-acting elements in or-
der to replicate and transcribe viral RNAs (9), our knowledge
about speciﬁc interactions that may be involved in the various
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Wadsworth Center, NYSDOH, New Scotland Avenue, P.O. Box
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steps of coronavirus RNA synthesis is extremely limited. RNA-
binding activity has been ascribed to a number of replicase
gene products (16, 32, 55, 56, 66) and to the N protein (41).
However, currently available structural and biochemical data
do not yet allow the assignment of any of these RNA-binding
proteins to deﬁned interactions with cis-acting elements. Ad-
ditionally, it is not known whether cellular proteins that have
been shown to bind to viral RNA, such as PTB (28), hnRNP
A1 (29), and a complex of mitochondrial aconitase and chap-
erones (45, 46, 64, 65), are critically involved in coronavirus
RNA synthesis.
A fairly comprehensive view of cis-acting elements located at
the 3 end of the coronavirus genome has come from studies of
mouse hepatitis virus (MHV) and its close relative, bovine
coronavirus (BCoV) (9, 42). Both MHV and BCoV are mem-
bers of the second of the three phylogenetic groups into which
coronaviruses are sorted. For MHV, work with viral mutants
has demonstrated that the 3 genomic cis-acting elements es-
sential for RNA synthesis lie entirely within the 301-nucleotide
(nt) 3 untranslated region (3 UTR) (13, 18), even though
earlier studies with defective interfering (DI) RNAs had sug-
gested a potential role for a portion of the adjacent N gene (33,
36, 40). The current picture of the MHV 3UTR, shown in Fig.
1, began with the deﬁnition of structures at its upstream end.
Immediately following the N-gene stop codon is a bulged
stem-loop (27). Adjacent to this is a classical hairpin-type
pseudoknot (60), ﬁrst discovered in BCoV. Exhaustive genetic
analyses, in addition to chemical and enzymatic probing, have
conﬁrmed the existence and the essential nature of these two
structures both in DI RNAs and in the intact viral genome (18,
26, 27, 60). Most signiﬁcantly, the bottommost stem of the
bulged stem-loop and stem 1 of the pseudoknot overlap, and
thus, the two cannot simultaneously fold to completion. Con-
sequently, we have previously proposed that these alternative
0123
FIG. 1. Structure of the MHV 3 UTR. The organization of the 31.3-kb MHV genome is shown at the bottom. Above this, at the right, is a
schematic of the current model of the RNA secondary structure of the entire 301-nt 3UTR. The 3UTR comprises an essential bulged stem-loop
(BSL; nt 234 through 301) (18, 26, 27) and overlapping pseudoknot (PK; nt 185 through 238) (18, 60, 63). Downstream of these structures is a
nonessential HVR (nt 46 through 156), which contains the highly conserved coronavirus octanucleotide motif (oct), 5-GGAAGAGC-3 (19, 39).
The arrangements shown for the segment downstream of the HVR (nt 1 through 67) and for part of the segment between the HVR and the
pseudoknot (nt 143 through 160) are those proposed by Liu and coworkers (38) but are modiﬁed in the work reported herein. At the upper left
is a detailed view of the upstream end of the 3 UTR, denoting the pseudoknot stems (S1 and S2) and loops (L1 and L2). Broken lines represent
alternative base pairings either for the bottom stem segment of the bulged stem-loop or for pseudoknot stem 1. Also indicated is the 6-nt insertion
(AACAAG) in pseudoknot loop 1 that was constructed in the mutant Alb391 (18). All nucleotide numbering is from the ﬁrst base at the 3 end
of the genome, excluding poly(A), and the N-gene stop codon is boxed.
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structures are components of a molecular switch regulating
a transition between individual steps of viral RNA synthesis
(18, 26).
Overlapping bulged stem-loops and pseudoknots are main-
tained in the upstream 3 UTRs of all group 2 coronaviruses,
including severe acute respiratory syndrome coronavirus
(SARS-CoV) (18, 20), human coronavirus HKU1 (61), and the
recently discovered bat coronaviruses HKU4, HKU5, and
HKU9 (62). (Although it is stated otherwise in reference 62,
HKU9 clearly harbors a pseudoknot, running from nucleotide
28898 through 28947, and two candidate overlapping bulged
stem-loops can be found upstream of it.) This structural con-
servation, despite considerable primary sequence divergence,
strongly implies functional conservation. More to the point, it
has been shown that the entire 3 UTR of either BCoV (27) or
SARS-CoV (20) can functionally replace the MHV 3 UTR.
Similarly, multiple group 2 coronaviruses closely related to
MHV and BCoV are competent to serve as helper viruses for
the replication of a BCoV DI RNA (63).
Most of the downstream remainder of the MHV 3 UTR is
composed of a hypervariable region (HVR) (Fig. 1); the HVR
is highly divergent in both sequence and structure, even among
closely related coronaviruses like MHV and BCoV. The struc-
ture of the MHV HVR has been conﬁrmed by enzymatic
probing (38). Detailed genetic analysis has shown that unlike
the RNA elements in the upstream portion of the 3 UTR, the
HVR can be mutated or entirely removed from the viral ge-
nome with little effect on virus replication in tissue culture
(19). The nonessential nature of the HVR is surprising, since
the region harbors the octanucleotide 5-GGAAGAGC-3,
which is almost universally conserved among coronaviruses
and is always situated some 70 to 80 nt from the 3 end of the
genome. Although deletion of the HVR greatly attenuates
MHV virulence in the mouse host, the HVR’s dispensability
with respect to in vitro replication greatly simpliﬁes consider-
ation of the basic mechanism of RNA synthesis.
In our previous mutational analysis of the bulged stem-loop
and pseudoknot, we observed that loop 1 of the pseudoknot is
extremely sensitive to insertions of various sizes (18). A thresh-
old of viability was seen to occur at an insertion size of six
nucleotides: an insertion one base smaller, AACAA, was fully
tolerated, whereas an insertion one base larger, AACAACA,
was lethal. One particular 6-nt insertion, AACAAA, had only
a minimal effect on the viral phenotype. By contrast, a mutant
designated Alb391, with a 6-nt insertion of AACAAG, was
extremely unstable. Alb391 formed very small plaques com-
pared to those of the wild type, and it gave rise to large-plaque
revertants within a single passage. In the work described here,
we carried out an analysis of multiple revertants of Alb391.
The results of this study provide the ﬁrst indication of an
interaction between a 3 cis-acting element required for viral
RNA synthesis and components of the coronavirus replicase.
In addition, our results point to an interaction between stem 1
of the pseudoknot and the extreme 3 terminus of the MHV
genome. These two sets of interactions suggest a model for the
initiation of viral negative-strand RNA synthesis.
MATERIALS AND METHODS
Cells and viruses. Wild-type MHV-A59, MHV mutants, and revertants were
propagated in mouse 17 clone 1 (17Cl1) cells. MHV plaque assays and plaque
puriﬁcations were carried out in mouse L2 or L929 cells, which were overlaid
with 1% Noble agar and stained with neutral red at 48 h postinfection. The
interspecies chimeric virus fMHV.v2 (18) was grown in feline FCWF cells.
Vaccinia viruses were propagated in CV-1 and BHK-21 cells, and plaque puri-
ﬁcations were performed on CV-1 and D980R cells (11).
Vaccinia virus-based MHV reverse genetics. The recombinant MHV mutants
rAlb391, rN8-Alb391, rN9-Alb391, rN8, and rN9 were derived from vaccinia
virus vMHV-inf-1, which contains a cloned full-length MHV-A59 cDNA
(GenBank accession number AY700211). Mutagenesis was done using the re-
verse-genetics system described previously (11, 24). Brieﬂy, two rounds of vac-
cinia virus-mediated homologous recombination were performed using the Esch-
erichia coli guanine-phosphoribosyltransferase (GPT) gene as a selection marker.
First, the target region within the MHV cDNA was replaced by the GPT gene,
and second, the GPT gene was replaced by a mutated version of the target
region. To construct recombinant vaccinia viruses encoding the Alb391-speciﬁc
AACAAG insertion in the MHV 3 UTR, we used the plasmid pRec5 for
recombination with vaccinia virus vMHV-inf-1. The GPT gene in pRec5 is
ﬂanked on its left by MHV-A59 nt 28510 to 29024 and on its right by 500 bp of
vaccinia DNA that is encoded downstream of the MHV-A59 3 terminus in
vMHV-inf-1. The resulting recombinant vaccinia virus, vRec5, was used for
recombination with the plasmid pRec7 to insert the Alb391-speciﬁc 3 terminus.
The plasmid pRec7 contains MHV Alb391 nt 28510 to 31335, followed by a
synthetic poly(A) sequence and 500 bp of vaccinia virus DNA. The resulting
recombinant vaccinia virus clone was designated vMHV-rAlb391. To mutagenize
nsp8 and nsp9, the region encoding MHV nsp7 to nsp11 was replaced by GPT,
using vaccinia virus-mediated homologous recombination of vMHV-inf-1 or
vMHV-rAlb391 with plasmid pRec3. The plasmid pRec3 encodes the GPT gene
ﬂanked on its left by MHV-A59 nt 11464 to 11956 and on its right by MHV-A59
nt 13594 to 14151. The resulting recombinant vaccinia viruses were then recom-
bined with reverse transcription (RT)-PCR-derived DNA fragments obtained
from RNA isolated from the Alb391 revertant Rev2 or Rev3. The resulting
recombinant vaccinia viruses thus produced were designated vMHV-rN8 (carry-
ing the Rev2 mutations in nsp8 and the wild-type MHV 3 UTR), vMHV-rN9
(carrying the Rev3 mutation in nsp9 and the wild-type MHV 3 UTR), vMHV-
rN8-Alb391 (carrying the Rev2 mutations in nsp8 and the Alb391 3 UTR), and
vMHV-rN9-Alb391 (carrying the Rev3 mutation in nsp9 and the Alb391 3
UTR). The identities of plasmids and recombinant vaccinia viruses were con-
ﬁrmed by sequencing analysis of the mutated regions. Further cloning details,
plasmid maps, and sequences are available from the authors upon request.
Recombinant coronaviruses were rescued from cloned cDNA using puriﬁed,
EagI-cleaved vaccinia virus DNA as a template for the in vitro transcription of
recombinant full-length MHV genomic RNA, which was electroporated into
BHK-MHV-N cells as described previously (11). Following electroporation, the
transfected BHK-MHV-N cells were mixed with a fourfold excess of murine
17Cl1 cells and cultured at 37°C. At days 1 and 2 postelectroporation, tissue
culture supernatants were taken for further analysis.
Targeted RNA recombination. For the construction of the HVR3 mutant and
the reconstruction of the 3 UTR A2G mutation, targeted RNA recombination
with host range-based selection was used, as described in detail previously (13,
18, 19, 20, 34, 35, 43). In brief, monolayers of feline FCWF cells were infected
with fMHV.v2 and were then transfected by electroporation with capped, T7
polymerase-transcribed donor RNAs (mMessage mMachine transcription kit;
Ambion). Templates for donor RNAs were derived from pSG6 (18) via PCR-
based mutagenesis methods, which replaced plasmid segments between unique
restriction sites in the 3 UTR or the downstream polylinker. pSG6 contains a
cDNA segment of the 5-most 0.5 kb of the MHV genome linked to the 3-most
8.6 kb of the MHV genome. Progeny virus from infected and transfected feline
cells were selected on the basis of having regained the ability to form plaques on
murine L2 cell monolayers, and the resulting recombinant candidates were
puriﬁed through two rounds of plaque titration. For mutants constructed by
targeted RNA recombination, the wild-type virus used for comparisons was
Alb240, a well-characterized isogenic recombinant that was previously recon-
structed from fMHV and pMH54 donor RNA (35).
Characterization of mutants and revertants. For analysis of the sequences of
constructed mutants and isolated revertants, total cellular RNA was extracted
from infected monolayers and reverse transcribed with avian myeloblastosis virus
(Life Sciences) or Superscript II (Invitrogen) reverse transcriptase using random
hexanucleotide (Boehringer Mannheim) or MHV sequence-speciﬁc primers.
Regions of the genome were then ampliﬁed by PCR under standard conditions
using AmpliTaq polymerase (Roche), and PCR products were puriﬁed with
Quantum-prep columns (Bio-Rad) prior to automated sequencing. For viruses
for which the entire genome was sequenced (Rev2, Rev5, and Rev6), the extreme
5-end sequence was obtained through rapid ampliﬁcation of cDNA ends (5/3
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RACE kit; Roche). In order to resolve the mixed sequence obtained for the
mutant rAlb391 isolate S3, we cloned RT-PCR products using the pGEM-T Easy
Vector System (Promega), and individual plasmids were subsequently se-
quenced.
For the measurement of growth kinetics, conﬂuent monolayers of 17Cl1 cells
were inoculated at a multiplicity of 0.01 or 5.0 PFU per cell (for the HVR3
mutant) or at a multiplicity of 1.0 PFU per cell (for all other mutants) for 2 h at
37°C. Inocula were removed, monolayers were washed three times, and incuba-
tion was continued in fresh medium at 37°C. Sample aliquots of medium were
then withdrawn at various times from 2 to 32 h postinfection, and infectious titers
were subsequently determined on mouse L2 cells.
RNA structural predictions were carried out with the mfold software (44, 68),
available at http://www.bioinfo.rpi.edu/applications/mfold.
Radiolabeling of viral RNA. Intracellular viral RNA was metabolically labeled
in 17Cl1 cells as described previously (18–20, 27). In brief, 20-cm2 conﬂuent
monolayers were infected with the HVR3 mutant or wild-type MHV at a
multiplicity of 5.0 PFU per cell at 37°C. Infected cells were starved from 2 h
through 8 h postinfection in Eagle’s minimal essential medium containing 5%
dialyzed fetal bovine serum with 1/10 of the normal concentration of phosphate.
Cells were then labeled from 8 h through 10 h postinfection in 1 ml phosphate-
free medium containing 100 Ci per ml [33P]orthophosphate (MP Biomedicals),
5% dialyzed fetal bovine serum, and 20 g of actinomycin D (Sigma) per ml.
Total cytoplasmic RNA was puriﬁed, and samples were analyzed by electro-
phoresis through 1% agarose containing formaldehyde and were visualized by
ﬂuorography.
RESULTS
Initial revertant analysis of a 3 UTR pseudoknot mutant. In
a previous study, we used targeted RNA recombination to
construct a number of mutants of the MHV 3 UTR bulged
stem-loop and pseudoknot in order to obtain an understanding
of the structural requirements of these two elements and their
interrelationship (18). An additional goal was to generate se-
verely impaired viral mutants that might direct us to genetic
interactions between the 3 UTR and other regions of the
genome. A mutant that met the latter criterion was Alb391, in
which an insertion of 6 nt, AACAAG, was made between bases
226 and 227 of pseudoknot loop 1 (Fig. 1). Alb391 had a
markedly defective phenotype, exhibiting slow growth and
forming much smaller plaques than did wild-type virus at 33°C,
37°C, and 39°C. Revertants of this mutant were rapidly se-
lected in as few as one or two passages. Six independent re-
vertants (Rev1 to Rev6), which formed plaques identical to or
slightly smaller than those of the wild type, were isolated and
analyzed by partial or total genomic sequencing (Table 1). One
of these, Rev1, had lost the ﬁrst ﬁve bases of the insertion,
retaining a footprint of only the ﬁnal G residue. This ﬁnding
constituted strong evidence that the 6-nt insertion, rather than
some extraneous mutation, was indeed responsible for the
Alb391 phenotype.
All of the other revertants retained the complete 6-nt inser-
tion, indicating that second-site suppressor mutations had to
account for their observed reversion. For one of these, Rev2,
we determined the sequence of the entire viral genome and
compared it to the particular database reference sequence
(GenBank accession number NC001846) that is closest to the
laboratory strain from which Alb391 had been derived. A total
of nine mutations, two synonymous and seven nonsynonymous,
were found relative to the reference sequence. However, all
except two of these base changes also occurred in the corre-
sponding wild-type virus or in the immediate fMHV precursor
to Alb391, and they were therefore not associated with rever-
sion. The two remaining mutations produced a pair of closely
spaced coding changes in nsp8 (Table 1), which is one of a
group of four small processed polypeptide products encoded
by the downstream-most end of replicase gene 1a. Similarly,
sequencing of the nsp7-through-nsp10 region of both Rev3 and
Rev4 revealed single coding mutations in nsp9 and in nsp8,
respectively (Table 1). Notably, both nsp8 and nsp9 have been
described as RNA-binding proteins, and nsp8 has been shown
to possess an RNA-dependent RNA polymerase (RdRp) ac-
tivity (16, 30, 56, 66). By contrast, Rev5 and Rev6 were found
to have no mutations in the nsp7-through-nsp10 region, but
each had the same A-to-G transition at the penultimate nu-
cleotide preceding the poly(A) tail (denoted A2G in the num-
bering system used for the 3 UTR) (Table 1). Initially we did
not consider this mutation to be signiﬁcant, since A2G is dis-
tant from the pseudoknot and since the same base change
occurs naturally in MHV strain 3 (47). Accordingly, we se-
quenced the entire genomes of Rev5 and Rev6 and found no
other base changes. Thus, our initial revertant analysis de-
tected three classes of candidate reverting mutations for the 3
UTR pseudoknot insertion in Alb391: one mapping to the
original site of the insertion, a second falling within the repli-
case gene, and the last near the 3 genomic terminus.
Reconstruction of Alb391 by full-length cDNA cloning. To
test whether replicase gene mutations, mapping some 20 kb
distant from the original lesion, were responsible for reversion
of the Alb391 mutation, we aimed to reconstruct a subset of
the revertants. To accomplish this, we decided to use the vac-
cinia virus-based complete reverse genetics system for MHV
(11, 58), which, unlike targeted RNA recombination (43), al-
lows access to the huge coronavirus replicase gene. However,
we ﬁrst needed to clarify whether the Alb391-speciﬁc 6-nt
insertion would confer the same phenotype in the genetic
background of the recombinant MHV-inf-1 molecular clone.
Therefore, we generated the 6-nt pseudoknot insertion muta-
tion in the MHV-inf-1 genome and analyzed the rescued mu-
tant, designated rAlb391. In accord with previous results, the
reengineered mutant was found to be extremely unstable, even
at the earliest stages of recovery. As shown in Fig. 2A, rAlb391
virus obtained from N protein-expressing cells that had been
TABLE 1. Sequence analysis of initial set of candidate reverting
mutations of Alb391a
Mutant Gene orregion Nucleotide change(s)
b Amino acid
change(s)c
Rev1 3 UTR Deletion of nt 1 through 5 of
the 6-nt insertion between
bases 226 and 227
None
Rev2 nsp8 G12439A, C12452U D62N, T66I
Rev3 nsp9 U13017G N60K
Rev4 nsp8 A12344G Q30R
Rev5 3 UTR A2G None
Rev6 3 UTR A2G None
a For Rev2, Rev5, and Rev6, the entire genomes were sequenced. For Rev1,
Rev3, and Rev4, the genomic regions sequenced were as follows: the 5-most 510
bases, the segment of gene 1a encoding nsp7 through nsp10, and the entire
3 UTR.
b Nucleotide numbering is from the 5 end of the genome for replicase (gene
1) mutations and from the 3 end of the genome, excluding poly(A), for 3 UTR
mutations. All mutants, except Rev1, retained the 6-nt insertion (AACAAG)
between bases 226 and 227 of the 3 UTR.
c Amino acid numbering indicates the residue position in each processed
replicase protein product.
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transfected with synthetic mutant genomic RNA had a mixture
of mutant and wild-type sequence at the position of the inser-
tion (and consequently at all points downstream in a positive-
strand sequence). Plaques of rAlb391 exhibited considerable
heterogeneity, ranging from very small to wild-type size (data
not shown). To analyze this in more detail, we picked 3 of the
smallest plaques (S1 through S3) and 2 of the largest plaques
(L1 and L2) and propagated them for 6 and 10 passages,
respectively. Isolates L1 and L2 formed uniformly large
plaques at passages 2 and 10 (Fig. 2B), and sequence analysis
revealed that they had exactly lost the 6-nt insertion (data not
shown); this identiﬁed them as precise primary-site revertants.
By contrast, isolates S1 through S3 had a variety of plaque
sizes by passage 2. By passage 6, they formed fairly uniform
plaques that were the same size, or nearly the same size, as
those of the wild type (Fig. 2B). Sequencing showed that this
stability had been achieved through the acquisition of one of a
number of new mutations. In the stock of isolate S1, the 6-nt 3
UTR pseudoknot insertion was retained. However, by passage
6, a previously unseen nsp9 mutation had been selected
(A13010G), resulting in the amino acid change D58G (Fig.
2C). For isolate S2, the passage-6 stock was composed of a new
type of primary site footprint mutant, in which the last three
bases of the 6-nt insertion (AAG), as well as the next down-
stream base (U), were deleted (Fig. 2D). There were no addi-
tional changes in either the nsp7-through-nsp10 region or the
remainder of the 3 UTR of S2 passage 6. Finally, bulk se-
quencing of the passage-6 stock of isolate S3 gave a mixture of
sequences, which were resolved through TA cloning of RT-
PCR products from the 3 UTR. Five out of nine TA clones
were found to have the same 3-nt footprint of the original
insertion that had been found in the S2 isolate by passage 6
(Fig. 2E, left), with no other mutations in the 3 UTR. On the
other hand, the remaining four TA clones showed an intact
6-nt insertion, accompanied by the same A2G mutation that
had been found in Rev5 and Rev6 (Fig. 2E, right). The S3
passage-6 stock had no additional changes in the nsp7-
through-nsp10 region of the genome. In accord with the ap-
parently strong selective pressure against the original Alb391
mutation, the growth of passage-2 stocks of the S1 through S3
isolates was greatly impaired relative to that of the wild type
for at least the ﬁrst 11 h of infection (Fig. 3A). Later, by 26 h
postinfection, S1 through S3 mutant titers appeared to ap-
proach that of the wild type, but this may have reﬂected the
emergence and overrunning of the cultures by revertants. By
passage 6, the small-plaque isolates replicated with kinetics
comparable to that of the wild type (Fig. 3B). As expected, the
growth kinetics for either the passage-2 or passage-10 stocks of
the L1 and L2 isolates were indistinguishable from the kinetics
for the wild type (data not shown).
Taken together, these results showed that the AACAAG
insertion mutation in pseudoknot loop 1 conferred the same
phenotype in the MHV-inf-1 genetic background as had been
seen in the initial Alb391 mutant (18). Furthermore, the anal-
yses of the Alb391 and rAlb391 revertants revealed the same
three classes of compensatory mutations, as summarized in
Fig. 4A. First, there were primary-site revertants, in which
there occurred loss of the entirety or a portion of the
AACAAG insertion, as in rAlb391 isolates L1 and L2 or in the
two types of footprint mutations in Rev1 and rAlb391 isolates
FIG. 2. Reconstruction of the Alb391 3 UTR insertion mutant by using the vaccinia virus-based reverse-genetics system for MHV. (A) Se-
quence of RT-PCR product from the 3 UTR of the initially recovered mutant, rAlb391. The position of the AACAAG insertion is denoted, and
mixed sequence downstream of the site of the insertion is boxed. (B) Plaques from passages 2 and 6 of three small-plaque isolates of rAlb391 (S1
to S3), compared with plaques from passages 2 and 10 of two large-plaque isolates of rAlb391 (L1 and L2) and a wild-type control. (C) Sequences
of RT-PCR products from the pseudoknot region (3 PK) of the 3 UTR and nsp9 from passages 2 and 6 of the S1 isolate; note that the nsp9
sequence is the negative sense. (D) Sequences of RT-PCR products from the pseudoknot region of the 3 UTR from passages 2 and 6 of the S2
isolate. (E) Sequences of the pseudoknot region and the downstream terminus (3 end) of the 3 UTR of representative TA clones from passage
6 of the S3 isolate. In C to E, the insertion or its remnant is boxed, and mutant nucleotides or their wild-type counterparts are circled.
FIG. 3. Growth kinetics for small-plaque isolates S1 to S3 of rAlb391, compared with a wild-type control. Cultures were inoculated with
passage-2 virus (A) or passage-6 virus (B) at a multiplicity of 1.0 PFU per cell. Data shown are a set from one representative of duplicate
experiments, which gave highly similar results.
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FIG. 4. Genetic cross talk between loop 1 of the 3 UTR pseudoknot and both gene 1a and the 3 end of the MHV genome. (A) Summary of
all types of reverting mutations from the original Alb391 mutant and the reconstructed mutant rAlb391. In the expansion of the region of the
genome encoding nsp7 to nsp10, main protease cleavage sites (8, 52) are denoted by open arrowheads and the ﬂanking amino acid residues are
indicated; alternate names for the MHV nsp7-to-nsp10 polypeptides are given in italics. In the expansions of regions of the 3 UTR, nucleotide
numbering is from the ﬁrst base at the 3 end of the genome, excluding poly(A). The original 6-nt insertion and remnants thereof are boxed;
mutated nucleotides are shown in bold. For each type of reverting mutation, the designations of independently obtained isolates are given in
parentheses. (B) Loci of the reverting mutations in nsp8. The schematic of the secondary structure of nsp8 of SARS-CoV corresponds to the crystal
structure reported by Zhai and coworkers (66). (C) Loci of the reverting mutations in nsp9. The schematic of the secondary structure of nsp9 of
SARS-CoV corresponds to the crystal structure reported by Egloff and coworkers (16), but it is also substantially the same as that reported by
Sutton and coworkers (56). Beneath the schematics in panels B and C are alignments for portions of nsp8 and nsp9 of coronaviruses spanning all
three phylogenetic groups. GenBank accession numbers for the sequences shown are as follows: MHVA, MHV strain A59, AY700211; BCVM,
bovine coronavirus strain Mebus, U00735; HKU1, human coronavirus strain HKU1, AY597011; SARS, SARS coronavirus strain Urbani,
AY278741; IBVB, infectious bronchitis virus strain Beaudette, M94356; 229E, human coronavirus strain 229E, AF304460; TGEV, transmissible
gastroenteritis virus strain Purdue, AJ271965; NL63, human coronavirus strain NL63, AY567487; and PEDV, porcine epidemic diarrhea virus
strain CV777, AF353511. MHV mutant Alb391 reverting mutations are boxed above each alignment. Filled circles mark residues that are identical
among at least seven of the nine sequences; open circles mark additional residues that are identical among all group 2 coronaviruses. Amino acid
numbering indicates the residue position in each processed replicase protein product.
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S2 and S3. Second, four independent reverting mutations,
Rev2 through Rev4 and rAlb391 isolate S1, mapped to three
loci in nsp8 and nsp9, altering moderately conserved residues
in these RNA-binding proteins. Finally, three independent re-
vertants, Rev5, Rev6, and rAlb391 isolate S3, each had a single
point mutation, changing the second residue of the 3 UTR
from A to G.
Interactions between the 3 UTR pseudoknot and replicase
gene products. Having shown that Alb391 and the recon-
structed rAlb391 mutants displayed the same phenotype, we
next examined the effects of reconstruction of two of the gene
1a candidate reverting mutations in both the presence and the
absence of the 3 UTR pseudoknot AACAAG insertion. For
this purpose, we chose the pair of nsp8 mutations from Rev2
(G12439A and C12452U) and the single nsp9 mutation from
Rev3 (U13017G) (Table 1). We analyzed three independent
isolates bearing the nsp8 mutations in the presence of the 3
UTR insertion (mutant rN8-Alb391) and two isolates bearing
the nsp8 mutations alone (mutant rN8). Likewise, two isolates
each were analyzed for the nsp9 mutation in the presence
(mutant rN9-Alb391) or the absence (mutant rN9) of the 3
UTR insertion (Fig. 5A). The rN8-Alb391 and rN9-Alb391
reconstructed revertants produced plaques that were only
slightly smaller than those of the wild type (Fig. 5B), demon-
strating that the nsp8 and nsp9 mutations were indeed respon-
sible for the suppression of the Alb391 phenotype in Rev2 and
Rev3. In general, the rN8-Alb391 and rN9-Alb391 mutants
were stable for up to 10 passages: the nsp8 or nsp9 mutation
remained unchanged, and the 6-nt insertion in the 3UTR was
retained. However, an exception to this trend was that for 2 of
the rN8-Alb391 isolates, the 6th residue of the 3 UTR inser-
tion (G) was gradually replaced by A over the course of 10
passages. An example of this replacement is shown in Fig. 5C.
This suggested that the nsp8 mutations could not optimally
compensate for the distortion of the 3 UTR pseudoknot and
that there was some residual selective pressure to mitigate the
effect of the AACAAG insertion. The suppression of the
Alb391 phenotype was also evident in the growth kinetics for
the rN8-Alb391 and rN9-Alb391 mutants, which closely resem-
bled the kinetics for the wild type at both passage 2 and pas-
sage 10 (Fig. 5D and E). At early times postinfection, both
mutants lagged slightly behind the wild type, but they were far
more robust than the passage-2 small-plaque isolates of
rAlb391 (Fig. 3).
Somewhat differently, plaques of the rN8 and rN9 mutants
were of fully wild-type size, indicating that the suppressor mu-
tations, in isolation, were not noticeably deleterious to the
virus (Fig. 5B). Sequence analysis conﬁrmed this inference.
The nsp8 and nsp9 mutations were stable over 10 passages, and
their presence did not select for any compensating changes
in the 3UTRs of these viruses. In addition, the growth kinetics
for the rN8 and rN9 mutants were highly similar to that for the
wild type (data not shown).
Collectively, these data demonstrated that the mutated rep-
licase gene products nsp8 and nsp9 are still functional in the
context of both the wild-type 3 UTR and the Alb391 3 UTR.
More importantly, it was directly proven, by reconstruction of
the Alb391 revertants Rev2 and Rev3, that the replicase gene
mutations mapping to nsp8 and nsp9 could compensate for the
markedly defective phenotype of Alb391, thus making it very
likely that the other two replicase gene mutations, found in
revertants Rev4 and rAlb391 isolate S1, were also genuine
suppressors of the severe growth defect mediated by the 6-nt
pseudoknot insertion. These data were indicative of an inter-
action of two replicase gene products, the RNA-binding
proteins nsp8 and nsp9, with an essential cis-acting RNA
pseudoknot located at the MHV 3 UTR.
Interactions between the pseudoknot and the 3 end of the
genome. The last class of revertant, the A2G mutation, was
very surprising, because the poly(A)-adjacent end of the ge-
nome was not obviously connected with the 3 UTR
pseudoknot in previous RNA structural analyses. To conﬁrm
whether A2G was truly a reverting mutation, we reconstructed
this base change in both the presence and absence of the 6-nt
pseudoknot insertion, using targeted RNA recombination. As
we had observed for the replicase gene mutations, the A2G
mutation, on its own, produced no detectable phenotype (as is
also the case for MHV strain 3 [47]). Similarly, recombinants
containing A2G together with the pseudoknot insertion
formed plaques that were only slightly smaller than plaques of
the wild type and were rescued at a much higher frequency
than Alb391 (data not shown). This proved conclusively that
the apparently simple A2G mutation could also suppress the
severe impairment caused by the AACAAG pseudoknot inser-
tion.
This result also provided the ﬁrst indication of the existence
of a direct interaction between pseudoknot loop 1 and the 3
genomic terminus. The folding of these regions that is shown in
Fig. 1 is derived from a study (38) in which a structure running
from nt 166 to the 3 end of the genome was predicted with the
mfold software (44, 68). At the outset, the chosen 5 upper
limit of nt 166 would have excluded potential interactions with
further-upstream portions of the 3 UTR, including the
pseudoknot. Indeed, we found that the lowest-free-energy
mfold predictions obtained for the distal end of the 3 UTR,
running instead from the start of pseudoknot loop 1 (nt 230)
through the 3 terminus, support a different RNA secondary
structure, which is shown in Fig. 6A. In this case, the 3-most
29 nt of the genome are seen to form two helices with further
upstream regions, one with pseudoknot loop 1 and one with
the segment immediately distal to pseudoknot stem 2. The
likelihood of this alternative structure is further supported by
its absolute phylogenetic conservation among all other known
group 2 coronaviruses, including the closely related BCoV
and human coronavirus OC43 as well as the more divergent
SARS-CoV, human coronavirus HKU1, and bat coronaviruses
HKU4, HKU5, and HKU9 (Fig. 6B). Thus, not only do mem-
bers of this coronavirus subfamily strictly maintain the 3 UTR
bulged stem-loop and pseudoknot but they also appear to be
required to preserve base pairing between loop 1 of the
pseudoknot and the 3 end of the genome. Similar loop 1–3-
end structures potentially occur in the genomes of the group 1
and group 3 coronaviruses, but as yet no experimental evidence
supports their existence.
To further test the loop 1–3-end interaction in MHV, we
designed a mutant harboring a large deletion within the 3
UTR that would retain the two putative helices of the new
model while eliminating the entire HVR and all of the adjacent
region that was formerly thought to base pair with the 3 end
of the genome. We had previously constructed a deletion mu-
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tant, the HVR2 mutant (Fig. 6A), in which 109 nt of the 3
UTR were excised with little consequence to the in vitro
growth of the virus (19). In the new mutant, designated the
HVR3 mutant, we created an even more extensive deletion,
of 141 nucleotides, in which all sequence between bases 29 and
171 was replaced by a tetraloop capping the helix downstream
of pseudoknot stem 2 (Fig. 6C). The HVR3 mutant was not
only viable but formed plaques that were 80% of the size of
wild-type plaques and were larger than those of the previously
characterized HVR2 virus. Moreover, the HVR3 mutant
exhibited growth kinetics comparable to those of the wild type
in single-step, high-multiplicity infections (Fig. 7A) and in mul-
ticycle, low-multiplicity infections (Fig. 7B). Under both con-
ditions, growth of the HVR3 mutant lagged behind that of
FIG. 5. Reconstruction of viruses harboring candidate gene 1a reverting mutations of Alb391. (A) Recombinants rN8-Alb391 and rN9-Alb391,
respectively, contain the nsp8 and nsp9 mutations from revertants Rev2 and Rev3 in the presence of the original Alb391 3 UTR insertion
mutation. Recombinants rN8 and rN9, respectively, contain the Rev2 and Rev3 mutations in the presence of the wild-type 3 UTR. (B) Plaques
from passages 2 and 10 of rN8-Alb391, rN9-Alb391, rN8, and rN9, compared with a wild-type control; the wild-type control plaques are the same
as those shown in Fig. 2. (C) Sequences of RT-PCR products from the pseudoknot region (3 PK) of the 3 UTR from passages 2, 7, and 10 of
one rN8-Alb391 isolate. The variable base of the AACAAG insertion is denoted. (D and E) Growth kinetics for reconstructed revertants
rN8-Alb391 and rN9-Alb391, compared with a wild-type control. Cultures were inoculated with passage-2 virus (D) or passage 10 virus (E) at a
multiplicity of 1.0 PFU per cell. Data shown for each mutant are a set from one representative of duplicate experiments, which gave highly similar
results. Also, duplicate sets from two additional independent isolates of rN8-Alb391 were essentially identical to the data shown.
FIG. 6. Interaction between loop 1 (L1) of the 3 UTR pseudoknot (PK) and the 3 end of the genome. (A) Reﬁnement of the complete
structure of the MHV 3 UTR, incorporating base pairing of the 3 end of the genome with both pseudoknot loop 1 and the region downstream
of pseudoknot stem 2 (S2); other abbreviations are the same as those used in Fig. 1. Arrows indicate points at which truncations were introduced
in the previously characterized HVR2 deletion mutant (19) and in a new mutant, the HVR3 mutant. (B) Phylogenetic conservation of the loop
1–3-end interaction among all group 2 coronaviruses. GenBank accession numbers for the sequences shown, other than those given in the legend
to Fig. 4, are as follows: HCoV-OC43, human coronavirus strain OC43, AF523847; and bat coronavirus (BatCoV) strains HKU4, HKU5, and
HKU9, respectively, EF065505, EF065509, and EF065513. (C) Detailed view of the complete 164-nt 3 UTR of the HVR3 mutant. Broken lines
represent alternative base pairings either for the bottom stem segment of the bulged stem-loop or for pseudoknot stem 1. Nucleotides of the
tetraloop introduced between positions 29 and 171 are circled. Nucleotide numbering is from the ﬁrst base at the 3 end of the genome, excluding
poly(A), and the N-gene stop codon is boxed.
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the wild type by 2 h but ultimately reached the same maximal
titers. Additionally, metabolic labeling of infected cells re-
vealed no signiﬁcant difference in gRNA or sgRNA synthesis
between the mutant and the wild type (Fig. 7C). Taken to-
gether, these results showed that the 3 genomic cis-acting
elements essential for MHV RNA synthesis are restricted to
two separate segments of the 3UTR, nucleotides 1 through 29
and nucleotides 171 through 301. Surprisingly, therefore, al-
most half of the 3 UTR is dispensable with respect to func-
tions required for growth in tissue culture.
DISCUSSION
All RNA viruses harbor cis-acting sequences and structures
in their genomes that are critical for replication. Within the
order Nidovirales, 3 cis-acting elements are currently best
characterized for the group 2 coronaviruses, in which an over-
lapping bulged stem-loop and pseudoknot in the 3 UTR have
been found to be essential for RNA synthesis (Fig. 1) (9, 42).
In the group 3 coronaviruses, a functionally essential stem-loop
is located at the upstream end of the 3 UTR (12), but the
status of different nearby candidate pseudoknots is unresolved
(20, 60). Conversely, the group 1 coronaviruses all contain a
very highly conserved pseudoknot, but a neighboring potential
counterpart of the bulged stem-loop (15) is not clearly identi-
ﬁable in every member of this group. Over a greater phyloge-
netic distance, in the arteriviruses, which have much smaller 3
UTRs, certain required cis-acting RNA structures have been
described that extend into the upstream N gene (5, 6, 59). It is
not obvious at present how closely analogous to coronavirus 3
elements these RNA structures will turn out to be, but the
genomes of members of the two virus families might be ex-
pected to interact in similar ways with their respective repli-
cases, which are highly homologous (21).
Interactions between the pseudoknot and the 3 end of the
genome. In the work presented here, we analyzed revertants of
a highly defective MHV mutant containing a particular inser-
tion, AACAAG, in loop 1 of the 3 UTR pseudoknot (sum-
marized in Fig. 4A). Our ﬁnding of six independent primary-
site reverting mutations that deleted or altered part or all of
the insertion conﬁrmed that the insertion was, in actuality, the
basis of the deleterious and unstable genotype of the original
mutant. More informative, however, were two groups of sec-
ond-site reverting mutations that were obtained in both the
original mutant, Alb391, which had been constructed by tar-
geted RNA recombination, and rAlb391, which was recon-
structed by vaccinia virus-based reverse genetics. These two
classes of suppressors mapped to distinct regions of the ge-
nome, thereby revealing two types of previously unsuspected
interactions. One class, independently isolated three times, was
represented by a single type of revertant, in which the second
3UTR residue upstream of the poly(A) tail was changed from
an A to a G. That this single base change could rescue the
Alb391 insertion mutant suggested that the 3 end of the ge-
nome must somehow communicate with loop 1 of the
pseudoknot. This conclusion led us to identify a longer-range
secondary structure in which the 3 end of the genome folds
into two helices through base pairing with pseudoknot loop 1
and with the region downstream of pseudoknot stem 2 (Fig. 6).
Additional evidence in support of this interaction came from
the following: (i) mfold-based structural predictions; (ii) the
total conservation of the interaction among all known group 2
coronaviruses (and possibly also among group 1 and group 3
coronaviruses); (iii) our construction of a mutant, the HVR3
mutant, which preserves this base pairing in a drastically min-
imized version of the 3 UTR; and (iv) our previous ﬁnding of
the lethality of a more extensive deletion in the 5-ward direc-
tion, HVR1, which suggested that at least some subset of
nucleotides 157 through 184 must be essential (19).
It is noteworthy that in our redeﬁned folding of the 3 end of
the genome, base A2 does not participate in a Watson-Crick
base pair (Fig. 6). Thus, it is not immediately obvious how the
A2G mutation relieves the problem caused by the AACAAG
insertion. We favor the explanation that the insertion in loop 1
forces an alternative folding of the pseudoknot-3 end interac-
FIG. 7. Replicational competence of the HVR3 mutant. Growth kinetics of the HVR3 mutant relative to that of the wild type at a high
multiplicity of infection (5.0 PFU per cell) (A) or a low multiplicity of infection (0.01 PFU per cell) (B). Open and solid symbols represent results
from two independent experiments. (C) RNA synthesis by the HVR3 mutant and the wild type. Infected or mock-infected 17Cl1 cells were
metabolically labeled with [33P]orthophosphate in the presence of actinomycin D, and RNA was isolated and electrophoretically separated in 1%
agarose containing formaldehyde as described in Materials and Methods.
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tion and that the A2G mutation destabilizes this alternative
structure, thereby allowing the wild-type fold to predominate.
This notion is supported by the fact that the A2G mutation, in
the context of an otherwise wild-type 3 UTR, has no detect-
able effect on the viral phenotype. A potentially related obser-
vation is that the mutation A2U, which is also neutral by itself,
is lethal in combination with the AACAAG insertion (data not
shown). Further mutational analysis will be needed to more
completely deﬁne the sequence and structural requirements
for the interaction between the extreme 3 end of the genome
and pseudoknot loop 1, as well as the region downstream of
pseudoknot stem 2.
The viability and nearly normal phenotype of the HVR3
mutant indicate that the minimal 3 cis-acting element re-
quired for MHV RNA synthesis is limited to no more than 160
nt of the 3 UTR. This means that nearly half of the 3 UTR,
bases 30 through 170, can be discarded without affecting the
basic mechanism of viral RNA synthesis. The deleted region in
the HVR3 mutant encompasses in vitro binding sites for a
number of host cell proteins, including PTB (27), hnRNP A1
(28), and a complex of mitochondrial aconitase and the chap-
erones mtHSP70, HSP60, and HSP40 (45, 46, 64, 65). It fol-
lows that these binding sites cannot be strictly required for
RNA synthesis, although they may play ancillary roles yet to be
deﬁned. Additionally, the region of the 3 UTR that was elim-
inated in the HVR3 mutant encompasses some RNA seg-
ments that were previously proposed to base pair with the 3
end of the genome (38) (Fig. 1). Our redeﬁned folding of the
3 UTR is also at variance with an alternative mfold-predicted
structure proposed for solely the 3-terminal 42 nt of the ge-
nome (31). Notably, our results prompt reconsideration of the
conclusions reached by a previous study, which mapped the
promoter for negative-strand RNA synthesis based on RNase
protection assays speciﬁc for the negative strand of a heterol-
ogous RNA that was connected to progressively decreasing
lengths of the MHV 3 UTR (37). That work concluded that
the promoter for negative-strand initiation constitutes the last
45 to 55 nt of the genome. However, it is now clear that the
essential sequence at the 3 end of the genome is no more than
29 nt, together with a poly(A) tail of at least 5 to 10 residues
(54). Moreover, we suggest that nt 1 to 29, on its own, is not
sufﬁcient for the initiation of negative-strand RNA synthesis,
but it likely acts in association with the pseudoknot. Such an
association would normally occur in cis, but in the promoter
mapping experiments (37), it must have occurred in trans,
between the heterologous RNA and the helper virus genome.
Interactions between the pseudoknot and gene 1a replicase
products. The second class of suppressor mutations found in
our genetic analysis was represented by four independently
isolated revertants that mapped to nsp8 or nsp9. These repli-
case components fall within a group of small proteins, nsp7
through nsp10 (each 10 to 22 kDa), that are encoded at the
downstream end of gene 1a (Fig. 4A) (8, 52). All four are
processed from the replicase polyproteins 1a and 1ab by the
main viral proteinase (nsp5), and they localize in discrete peri-
nuclear and cytoplasmic foci in infected cells as parts of the
membrane-associated replication complex (8, 10, 14, 22, 53).
Structural studies of each of the highly conserved SARS-
CoV homologs of nsp7 through nsp10 have recently been re-
ported. SARS-CoV nsp9, the crystal structure of which was
separately solved by two groups, has been shown to have non-
speciﬁc RNA-binding activity and a fold not previously seen in
any RNA-binding protein (16, 56). Nsp9 crystallizes in two
dimeric forms, and biophysical evidence has also been pre-
sented for the existence of an interaction between nsp9 and
nsp8 (56). A hexadecameric complex of SARS-CoV nsp8 and
nsp7 has been found to bind to double-stranded RNA. The
crystal structure of this complex (66), partially conﬁrmed by
the nuclear magnetic resonance solution structure of nsp7 (48),
is a hollow cylinder potentially able to encircle double-
stranded nucleic acid. Within this ring, which resembles a pro-
cessivity clamp, nsp8 monomers are folded in two different
conformations. Finally, there are two independently solved
structures of SARS-CoV nsp10, which reveal that it represents
a novel class of zinc ﬁnger protein which assembles into a
dodecameric complex having a weak afﬁnity for single- and
double-stranded RNA (32, 55). A classical MHV mutant,
tsLA6, which has the phenotype of shutoff of negative-strand
RNA synthesis at the nonpermissive temperature (3, 51), has
been mapped to nsp10 (50), and reverse-genetics analysis of
MHV nsp10 has also indicated that this protein plays an es-
sential role in viral RNA synthesis (14).
In the absence of further information, such as would be
provided by RNA cocrystals, we cannot yet use the abundance
of available structural data to draw strong conclusions about
the nature of the reverting mutations that suppress the Alb391
pseudoknot insertion mutation. Each of the four nsp8 or nsp9
reverting mutations introduces a more basic charge into its
respective molecule (Fig. 4B and C). The exact loci of the nsp8
mutations Q30R and D62N-T66I suggest that the mutations
are most likely to affect the packing between monomers at the
interface of the two nsp8 molecules in different conformations
in the asymmetric unit of the nsp7-nsp8 hexadecamer. Like-
wise, the nsp9 mutations D58G and N60K may affect intersub-
unit beta-sheet interactions that stabilize one type of dimer
formation (56). In both cases, these alterations could indirectly
inﬂuence the RNA-binding speciﬁcity or afﬁnity of nsp8 or
nsp9. Alternatively, the conformations of the nsp’s in a
polyprotein precursor or in an RNA-bound form may differ
from that revealed in the crystal structure, and thus, the in-
creased positive charge caused by the reverting mutations
might then directly enhance the afﬁnity of nsp8 or nsp9. We are
currently seeking in vitro biochemical data to corroborate
these ideas.
Very surprisingly, puriﬁed SARS-CoV nsp8 has recently
been found to possess RdRp activity, and it has been proposed
to function as a primase for the canonical coronavirus RdRp,
nsp12 (30). The in vitro enzymatic activity of SARS-CoV nsp8
has a dependence on manganese ion, and it exhibits a strong
preference for cytidine-rich RNA templates, synthesizing small
oligoribonucleotides of six or fewer residues. We have con-
ﬁrmed these same properties for the MHV homolog of nsp8
(S. J. Goebel and P. S. Masters, unpublished data). Imbert and
coworkers (30), who discovered the RdRp activity of nsp8,
have suggested that nsp8 could act at multiple points through-
out the genomic template, although it must be noted that the
characteristics of this enzyme may be substantially altered in
the company of nsp7, nsp9, nsp10, and the authentic viral RNA
substrate. In view of our suppressor results, we favor the idea
that nsp8 acts as a primase during the initiation of negative-
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strand synthesis. The interactions of the MHV 3 pseudoknot
loop 1 with the extreme 3 genomic terminus and with nsp8 and
nsp9 would position a template RNA secondary structure and
particular replicase components very close to the start site of
negative-strand RNA synthesis, which initiates with production
of a tract of oligo(U) some 9 to 26 residues into the poly(A) tail
(25). It is thus conceivable that the primase activity of nsp8 is
involved in the initiation of coronavirus negative-strand RNA
synthesis before the canonical RdRp activity, encoded by the
nsp12 gene, can resume negative-strand RNA synthesis by
elongating the nsp8-derived primer molecules. This idea is
supported by the fact that nsp12 can be targeted to replication
complexes when expressed in trans as a fusion protein with
green ﬂuorescent protein in MHV-infected cells; moreover,
nsp12 can be coimmunoprecipitated with nsp8 and nsp9 from
infected cell lysates (10).
Model for initiation of MHV negative-strand RNA synthe-
sis. Our suppressor results, integrated with the ﬁnding of pri-
mase activity of nsp8, thus lead us to propose a model for
initiation of MHV negative-strand RNA synthesis, which is
shown in Fig. 8. We speculate that the most stable conforma-
tion of the 3 UTR RNA is one in which the bulged stem-loop
is fully folded and the 3 end of the genome is annealed to
pseudoknot loop 1. These two folding alternatives would pre-
clude formation of stem 1 of the pseudoknot. The stem formed
by loop 1 and the 3 end of the genome is postulated to serve
as the site of assembly of a complex that includes at least nsp8
and nsp9 and probably also nsp7 and nsp10. These replicase
constituents may act as processed monomers, as shown. Alter-
natively, they may be part of a much larger nsp4-nsp11 pre-
cursor, which has been suggested to be the relevant species for
negative-strand RNA synthesis (50). Thus, the MHV 3
pseudoknot in conjunction with the 3 end of the genome may
constitute a cis-acting element that allows the speciﬁc recog-
nition of the gRNA as the template for initiation of minus-
strand RNA synthesis. Following substrate recognition, initia-
tion of negative-strand RNA synthesis by the nsp8 primase
complex leads to separation of the 3 end of the genome
from loop 1, thereby allowing formation of stem 1 of the
pseudoknot. Finally, the completely folded pseudoknot, in con-
junction with nsp8 and nsp9, then recruits the nsp12 RdRp and
the associated activities contained in nsp13 through nsp16, and
the resulting complex resumes the elongation of negative-
strand RNA.
We are aware that many mechanistic details of this process
remain to be elucidated. The proposed role of the MHV
pseudoknot in association with the 3 genomic end bears some
resemblance to the function of the 5 cis-acting element re-
quired for the assembly and positioning of the poliovirus
preinitiation RNA synthesis complex discussed above (4, 23).
FIG. 8. Hypothetical model of initiation of coronavirus negative-strand RNA synthesis. (A) At the outset, formation of the pseudoknot is
precluded by (i) closure of the bottom segment of the bulged stem-loop (BSL) and (ii) the interaction between pseudoknot (PK) loop 1 (L1) and
the 3 end of the genome. (B) The nsp8 primase, in conjunction with nsp7, nsp9, and nsp10, binds to the stem formed by loop 1 and the 3 end.
(C) Synthesis of the 5 end of negative-strand RNA by the nsp8 primase separates the 3 end of the genome from loop 1, thereby allowing the
pseudoknot to form (D). The nsp12 RdRp then binds to the pseudoknot, together with nsp13 (helicase), nsp14 (ExoN nuclease), nsp15 (NendoU
nuclease), and nsp16 (methyltransferase). (E) The nsp12 complex carries out elongation of the negative-strand primer. Not shown are possible
roles played by other nsp’s, the poly(A) binding protein, and the viral N protein.
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However, it remains to be established whether cis-acting ele-
ments located at the 5 end of the coronavirus genome also
participate in this process. Although the notion of genome
circularization has been previously invoked (29, 69), there is
currently no clear evidence that coronavirus 5 and 3 genomic
ends are bridged by viral or cellular proteins or by heretofore-
unidentiﬁed RNA-RNA interactions. Congruent with the anal-
ogy to the poliovirus system, however, it has been demon-
strated that the length of the poly(A) tail of coronavirus DI
RNA affects the efﬁciency of replication (54). Finally, the exact
composition of the coronavirus preinitiation complex remains
to be determined; the complex conceivably assembles cotrans-
lationally and involves more nsp’s than are pictured in our
model. We hope that our discovery of an interaction between
an essential 3 cis-acting pseudoknot, speciﬁc replicase gene
products, and the extreme 3 end of the MHV genome will
provide a starting point for further genetic, structural, and
biochemical analyses aimed at establishing a more detailed
understanding of the earliest events of coronavirus RNA syn-
thesis.
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This study demonstrates a unique and
crucial role of plasmacytoid dendritic cells
(pDCs) and pDC-derived type I interfer-
ons (IFNs) in the pathogenesis of mouse
coronavirus infection. pDCs controlled
the fast replicating mouse hepatitis virus
(MHV) through the immediate production
of type I IFNs. Recognition of MHV by
pDCs was mediated via TLR7 ensuring a
swift IFN- production following encoun-
ter with this cytopathic RNAvirus. Further-
more, the particular type I IFN response
pattern was not restricted to the murine
coronavirus, but was also found in infec-
tion with the highly cytopathic human
severe acute respiratory syndrome
(SARS) coronavirus. Taken together, our
results suggest that rapid production of
type I IFNs by pDCs is essential for the
control of potentially lethal coronavirus
infections. (Blood. 2007;109:1131-1137)
© 2007 by TheAmerican Society of Hematology
Introduction
Type I IFNs (IFN/) play a decisive role in shaping antiviral
immune responses.1 Signaling through the type I IFN receptor
leads to the activation of a particular set of genes, including protein
kinase R, and Mx proteins,2 which exert potent direct antiviral
effects. Other type I IFN–stimulated gene products, such as IFN-,
activate downstream elements of the innate immune system that
further promote rapid clearance of the viral pathogen.3 Although
almost all hematopoietic and nonhematopoietic cells are able to
produce IFN-/ after viral infections, plasmacytoid dendritic cells
(pDCs) are the major source of IFN-, both in humans and mice.4-7
One key feature of pDCs is the expression of receptors for
single-stranded RNAor DNAsuch as Toll-like receptor 7 (TLR7)8,9
and TLR9,10,11 respectively, which are essential to sense the viral
pathogen and to trigger the innate immune response. In mouse
cytomegalovirus (MCMV) infection, pDCs respond quickly and
generate the ﬁrst wave of IFN-.12,13 These previous studies have
clearly established an important role of pDCs for the rapid
production of type I IFNs in antiviral immune responses.
Coronaviruses are positive-stranded RNA viruses that are able
to infect a broad range of vertebrates and are associated mainly
with respiratory, enteric, and, sometimes, systemic diseases.14
Human coronaviruses are known to generally cause mild upper-
respiratory tract disease, including common cold, and occasional
enteric infections. The emergence of a novel coronavirus (COV)
causing severe acute respiratory syndrome (SARS) highlighted the
potential of coronaviruses to seriously impact on human health.14
Phylogenetic analyses revealed a close relationship of SARS-CoV
to group II coronaviruses,15 which is prototyped by the mouse
hepatitis virus (MHV). MHV causes enteritis, pneumonia, hepati-
tis, and demyelinating encephalomyelitis in mice and is one of the
most extensively studied coronaviruses in vitro and in vivo.16 Both
SARS-CoV and MHV have a similar genome organization and
share common mechanisms and enzymes involved in genome
expression.15,17 Because of these similarities, it is conceivable that
the pathogenesis of and the immune response against systemic
MHV infection in mice recapitulates some of the essential features
of SARS-CoV infection.
The immune response against MHV is characterized by a strong
cytotoxic T-cell (CTL) response that mediates initial clearance of
the virus,18,19 whereas neutralizing antibodies appear to be required
to prevent re-emergence of the persistent infection.20,21 In contrast
to the well-characterized defense mechanisms of the adaptive
immune response against MHV, the innate immune response has
not been sufﬁciently characterized. Similarly, the importance of
innate immune mechanisms triggered by SARS-CoV has remained
enigmatic. Several studies have shown that peripheral-blood mono-
nuclear cells (PBMCs) from SARS-CoV–infected individuals
produce high amounts of inﬂammatory cytokines and chemokines,
but not type I IFNs.22-24 Furthermore, in vitro studies have shown
that neither macrophages nor monocyte-derived DCs respond to
SARS-CoV infection with signiﬁcant IFN- production.25-28 None-
theless, there is clear evidence that treatment with recombinant
IFN- or IFN- can inhibit SARS-CoV replication in vitro,29-31
and, most importantly, diminish the severity of SARS-CoV infec-
tion in vivo.32,33 Thus, although the antiviral activity of type I IFNs
in SARS-CoV infections has been clearly demonstrated, it remains
to be established whether a signiﬁcant production of type I IFNs
can be achieved upon coronavirus infection and how this may
impact on virus replication and disease. The present study ad-
dressed this issue and identiﬁed pDCs as the major source of type I
IFNs during cytopathic coronaviral replication. We show further-
more that pDCs are crucial during the initial phase of MHV
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infection since widespread replication in various nonlymphoid
organs, and the associated organ damage, is efﬁciently kept in
check through pDC-derived type I IFNs.
Materials and methods
Mice and viruses
C57BL/6 (B6) mice were obtained from Charles River Laboratories
(Sulzfeld, Germany). TLR3/,34 TLR7/,35 TLR3//TLR7/, and
MyD88/36 mice were bred in the Institut fu¨r Labortierkunde (University
of Zurich, Switzerland). 129Sv and type I IFN receptor–deﬁcient (IF-
NAR/) mice37 were obtained from the Institut fu¨r Labortierkunde
(University of Zurich) and bred in our facilities. All mice were maintained
in individually ventilated cages and were used between 6 and 9 weeks of
age. All animal experiments were performed in accordance with the Swiss
federal legislation on animal protection.
MHVA59 was generated from a molecularly cloned cDNA38 based on
the Albany strain of MHVA59 and propagated on L929 cells. SARS-CoV
(isolate Frankfurt-1) was kindly provided by Stephan Becker (University of
Marburg, Germany) and propagated on Vero cells. The Newcastle disease
virus (NDV; strain H53) stock was grown on 10-day-old embryonated
chicken eggs.
Isolation of dendritic cells and ﬂow cytometry
Murine conventional DCs (cDCs) and pDCs were obtained from spleens of
129Sv or IFNAR/ mice following digestion with collagenase type II (Invitro-
gen, Basel, Switzerland) for 20 minutes at 37°C. Cells were resuspended in PBS
supplemented with 2% FCS and 2 mM EDTA and overlaid on 20% Optiprep
density gradient medium (Sigma-Aldrich, Basel, Switzerland). After centrifuga-
tion at 700g for 15minutes, low-density cellswere depleted ofCD3 andCD19
cells using DYNAL magnetic beads according to the instructions of the
manufacturer (Invitrogen). The DC-enriched preparations were stained with
–PDCA-1,-CD11b, and-CD11c, and the distinct pDC and cDC populations
were sorted using a ﬂuorescence-activated cell sorter (FACS) ARIA (BD
Biosciences,Allschwil, Switzerland). Purity of both cell preparations was always
more than 98%.
Murine bone marrow–derived cDCs or pDCs were generated by 6 to 7
days of culture with either granulocyte-monocyte colony-stimulating factor
(GM-CSF)–containing supernatant from the cell line X63-GM-CSF (kindly
provided by Dr Antonius Rolink, University of Basel) or Flt3-L (R&D
systems, Oxford, United Kingdom) at 20 ng/mL, respectively. Bone
marrow–derived cDCs were further puriﬁed using Optiprep density gradi-
ent centrifugation. Bone marrow–derived pDCs were puriﬁed using the
mouse pDC isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
adapted for the isolation of in vitro–derived pDCs by adding CD11b-biotin
to the negative selection cocktail.
Human circulating conventional dendritic cells and plasmacytoid
dendritic cells were isolated from healthy donors (obtained from the Blood
Bank of the University Hospital Freiburg, Germany). PBMCs were
obtained by Ficoll-Hypaque density gradient centrifugation. Human pDCs
or cDCs were further puriﬁed by magnetic sorting with human plasmacy-
toid dendritic-cell isolation kit (Miltenyi Biotec) or human BDCA-1
dendritic-cell isolation kit (Miltenyi Biotec), respectively. Purity of both
cell preparation was for all donors more than 90% (with B cells being the
major contaminating cell type).
Cells were analyzed with a FACSCalibur ﬂow cytometer using CellQuest
software (BD Biosciences). The antibodies CD123 biotin, CD11c PE, B220
APC, and CD11b FITC were purchased from Biolegend (San Diego, CA);
and CD303 (BDCA-2)–PE, mPDCA-1-FITC, mPDCA-1-PE, and CD11c-
APC, from Miltenyi Biotec.
Virus infections, determination of virus titers,
and liver enzyme values
Human pDCs and cDCs were exposed to SARS-CoV or NDV for 1 hour at
37°C, washed, and plated at 1.5 	 105/mL. Murine pDCs or cDCs were
infected with MHV A59 for 1 hour at 37°C, washed, and plated at 1 to
2 	 105/mL. CpG ODN 2216 was used as a positive control for IFN-
production as described previously.39
Mice were injected intraperitoneally with 5 pfu MHVA59 and killed at
the indicated time points. For depletion of pDCs, mice were injected
intraperitoneally with 0.5 mg –mPDCA-1 (Miltenyi Biotec) or 0.5 mg rat
IgG2b isotype control antibody (Biolegend) 12 hours prior to infection.
Organs were stored at70°C until further analysis. Blood was incubated at
room temperature to coagulate and was then centrifuged, and serum was
used for alanine 2-oxoglutarate-aminotransferase (ALT) measurements
using a Hitachi 747 autoanalyzer (Tokyo, Japan). Virus titers in organs were
determined from frozen organs after weighing and homogenization. Viral
titers were determined by standard plaque assay using L929 cells.
Histology, IFN- ELISA, and reverse-transcription–polymerase
chain reaction (RT-PCR)
Organs were ﬁxed in 4% formalin and embedded in parafﬁn. Sections were
stained with hematoxylin and eosin. Human IFN- and mouse IFN-
concentration in cell-culture supernatants or serum was measured by
enzyme-linked immunosorbent assay (ELISA; PBL Biomedical Laborato-
ries, Piscataway, NJ) according to the manufacturer’s instructions. To detect
cellular and viral mRNAs in pDCs and cDCs, total cellular RNA was
prepared using the RNeasy Kit for murine DCs (Qiagen, Basel, Switzer-
land) or Trifast (PEQLAB, Erlangen, Germany) for human DCs. Reverse
transcription was done with 100 ng total RNA using the SuperScript II
First-Strand Synthesis System (Invitrogen). PCR was performed with Red
Taq Polymerase (Sigma-Aldrich) using standard protocols. The following
primers were used for ampliﬁcation: mIFN- forward, 5-CATCAACTATA-
AGCAGCTCCA-3;mIFN- reverse, 5TTCAAGTGGAGAGCAGTTGAG3;
mIFN-4 forward, 5CTGGTCAGCCTGTTCTCTAGGATGT3; mIFN-4
reverse, 5TCAGAGGAGGTTCCTGCATCAC3; mIFN- total forward,
5ATGGCTAGRCTC TGTGCTTTCCT3; mIFN- total reverse, 5AG-
GGCTCTCCAGAYTTCTGCTCTG3; mGAPDH forward, 5CATCAA-
GAAGGTGGTGAAGC3; mGAPDH reverse, 5CCTGTTGCTGTAGCCG-
TATT3; MHV-N forward, 5TCCTGGTTTTCTGGCATTACCCAG3; and
MHV-N reverse, 5CTGAGGCAATACCGTGCCGGGCGC3. Primer se-
quences for amplifying human IFN- were 5CATACCCACG-
GAGAAAGGACATT3 and 5TGATAGACATTAGCCAGGAGGTTC3;
for ISG56, 5AAGTGGACCCTGAAAACCCTGAAT3 and 5TGC-
CCTTTTGTAGCCTCCTTGAT3; for MxA, 5GTTGTTTCCGAAGTG-
GACATCGCAAAA3 and 5CGGGCATCTGGTCACGAT3; and for
-actin, 5GCCGGTCGCAATGGAAGAAGA3 and 5CATGGCCGG-
GGTGTTGAAGGTC3. SARS-CoV transcription was detected by using
primer 5TGTCTAGCAGCAATAGCGCGAGGGC3 for reverse tran-
scription and primers 5GGAAAAGCCAACCAACCTCGATCTCT3 and
5AAGTTGTAGCACGGTGGCAGC3 for PCR.
Results
Rapid type I IFN production in pDCs following MHV infection
In a ﬁrst set of experiments, the type I IFN response of pDCs and
cDCs following encounter with MHV was determined. To this end,
CD11clowB220PDCA-1 pDCs and CD11cB220 cDCs were
sorted from spleen-cell suspensions (Figure 1A-B) and infected
with MHV. Primary pDCs but not cDCs responded with rapid and
signiﬁcant production of IFN- (Figure 1C). The high IFN-
production in pDCs correlated well with the control of the virus
infection (Figure 1D). Bone marrow–derived pDCs and cDCs that
were differentiated with the growth factors Flt-3L or GM-CSF,
respectively, responded in a similar pattern: rapid and high
production of IFN- in pDCs but not in cDCs (Figure 2A-B) and a
good containment of the viral replication by pDCs (Figure 2C-D).
A time-course RT-PCR analysis conﬁrmed that the type I IFN
response is considerably slower in cDCs (Figure 2E) compared
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with pDCs (Figure 2F). Furthermore, pDCs lacking the type I IFN
receptor were more susceptible to MHV infection than wild-type
pDCs (Figure 2G-H). It appears therefore that pDCs are well
equipped to respond efﬁciently against MHV with a strong type I
IFN production, and that this early reaction exerts a potent
protective effect against this cytopathic virus.
Type I IFN signaling is essential for the control of MHV infection
Signaling through the type I IFN receptor (IFNAR) is essential for
the control of several viral infections.40 To assess the importance of
type I IFN signaling in the course of an MHV infection, IFNAR-
deﬁcient (IFNAR/) and 129Sv wild-type (wt) mice were infected
with 5 pfu MHV. MHV infection in IFNAR/ mice was lethal
within only 48 hours, while wt mice survived without showing
signs of MHV infection–associated clinical disease (Figure 3A).
Furthermore, IFNAR/ but not wt mice showed rapidly rising
liver enzyme values in serum (Figure 3B) and an acute hemor-
rhagic liver disease with massive hepatocyte necrosis (Figure 3C).
The detailed time-course analysis of viral spread in both IFNAR/
and wt mice indicated that a functional type I IFN system is essential to
restrict the initial viral replication to the spleen and to prevent spread to
nonhematopoietic organs such as the lung and the central nervous
system (Figure 3D). Notably, the replication of the strongly hepato-
tropic MHV in the liver was efﬁciently reduced in the presence of a
functional type I IFN system with a reduction of viral titers of 3 to 4
orders of magnitude (Figure 3D). It is thus most likely that the
rapidly lethal disease in IFNAR/ mice following MHV infection
is a consequence of an insufﬁcient initial control of the cytopathic
virus in the spleen and the subsequent high-level replication in
various organs, eventually causing an acute multiorgan failure.
Early control of MHV infection through pDC-derived type I IFN
The above results suggested that the initial control of MHV
requires an efﬁcient type I IFN response that might be generated by
pDCs. It has been shown that pDCs use the TLR pathway rather
than the RNAhelicase RIG-I for recognition of RNAviruses and to
produce type I IFN.41 Therefore, to investigate how pDCs recog-
nize MHV, bone marrow–derived pDCs from TLR3-deﬁcient
(TLR3/), TLR3 and TLR7 double knock-out (TLR3//
TLR7/), TLR7-deﬁcient (TLR7/), and MyD88-deﬁcient
(MyD88/) mice were infected with a low dose of MHV
(moi 
 1), and the production of IFN- was determined after 24
Figure 2. Type I IFN production and viral replication in MHV-infected in vitro–derived cDCs and pDCs. Infection of bone marrow–derived pDCs and cDCs with MHV.
(A,C) IFN- and virus titers in tissue culture supernatants were determined at the indicated times after MHV infection (moi 
 1), or (B,D) at 24 hours after MHV infection with
different moi as indicated. Values in panels A-D represent means  SD from triplicate measurements. Experiments in panels A-D were repeated 3 times with comparable
results. Expression of IFN-, IP-10, IFN-4, IFN- , GAPDH, or MHV nucleoprotein (MHV-N) mRNAs was determined by RT-PCR using total RNA from bone marrow–derived
(E) cDCs or (F) pDCs infected with MHV (moi 
 1) or treated with PBS (mock). (G-H) Viral replication in MHV-infected wt or IFNAR/ pDCs. Cells were infected with MHVA59
at (G) an moi of 1 or (H) at different moi as indicated. Virus titers in culture supernatants were determined by plaque assay at (G) the indicated times after MHV A59 infection
(moi 
 1) or (H) 24 hours after MHV infection. (A-D,G-H) Data represent mean values SD pooled from 2 experiments. Statistical analysis was performed using Student t test
(*P  .05; **P  .01, ***P .001).
Figure 1. Type I IFN production and viral replication in MHV-infected splenic
cDCs and pDCs. (A) Flow cytometric analysis of splenic cDCs (CD11cPDCA-1)
and (B) splenic pDCs CD11clow B220 PDCA-1 before FACS sorting. Gates for
sorting are indicated. (C) Primary FACS-puriﬁed murine splenic cDCs or pDCs were
infected with MHV at a multiplicity of infection (moi) of 1. IFN- secretion to culture
supernatants was determined by ELISAat the indicated time points. (D) Virus titers in
culture supernatants were determined by plaque assay. (C-D) Data represent mean
values  SD pooled from 2 experiments. Statistical analysis was performed using
Student t test (*P  .05; **P  .01).
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hours. Comparable amounts of IFN- were found in the superna-
tants of TLR3/ and wt control pDC cultures (Figure 4). In
contrast, pDCs from neither TLR7/, TLR3//TLR7/, nor
MyD88/ mice responded with a signiﬁcant IFN- production to
MHV infection (Figure 4), clearly indicating that MHV recognition
by pDCs is triggered exclusively via the TLR7/MyD88 pathway.
To assess the importance of pDC-derived IFN- during MHV
infection in vivo, pDCs were ablated by the depleting antibody
PDCA-1. As described for MCMV by Krug et al,11 pDC depletion
was accompanied by severely diminished IFN- levels in serum
followingMHV infection (Figure 5A). The treatment with PDCA-1
resulted in an 80% depletion of splenic pDCs for roughly 48 hours
(not shown). Although profound effects on viral titers could be
observed (Figure 5B), transient pDC depletion did not lead to
lethality following low-dose MHV infection. Nevertheless, initial
viral titers in spleens were more than 1000-fold increased in
pDC-depleted compared with isotype control antibody–treated
mice, and virus was found in other organs such as lung or brain
(Figure 5B). To exclude complement-mediated global changes in
the status of the immune system, we evaluated the effect of natural
killer (NK) cell depletion via anti–asialo GM1. Depletion of NK
cells altered neither initial viral replication and distribution nor
IFN- levels in serum (not shown). Finally, ALT values in
PDCA-1–depleted mice were elevated compared with control
animals (Figure 5C), indicating signiﬁcant liver damage. These
data clearly show that pDCs are important for the early control of
MHV infection and that the lack of pDCs not only leads to
uncontrolled viral replication and spread to different organs but
also impacts on the severity of viral disease.
Rapid induction of type I IFNs in pDCs following
SARS-CoV infection
In order to relate the above ﬁndings to a pathogenic and
potentially lethal human coronavirus infection, the ability of
pDCs to produce IFN- following encounter with SARS-CoV
was assessed. Primary pDCs and cDCs were isolated from
peripheral blood of healthy donors and infected with SARS-
CoV. As described for monocyte-derived cDCs,28 primary cDCs
from healthy donors were also not able to produce signiﬁcant
amounts of IFN- (Figure 6A) and did not up-regulate tran-
scripts of IFN- and IFN-stimulated genes such as ISG56 and
MxA, located downstream in the type I IFN signaling pathway
Figure 3. Impact of type I IFN signaling duringMHV infection. IFNAR/ or wt mice were injected intraperitoneally with 5 pfu MHVA59. (A) Health status of IFNAR/ and wt
mice was monitored twice daily after infection (n 
 6). (B) ALT values were measured at the indicated time points after infection. (C) Liver pathology in IFNAR/ and wt mice
before or 48 hours after MHV A59 infection. Hematoxylin-eosin staining of 4% formaldehyde-ﬁxed sections. Images were acquired using a Leica DMRA microscope (Leica,
Heerbrugg, Switzerland) with a 25	/0.65 NAobjective (total magniﬁcation,	162). Images were processed usingAdobe Photoshop (Adobe Systems, San Jose, CA). (D) Viral
titers in liver, spleen, brain, and lung of MHV A59–infected IFNAR/ or wt mice were determined at different time points after infection. Results represent the mean of
6 individual mice per time point. Solid horizontal lines in panel D represent limit of detection in the plaque assay. Data in panels B and D represent means  SD from
2 experiments with a total of 3 or 6 mice evaluated per time point. Statistical analysis was performed using Student t test (ns, P  .05; *P  .05; **P  .01; ***P  .001).
Figure 4. pDCs sense MHV via TLR7. Bone marrow–derived pDCs from TLR3/,
TLR7/, TLR3//TLR7/, MyD88/, or wt mice were infected with MHV A59
(moi 
 1) or treated with CpG oligonucleotides. IFN- in tissue culture supernatants
was determined 24 hours after infection by ELISA. Bars represent means with values
from individual mice shown as open circles. Statistical analysis was performed using
Student t test (**P  .01).
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(Figure 6B). In contrast and as expected from the MHV
experiments, pDCs were able to produce IFN- early after
SARS-CoV infection (Figure 6A). Furthermore, IFN-, MxA,
or ISG56 mRNA expression was found in infected pDCs (Figure
6C). Based on this evidence and the unsuccessful efforts from
previous studies to determine a cell type that produces IFN- in
response to SARS-CoV,25-28 we conclude that pDCs are most
likely the major source of type I IFNs in SARS-CoV infection.
Discussion
In this study, we demonstrate a unique and essential function for type I
IFN–producing pDCs: protection against the rapidly replicating and
cytopathic murine coronavirus. Furthermore, we have identiﬁed pDCs
as the source of type I IFN in response to humanSARS-CoV, suggesting
an important biologic role of pDC-derived type I IFNs for highly
pathogenic coronavirus infections in humans.
The expression of TLRs that recognize viral products such as
CpG oligonucleotides10,11 or ssRNA9 has indicated that pDCs
represent a highly specialized cell type that provides an early
response against a particular set of infectious agents. A further
characteristic of pDCs is the constitutively high expression of IFN
regulatory factor-7 (IRF-7),42,43 which directly stimulates IFN-
expression, independently of an IFN-–mediated feedback loop.44
In MHV infection, this efﬁcient direct IFN- induction appears to
be not only essential for the regulation of the magnitude of the type
I IFN response, but also important to restrict replication of this
cytopathic virus within pDCs. Furthermore, pDC-derived type I
IFNs provide an efﬁcient “bystander” protection because the initial
replication of MHV in lymphoid organs such as the spleen was
diminished in the presence of pDCs. Notably, in MHV infection
this function of pDCs cannot be substituted by other cells as
demonstrated, for example, in MCMV infection.11,13 It is possible
that viruses that replicate rather slowly, such as MCMV, cannot
reveal the full importance of pDCs in the control of cytopathic
viruses that require a swift type I IFN response.
Within secondary lymphoid organs, macrophages are the major
target cell of MHV,14 and recent studies indicate that cDCs can also be
readily infected with MHV A5945 or MHV JHM.46 It is important to
note that the uncontrolled infection of cDCs byMHV is detrimental for
the initiation of the adaptive antiviral immune response.46 The rapid
control of MHV through pDC-derived type I IFN in secondary
lymphoid organs ensures therefore the subsequent induction of adaptive
immune responses. Likewise, a recent study bySmit et al47 indicates that
pDCs not only help to minimize respiratory syncytial virus infection–
associated immunopathologic damage, but also facilitate establishment
of antiviral T-cell responses in the lung.
Fatal SARS-CoV infection–associated clinical disease is charac-
terized by respiratory insufﬁciency and, eventually, respiratory
failure. One of the reasons for this outcome may be the down-
regulation of angiotensin-converting enzyme 2 by the viral spike
protein leading to an exacerbation of the pulmonary damage.48
Furthermore, it is well-documented that SARS-CoV infects macro-
phages and lymphocytes leading to a pronounced atrophy of
lymphoid organs in those patients who succumbed to the infec-
tion.49 Extrapolating from the data obtained in the MHVmodel, it is
likely that these patients may have suffered from an insufﬁcient
early control of the virus within lymphoid organs that eventually
led to the unrestrained replication in the respiratory tract. Because
SARS-CoV is sensitive to type I IFNs both in vitro30,31,50 and in
vivo,32,33 an early control of SARS-CoV by type I IFNs might have
been a decisive advantage for those patients who have survived the
Figure 5. Effect of antibody-mediated pDC depletion on MHV infection. 129Sv
mice were treated with rat IgG2b (wt isotype control) or –mPDCA-1 (wt PDCA-1)
and infected intraperitoneally with 5 pfu MHV A59 (n 
 6). IFNAR/ mice (n 
 3)
were used to demonstrate uncontrolled MHV spread in the absence of a functional
IFN system. (A) IFN- concentration in serum (means  SD), (B) viral titers
(means  SD) in liver, spleen, brain, and lung, and (C) serum ALT values (means 
SD) were assessed at 48 hours after infection. (A-C) Statistical analysis was
performed using Student t test (*P  .05; **P  .01).
Figure 6. Infection of human pDCs and cDCs with SARS-CoV. Primary pDCs or cDCs were isolated from peripheral blood of healthy donors and infected with either
SARS-CoV (moi 
 1) or Newcastle disease virus (NDV) as positive control (moi 
 5), or were left uninfected (mock). (A) IFN- in culture supernatants was determined at the
indicated time points. Results represent pooled data (means  SD) using pDCs and cDCs from 4 healthy donors. Statistical analysis was performed using Student t test
(*P  .05). (B-C) Expression of IFN-, ISG56, MxA, SARS-CoV N protein, and -actin mRNAs in (B) cDCs and (C) pDCs was determined by RT-PCR. One representative
result of 4 individual experiments is shown.
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infection. It is noteworthy that neither macrophages, cDCs, ﬁbro-
blasts, nor lung epithelial cells28 are able to mount a signiﬁcant type
I IFN response against SARS-CoV. The lack of a signiﬁcant type I
IFN response in PBMCs of SARS-CoV–infected patients23 might
be due to a partial inhibition of type I IFN signaling not only in
nonlymphoid cells,51,52 but also in pDCs. Therefore, the potential of
the various SARS-CoV nonstructural proteins that might inhibit
and/or modulate type I IFN responses in pDCs and other important
target cells should be addressed in future studies.
Taken together, the results of this study provide insight into the
immunopathogenesis of coronavirus-associated diseases by demonstrat-
ing an exclusive role of pDC-derived type I IFNs for initial viral control.
Triggering of this pathway, for example via speciﬁc TLR agonists,
might open new avenues for the treatment of coronavirus infections.
Indeed, stimulation of TLR3 at the vaginal mucosa can protect mice
against herpes simplex virus-2 challenge via the mucosal route.53 In a
clinical setting, systemic administration of a TLR7 agonist elicited
potent antiviral effects against hepatitis C virus with signiﬁcant reduc-
tion of plasma viremia.54 Our data provide the rationale that such a
treatment approachmight help to reduce initial viral load and eventually
favor a mild course of SARS.
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Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational
design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-
structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog,
strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed
using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew
normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was
restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes
efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting
cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells,
was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and
protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation
strategy provides a paradigm for the development of highly efficient coronavirus vaccines.
Citation: Zu¨st R, Cervantes-Barraga´n L, Kuri T, Blakqori G, Weber F, et al. (2007) Coronavirus non-structural protein 1 is a major pathogenicity factor: Implications for the
rational design of coronavirus vaccines. PLoS Pathog 3(8): e109. doi:10.1371/journal.ppat.0030109
Introduction
Coronaviruses are vertebrate pathogens mainly associated
with respiratory and enteric diseases [1]. They can cause
severe diseases in livestock animals and lead thereby to high
economic losses. In humans, coronavirus infections manifest
usually as mild respiratory tract disease (common cold) that
may cause more severe symptoms in elderly or immune-
compromised individuals [2,3]. In 2002–2003, the appearance
of severe acute respiratory syndrome (SARS), caused by a
formerly unknown coronavirus (SARS-CoV), exempliﬁed the
potential of coronaviruses to seriously affect human health
[4–7]. The frequent detection of SARS-like coronaviruses in
horseshoe bats (Rhinolophus sp.) and the broad range of
mammalian hosts that are susceptible to SARS-CoV infection
may facilitate a potential reintroduction into the human
population [8]. Therefore, the development of efﬁcacious
coronavirus vaccines is of high medical and veterinary
importance.
Effective vaccines controlling virus spread and disease are
available for a number of infections, such as smallpox,
poliomyelitis, measles, mumps, rubella, inﬂuenza, hepatitis
A, and hepatitis B [9,10]. Some of these vaccines consist of
virus subunits or inactivated virus preparations that mainly
induce the production of pathogen-speciﬁc antibodies. In
contrast, live attenuated vaccines consist of replication-
competent viruses that induce broad cellular and humoral
immune responses without causing disease [10]. The most
prominent live attenuated vaccines are vaccinia virus [11],
poliovirus [12], and yellow fever virus (YF-17D) [13]. Despite
their documented efﬁcacy, it is still not fully understood why
and how successful vaccines work [10,14]. However, recent
concepts in immunology provide a link between innate and
adaptive immune responses and suggest that the quality,
quantity, and longevity of adaptive immune responses is
determined very early after infection or vaccination [14]. Of
major importance are professional antigen-presenting cells
(pAPCs) such as dendritic cells (DCs) and macrophages, which
play a major role in (i) sensing pathogen-associated molecular
patterns, (ii) inducing innate immune responses, and (iii)
shaping the upcoming adaptive immune response. Efﬁcient
live attenuated vaccines should therefore not only lack
signiﬁcant pathogenicity, but should also deliver antigens to
pAPCs and activate the innate immune system.
Notably, the majority of currently available attenuated
vaccines have been derived empirically. Given the recent
proceedings in the areas of virus reverse genetics and virus–
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host interactions, the time should be ripe for more rational
approaches in vaccine development. An attractive strategy is
to target virally encoded pathogenicity factors, such as
interferon (IFN) antagonists [15], to attenuate virulence while
retaining immunogenicity. This concept has been proposed
for the generation of live attenuated inﬂuenza virus vaccines
encoding altered NS1 proteins [16,17].
Our rudimentary knowledge on coronavirus-encoded
pathogenicity factors is reﬂected by the fact that only a few
putative coronaviral pathogenicity factors have been identi-
ﬁed and that functional analyses are still limited to the
description of in vitro effects [18–20]. For a number of
reasons, the non-structural protein 1 (nsp1) is of particular
interest in this context. First, coronaviruses are positive-
stranded RNA viruses, and the replicase-encoded nsps are
expressed from the viral genomic RNA immediately after
virus entry by translation of two large polyproteins. nsp1 is
encoded at the 59 end of the replicase gene and is therefore
the ﬁrst mature viral protein expressed in the host cell
cytoplasm [21]. Second, a recent in vitro study suggests that
SARS-CoV nsp1 may be associated with host cell mRNA
degradation and may counteract innate immune responses
[18]. Finally, nsp1 is encoded by all mammalian coronaviruses
known to date (coronavirus groups 1, 2a, and 2b) [22], and
recent structural data on SARS-CoV (group 2b) nsp1 suggest
functional similarities to mouse hepatitis virus (MHV; group
2a) nsp1 [23].
Using a reverse genetics approach, we show here that nsp1
is a major pathogenicity factor. Recombinant MHV mutants
encoding a deletion in nsp1 replicated as efﬁciently as wild-
type virus in cell culture, but displayed an unprecedented
degree of attenuation in mice. Interference with the type I
IFN system appears to be the dominant mode of action of
murine coronavirus nsp1. Vaccination with the nsp1 mutant
virus elicited efﬁcient memory cytotoxic T cell responses and
protected against homologous and heterologous virus in-
fections. Our study will pave the way for the generation of
novel coronavirus vaccines based on modiﬁed coronavirus
replicase genes.
Results
Transient nsp1 Expression Affects Cellular Gene
Expression
We assessed several replicase-encoded nsps of MHV (strain
A59), SARS-CoV, and human coronavirus 229E (HCoV-229E)
for their ability to interfere with host cell gene expression.
Using transient gene expression studies, we found that MHV-
A59, SARS-CoV, and HCoV-229E nsp1 signiﬁcantly reduced
luciferase reporter gene expression under the control of IFN-
b, IFN-stimulated response element (ISRE), and SV40
promoters (Figure 1). This is consistent with a recent report
suggesting that SARS-CoV nsp1 induces general host cell
mRNA degradation [18]. Nevertheless, it should be noted that
the nsp1-mediated reduction in reporter protein expression
appeared more robust for ISRE and SV40 than for IFN-b
promoter-driven expression. Our data also support the
hypothesis that MHV encodes a SARS-CoV nsp1 homolog
that displays the same function [23]. Although comparative
sequence analyses suggest that nsp1 of group 2a/2b corona-
viruses (e.g., MHV and SARS-CoV, respectively) and the nsp1
of group 1 coronaviruses (e.g., HCoV-229E) may belong to
different protein families [22,23], we also observed reduced
reporter gene expression in HCoV-229E nsp1-transfected
cells (Figure 1). Whether functional similarities may exist
between nsp1 molecules encoded by coronaviruses of differ-
ent phylogenetic lineages remains to be established in future
studies. Importantly, our data also revealed that reporter
gene expression from all tested promoters was not affected
when C-terminally truncated MHV nsp1 molecules were
tested (Figure 1).
Generation of the MHV nsp1 Deletion Mutant
To assess the role of nsp1 in the context of virus
replication, we constructed a recombinant MHV encoding a
truncated nsp1 protein using our reverse genetic system [24].
Based on the results shown in Figure 1, we decided to delete
MHV nucleotides (nts) 829–927 (99 nts). In the resulting
mutant virus, MHV-nsp1D99, the replicase gene start codon,
the translational reading frame, and the residues required for
proteolytic release of nsp1 from the replicase polyprotein
were maintained (Figure 2A). As reported for a set of similar
MHV mutants by Brockway et al. [25], viral growth and peak
titers of MHV-nsp1D99 in murine 17Clone1 cells were
indistinguishable from that of wild-type virus (Figure 2B).
To assess the stability of the recombinant MHV-nsp1D99, we
analyzed the nsp1-coding region by RT-PCR sequencing after
seven passages in tissue culture and no nucleotide changes
were detected (unpublished data).
Infection of conventional DCs (cDCs) is an early and crucial
event for the generation of protective antiviral immunity
[26]. MHV productively infects cDCs and activates plasmacy-
toid DCs (pDCs) to generate a ﬁrst wave of protective type I
IFN [27]. To assess whether the mutant MHV-nsp1D99 has
retained the ability to infect pAPCs, peritoneal macrophages
(Figure 2C), bone marrow–derived CD11cþ cDCs (Figure 2D),
and splenic, FACS-sorted CD11cþ cDCs (Figure 2E) were
exposed to MHV-nsp1D99 and wild-type control virus.
Similar to replication kinetics in cell lines (Figure 2B),
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Author Summary
Prevention of viral diseases by vaccination aims for controlled
induction of protective immune responses against viral pathogens.
Live viral vaccines consist of attenuated, replication-competent
viruses that are believed to be superior in the induction of broad
immune responses, including cell-mediated immunity. The recent
proceedings in the area of virus reverse genetics allows for the
rational design of recombinant vaccines by targeting, i.e.,
inactivating, viral pathogenicity factors. For coronaviruses, a major
pathogenicity factor has now been identified. The effect of
coronavirus non-structural protein 1 on pathogenicity has been
analyzed in a murine model of coronavirus infection. By deleting a
part of this protein, a recombinant virus has been generated that is
greatly attenuated in vivo, while retaining immunogenicity. In
particular, the mutant virus retained the ability to replicate in
professional antigen-presenting cells and fulfilled an important
requirement of a promising vaccine candidate: the induction of a
protective long-lasting, antigen-specific cellular immune response.
This study has implications for the rational design of live
attenuated coronavirus vaccines aimed at preventing coronavirus-
induced diseases of veterinary and medical importance, including
the potentially lethal severe acute respiratory syndrome.
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MHV-nsp1D99 showed no signiﬁcant growth defect in
primary pAPCs (Figure 2C–2E), indicating that the deletion
of nsp1 did not alter the pronounced tropism of MHV for
cDCs and macrophages.
Deletion in nsp1 Confers Strong Attenuation In Vivo
MHV-A59 is a hepatotropic and neurotropic virus that can
cause acute hepatitis and encephalitis. Following intraper-
itoneal infection, virus replication is ﬁrst detectable in spleen
and liver, followed by virus spread to other organs, including
the central nervous system. Hepatitis is the ﬁrst clinical sign
of disease, accompanied by elevated liver enzyme values in
serum. Associated with the appearance of cytotoxic T cell
responses approximately at day 5 post infection (p.i.), virus
titers usually decline and are no longer detectable after day 7
p.i. Infections with a high dose ( 5 3 106 pfu, intra-
peritoneal) may, however, occasionally result in fatality. To
evaluate the importance of nsp1 for virus replication and
viral pathogenicity in vivo, C57BL/6 mice were infected
intraperitoneally with different doses of wild-type MHV or
MHV-nsp1D99. Both viruses replicated in the spleen, whereby
MHV-nsp1D99 titers were consistently lower than wild-type
virus titers (Figure 3A). Furthermore, MHV-nsp1D99 was
rapidly cleared and not detectable after day 2 p.i. (Figure 3A).
Wild-type, but not mutant virus, was detectable in the liver at
low and intermediate dose (50 pfu and 5,000 pfu, respectively)
(Figure 3B). When high virus doses (53 106 pfu) were applied,
MHV-nsp1D99 eventually reached the liver at day 2 p.i., but
was not detectable at later time points (Figure 3B). MHV-
nsp1D99 was not detectable in other non-hematopoietic
organs, such as lung and central nervous system (unpublished
data). Mice infected with wild-type virus showed acute liver
disease with elevated liver enzyme values in serum. Further-
more, after high dose infection with wild-type virus (53 106
pfu), a signiﬁcant weight loss that peaked at approximately
10%–15% at day 4 was observed (Figure 3E). In contrast, mice
infected with the nsp1 mutant virus remained healthy after
low, intermediate, or high dose infections. Even at the highest
dose applied (53 106 pfu), MHV-nsp1D99–infected mice did
not lose weight (Figure 3E), and no elevated liver enzyme
values were detected in the serum (Figure 3C). This
observation correlated well with the absence of hepatocyte
necrosis and parenchymal inﬂammation following MHV-
nsp1D99 infection (Figure 3D). To further assess the
attenuation of the MHV nsp1 mutant, mice were infected
intracranially with 200 pfu and 20,000 pfu of MHV-nsp1D99
Figure 1. Coronavirus nsp1 Reduces Cellular Gene Expression
(A–C) 293 cells were transfected with p125-Luc reporter plasmid ([A, B];
IFN-b promoter), or p(9–27)4tkD(39)lucter reporter plasmid ([C]; ISRE
promoter) and cotransfected with pRL-SV40, and an expression plasmid
encoding a full-length coronavirus nsp1 of HCoV-229E, SARS-CoV, or
MHV, or a truncated MHV nsp1 variant (49-nt or 100-nt 39 end
truncations, respectively). At 8 h post transfection, cells were treated
with viral single-stranded RNA containing 59 triphosphates (A) or
poly(I:C) (B), or IFN-a (C), and 16 h later luciferase activity was measured.
Firefly luciferase activity was normalized to renilla luciferase activity and
indicated as fold induction compared to that of control plasmid-
transfected cells (control).
(D) 293 cells were transfected with pRL-SV40 and the indicated
expression plasmids. Then, 24 h post transfection, luciferase activity
was measured. Results represent the mean 6 SD of at least four
independent experiments. Statistical analysis was performed using
paired Student’s t-test (***, p , 0.001; **, p , 0.01; *, p , 0.05; n.s.
(not significant), p . 0.05).
doi:10.1371/journal.ppat.0030109.g001
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or MHV-A59. All mice infected with 200 pfu survived for at
least 30 d (unpublished data). Mice infected with 20,000 pfu of
MHV-A59 succumbed to the infection, whereas mice infected
with 20,000 pfu of MHV-nsp1D99 survived and showed no
signs of clinical disease (Figure 3F). Collectively, these data
demonstrate that MHV-nsp1D99 is strongly attenuated in
vivo, but has retained the ability to replicate in secondary
lymphoid organs, such as the spleen.
Effect of nsp1 on Innate Immune Responses
We have previously shown that pDCs are the major source
of IFN-a in the early stages of MHV infection and that type I
IFN responses in CD11cþ cDCs are only weakly triggered by
MHV [27]. To test whether nsp1 has an inﬂuence on the
induction of IFN-a, we infected both cDCs and pDCs with
MHV-nsp1D99 or wild-type MHV. Both viruses elicited rapid
and high IFN-a production in Flt3-L–differentiated bone
marrow–derived pDCs (Figure 4A) and FACS-sorted primary
pDCs (Figure 4B). Furthermore, both wild-type and mutant
MHV elicited only a late and weak IFN-a production in cDCs
(Figure 4A and 4B). These results suggest that nsp1 does not
affect the induction of type I IFN. To assess a potential
impact of nsp1 on type I IFN signaling and antiviral effector
mechanisms in target cells that efﬁciently support MHV
replication, cDCs and macrophages were pretreated with
different dosages of IFN-a and infected with MHV-nsp1D99
or wild-type MHV. In cDCs, IFN-a treatment had a
comparable effect on the replication of both MHV-nsp1D99
and the wild-type control virus (Figure 4C). However,
replication of MHV-nsp1D99 was, in a dose-dependent
manner, more vulnerable to IFN-a treatment in macrophages
(Figure 4D), suggesting that nsp1 might counteract IFN
signaling and/or the antiviral activities of IFN-induced
effector proteins.
Indeed, in vivo experiments in type I IFN receptor-
deﬁcient (IFNAR/) mice [28] strongly support this inter-
pretation. Infection of IFNAR/ mice with wild-type MHV
led to high titers in all tested organs (Figure 5A–5D),
indicating that signals transmitted via the IFNAR are crucial
for preventing uncontrolled spread of the virus [27].
Surprisingly, the severe attenuation of MHV-nsp1D99 in
wild-type 129Sv mice was not present in IFNAR/ mice
(Figure 5A–5D). Replication of MHV-nsp1D99 in IFNAR/
mice was largely restored and virus titers reached about 104–
105 pfu/g tissue in several organs after only 36 h (ﬁgures 5A–
5D). These data strongly suggest that nsp1 has a pivotal role in
counteracting type I IFN host responses and provide an
explanation for the rapid clearance of MHV-nsp1D99 in wild-
type mice. Interestingly, liver damage, measured as alanine 2-
oxoglutarate-aminotransferase (ALT) levels in serum, was not
yet detectable in MHV-nsp1D99–infected IFNAR/ mice at
36 h p.i. (Figure 5E). At 72 h p.i., MHV-nsp1D99 reached titers
and ALT levels in IFNAR/ mice comparable to those
observed in MHV-A59–infected IFNAR/ mice at 36 h p.i.,
demonstrating that MHV-nsp1D99 replication in IFNAR/ is,
although with slower kinetics, restored.
Immunization with the MHV nsp1 Deletion Mutant
Protects against Homologous and Heterologous Virus
Challenge
The phenotypic analysis of MHV-nsp1D99 revealed a
number of features that are advantageous for live attenuated
vaccines. MHV-nsp1D99 grows to high titers in cell culture,
infects pAPCs, replicates almost exclusively in secondary
lymphoid organs, and is strongly attenuated in vivo. To assess
the potential of MHV-nsp1D99 as an attenuated live vaccine,
we replaced accessory gene 4 of MHV-nsp1D99 and wild-type
MHV-A59 by a gene encoding a fusion protein of the
immunodominant cytotoxic T lymphocyte (CTL) epitope
(KAVYNFATC) of the lymphocytic choriomeningitis virus
(LCMV) and the enhanced green ﬂuorescent protein (GP33-
GFP) [29]. The resulting recombinant viruses, MHV-nsp1D99-
GP33-GFP and MHV-GP33-GFP, were used to infect C57BL/6
mice with different doses (50 and 5,000 pfu, intraperitoneal),
and CD8þ T cell responses were assessed using ﬂow
cytometry–based detection of intracellular IFN-c following
antigen-speciﬁc short-term in vitro restimulation. As shown
in Figure 6A and 6B, infection with as few as 50 pfu of MHV-
nsp1D99-GP33-GFP elicited strong CD8þ T cell responses
Figure 2. Construction and In Vitro Analysis of MHV-nsp1D99
(A) Schematic representation of the MHV-nsp1D99 genome organization.
The replicase gene, comprised of open reading frames (ORFs) 1a and 1b,
is depicted together with viral proteinase cleavage sites (arrowheads)
that separate nsps 1–16. The 99-nt deletion within the nsp1-coding
region of MHV-nsp1D99 is illustrated on the nucleotide and amino acid
level. The arrowhead (far right) indicates the nsp1/nsp2 cleavage site.
(B–E) Growth kinetics of MHV-nsp1D99– or MHV-A59–infected (MOI¼ 1)
murine 17Clone1 cells (B), inflammatory macrophages (C), bone marrow–
derived cDCs (D), and ex vivo cDCs (E). Experiments (C–E) were
performed with cells obtained from C57BL/6 mice. Results represent
the mean 6SD of two independent experiments. Statistical analysis was
performed using Student’s t-test (n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g002
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against both the H2-Db–restricted GP33 and the H2-Kb–
restricted MHV S598 epitope.
To assess the level of protection against homologous MHV-
A59 challenge, groups of C57BL/6 mice were immunized
(5,000 pfu) with MHV-nsp1D99-GP33-GFP, MHV-GP33-GFP,
or treated with PBS. Sixteen days p.i., mice were challenged
with wild-type MHV (5,000 pfu) and viral titers were
determined 5 d post challenge infection. Viral titers were
below the limit of detection in MHV-nsp1D99-GP33-GFP–
and MHV-GP33-GFP–immunized mice (Figure 6C). Together
with the absence of elevated liver enzyme values in immu-
nized mice (Figure 6D), these data indicate that vaccination
with the attenuated MHV nsp1 mutant provides complete
protection against homologous virus challenge.
The reverse genetic system facilitates incorporation of
antigens derived from other infectious organisms. In order to
determine whether the attenuated nsp1 mutant virus could
confer protection against heterologous virus infection, MHV-
nsp1D99-GP33-GFP–immunized C57BL/6 mice were chal-
lenged after 4 wk with LCMV (200 pfu, intravenous). LCMV
titers in spleens were signiﬁcantly reduced both in mice
vaccinated with MHV-GP33-GFP and the attenuated MHV-
nsp1D99-GP33-GFP virus (Figure 6E). Remarkably, only 50
pfu of nsp1 mutant virus expressing the GP33 epitope were
Figure 3. MHV-nsp1D99 Is Highly Attenuated In Vivo
C57BL/6 mice were infected intraperitoneally (A–E) or intracranially (F) with the indicated dose of MHV-nsp1D99 or MHV-A59. Viral titers in spleens (A)
and livers (B) were determined at the indicated time points p.i. (C) Liver enzyme ALT values were measured at the indicated time points p.i. (D)
Hematoxylin and eosin–stained liver sections of C57BL/6 mice infected intraperitoneally with 5,000 pfu of MHV-nsp1D99 or MHV-A59. The time points
of analysis p.i. are indicated. (E) Groups of four mice were either untreated (mock) or infected (intraperitoneally) with 53 106 pfu of MHV-nsp1D99 or
MHV-A59. The weight was monitored daily.  denotes death of mice. (F) Survival of mice (three per group) infected with 20,000 pfu (intracranially) of
MHV-nsp1D99 or MHV-A59. Mice with severe weight loss (.25%) were defined as moribund and sacrificed. Results (A–C) and (E) represent the mean
6SD of at least three individual mice per time point.
doi:10.1371/journal.ppat.0030109.g003
PLoS Pathogens | www.plospathogens.org August 2007 | Volume 3 | Issue 8 | e109
Generation of Attenuated Coronavirus Vaccines
67
sufﬁcient to achieve a reduction of LCMV titers by more than
4 orders of magnitude, indicating that nsp1 mutant viruses
are well-suited to serve as attenuated recombinant virus
vectors against heterologous viral infections.
Discussion
The rational design of live attenuated viral vaccines is
greatly facilitated by the identiﬁcation and targeting of
pathogenicity factors. This study demonstrates an unprece-
dented level of attenuation of a murine coronavirus through
a 99-nt deletion in nsp1. The nsp1 mutant virus was rapidly
cleared in mice and did not induce clinical signs of disease in
immunocompetent mice. These ﬁndings in the murine
coronavirus model demonstrate that nsp1 is a major
pathogenicity factor. In a stepwise approach, we made use
of these observations to provide a blueprint for the
construction and evaluation of live attenuated coronavirus
vaccines encoding a truncated nsp1.
The presented results indicate that nsp1 plays a crucial role
in the MHV life cycle by interfering with host innate immune
responses. In accordance with the recent report by Kamitani
et al. [18], we observed reduced reporter gene expression in
transient nsp1 expression studies. The suggestion that SARS-
CoV nsp1 may play a role in SARS-CoV pathogenesis by
promoting host cell mRNA degradation [18] has now received
support through the analysis of a coronavirus nsp1 mutant in
a murine model. The MHV nsp1 mutant phenotype led us to
conclude that nsp1 mainly affects IFN signaling pathways or
other downstream events. The inﬂuence on IFN-a induction
appears to be limited. These conclusions are based on several
observations. First, the analysis of IFN-a production by pDCs
and cDCs revealed no signiﬁcant differences between wild-
type and nsp1 mutant virus infections. Second, treatment of
macrophages with IFN-a revealed a more efﬁcient reduction
of MHV-nsp1D99 replication compared with that of wild-type
MHV. Finally, and most strikingly, IFNAR/mice were highly
permissive for the mutant virus, and organ titers almost
reached those of wild-type MHV-infected IFNAR/ mice.
Nevertheless, it should be noted that the nsp1 mutant virus
replication was still slightly delayed in IFNAR/ mice.
Therefore, further studies are required to deﬁne molecular
target(s) and the precise function(s) of coronavirus nsp1.
Likewise, further studies are required to assess the impact of
other coronaviral gene products on coronavirus pathogenic-
ity. Recent reports indicate that coronaviruses most likely
express a number of proteins, such as MHV and SARS-CoV
nucleocapsid proteins, and SARS-CoV ORF3b and ORF6
proteins, that may interact with innate immune responses
[19,20]. Also, the coronavirus replicase gene may harbor
additional functions that play a role in virus–host interac-
tions. It has been shown that the MHV and SARS-CoV nsp2
proteins [30], and the highly conserved ADP-ribose-199-
monophosphatase activity [31] encoded in nsp3, are both
dispensable for virus replication in tissue culture, and that a
single point mutation in the MHV nsp14 confers a strong
attenuation of MHV in mice [32]. Clearly, the murine model,
with MHV as a natural mouse pathogen, will be highly
Figure 4. Effect of nsp1 on IFN-a Production and Signaling
C57BL/6 bone marrow–derived (A) or primary (B) splenic cDCs or pDCs were infected with MHV-nsp1D99 or MHV-A59 at an MOI of 1. IFN-a secreted
into cell culture supernatants was determined by ELISA at the indicated time points. Bone marrow–derived cDCs (C) or inflammatory macrophages (D)
from 129Sv mice were treated with 50, 200, 500, or 1,000 U IFN-a/100,000 cells or left untreated. Four hours later, cells were infected with MHV-nsp1D99
or MHV-A59 (MOI¼ 1). Twelve hours p.i., virus titers in culture supernatants were determined by plaque assay. Representative experiments out of two
(A, B) or the mean6 SD of two independent experiments (C, D) are shown. Statistical analysis was performed using Student’s t-test (***, p, 0.001; **, p
, 0.01; *, p , 0.05; n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g004
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advantageous in the examination of this issue, because it
allows the use of well-characterized inbred and transgenic
mice in combination with well-established immunological
techniques required to assess the full range of coronavirus–
host interactions.
The most remarkable ﬁnding of this study is the level of
attenuation of the nsp1 mutant virus and its restricted
replication in secondary lymphoid organs. It may well be that
other coronaviral nsp1 molecules exert similar functions as
the MHV nsp1. The coronavirus nsp1 has been suggested as a
group-speciﬁc marker to differentiate group 1 coronaviruses
from group 2a/2b coronaviruses [22]. Our transient nsp1
expression data indeed support the notion that SARS-CoV
and MHV may encode evolutionarily conserved nsp1 homo-
logs [22,23]. Nevertheless, further in vivo studies are required
to determine whether the group 2b SARS-CoV nsp1 is indeed
a functional equivalent to the structurally highly conserved
group 2a nsp1 molecules encoded by MHV, bovine corona-
virus, porcine hemagglutinating encephalomyocarditis virus,
HCoV-OC43, and HCoV-HKU1. Likewise, it will be impor-
tant to clarify in vivo, whether, despite the apparent lack of
any sequence homology [22,23], the nsp1 of group 1
coronaviruses (e.g., HCoV-229E) may represent a functional
correlate to the nsp1 of group 2a/2b coronaviruses. Recent
progress in the establishment of suitable mouse models for
SARS-CoV [33–35] and HCoV-229E [36] will enable research-
ers to address these questions in future studies.
The chosen attenuation strategy has resulted in the
generation of a recombinant virus that fulﬁlls important
criteria of a live virus vaccine candidate: (i) growth to high
titers in cell culture, which facilitates vaccine production, and
(ii) generation of immunological memory that mediates
efﬁcient protection against viral challenge. One important
aspect of protection against viral infections is the induction
of speciﬁc cytotoxic T cells by pAPCs in secondary lymphoid
organs [14]. A number of coronaviruses, such as MHV, HCoV-
229E, feline infectious peritonitis virus, and SARS-CoV, have
been shown to infect pAPCs and to replicate in the secondary
lymphoid organs [27,37–42]. Because of their pronounced
tropism for pAPCs and the induction of strong CTL
responses, we propose that coronaviruses represent promis-
ing vectors for the expression of heterologous antigens. The
identiﬁcation of nsp1 as a major pathogenicity factor will
signiﬁcantly increase the safety of coronavirus-based vectors
Figure 5. nsp1-Dependent Attenuation Is Reversed in IFNAR/ Mice
IFNAR/ or wild-type 129Sv mice were infected intraperitoneally with 500 pfu of MHV-nsp1D99 or MHV-A59. At the indicated time points p.i., viral titers
in livers (A), spleens (B), peritoneal exudates cells (PEC) (C), and lungs (D) were determined. (E) ALT values in serum were measured at the indicated time
points p.i. Horizontal lines represent means with values from individual mice shown as open squares (MHV-A59) or filled triangles (MHV-nsp1D99) from
two experiments with a total of three to six mice. Statistical analysis was performed using Student’s t-test (***, p , 0.001; *, p , 0.05; n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g005
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[43]. For example, the deletion of accessory genes (i.e., not
replicase or structural genes) has been described for some
coronaviruses to confer attenuation in the natural host [44–
46], and the deletion of the structural envelope protein E has
resulted in the development of replication-competent, but
propagation-deﬁcient, coronavirus vectors [47,48]. Now, with
an accompanying deletion in the nsp1-coding sequence, such
vectors would be considered ‘‘recombination proof’’, because
the deletions are located at opposite genomic regions (i.e.,
within the replicase gene at the 59 end and within the
structural gene region at the 39 end of the coronavirus
genome), which make the reconstruction of virulent viruses
by recombination unlikely. We therefore suggest that
accessory gene, E gene, and partial nsp1 gene deletions will
result in particular safe vectors with the potential to express
multiple heterologous antigens [40,49].
Taken together, our results describe a novel type of
coronavirus vaccines based on impaired function of a
replicase gene product. We expect that our approach is
applicable to most, if not all, mammalian coronaviruses and
that it will enable the development of long-desired live
attenuated vaccines for important coronavirus-induced dis-
eases in humans and animals.
Materials and Methods
Mice and cells. C57BL/6 mice were obtained from Charles River
Laboratories (http://www.criver.com/). 129Sv and type I IFN receptor-
deﬁcient mice (IFNAR/) [28] were obtained from the Institut fu¨r
Labortierkunde (University of Zu¨rich) and bred in our facilities. All
mice were maintained in individually ventilated cages and were used
between 6 and 9 wk of age. All animal experiments were performed in
accordance with the Swiss Federal legislation on animal protection.
MC57, BHK-21, L929, 293, and CV-1 cells were purchased from the
European Collection of Cell Cultures (http://www.ecacc.org.uk/).
D980R cells were a kind gift from G. L. Smith, Imperial College,
London, United Kingdom. 17Clone1 cells were a kind gift from S. G.
Sawicki, Medical University of Ohio, Toledo, Ohio, United States.
BHK-MHV-N cells, expressing the MHV-A59 nucleocapsid protein
under the control of the TET/ON system (Clontech, http://www.
clontech.com/), have been described previously [24]. All cells were
Figure 6. MHV-nsp1D99-GP33-GFP and MHV-GP33-GFP Elicit Strong CTL Responses and Protect Mice from Homologous and Heterologous Viral
Infections
(A, B) Groups of three C57BL/6 mice were immunized with the indicated doses of MHV-nsp1D99-GP33-GFP or MHV-GP33-GFP. IFN-c–secreting CD8þ
splenocytes were determined 8 d post immunization following short-term in vitro restimulation with GP33 or S598 peptide. Values in (A) represent the
percentage6SD of IFN-c–secreting CD8þ T cells restimulated with GP33 or S598; values in (B) represent the absolute numbers of CD8þ IFN-cþ cells6SD
(n¼ 6 for GP33, n ¼ 3 for S598). Pooled data from two separate experiments are shown.
(C, D) Groups of three mice were immunized with 5,000 pfu of the indicated virus or PBS-treated and 14 d later challenged with 5,000 pfu of wild-type
MHV-A59. At 5 d post challenge, viral titers in liver and spleen were determined (C) and ALT values (D) were measured. Data in graphs (C) and (D)
represent means 6SD from one representative experiment. n.d., not detected.
(E) Protection against heterologous viral challenge. Groups of four C57BL/6 mice have been immunized with the indicated viral doses or PBS-treated
and 28 d later challenged with 200 pfu of LCMV-WE. At 4 d post challenge, viral titers in spleens were determined. Data in graph represent means 6SD
from two pooled experiments with a total of eight mice per group. Statistical analysis was performed using Student’s t-test (***, p , 0.001; **, p, 0.01;
n.s., p . 0.05).
doi:10.1371/journal.ppat.0030109.g006
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maintained in minimal essential medium supplemented with fetal
bovine serum (5%–10%) and antibiotics.
Isolation of dendritic cells and macrophages, ﬂow cytometry, and
antibodies. Murine cDCs and pDCs were obtained from spleens of
C57BL/6, 129Sv, or IFNAR/ mice following digestion with collage-
nase type II (Gibco-BRL, http://www.invitrogen.com/) for 20 min at 37
8C. Cells were resuspended in PBS supplemented with 2% FCS and 2
mM EDTA and overlaid on 20% Optiprep density gradient medium
(Sigma-Aldrich, http://www.sigmaaldrich.com/). After centrifugation
at 700g for 15 min, low density cells were depleted of CD3- and CD19-
positive cells using DYNAL magnetic beads according to the
instructions of the manufacturer (Invitrogen, http://www.invitrogen.
com/). The DC-enriched preparations were stained with a-PDCA-1, a-
CD11b, and a-CD11c, and the distinct pDC and cDC populations
were sorted using a FACS ARIA (BD Biosciences, http://www.
bdbiosciences.com/) sorter. Purity of both cell preparations was
always .98%.
Murine bone marrow–derived cDCs or pDCs were generated by 6
to 7 d of culture with either granulocyte-monocyte colony stimulating
factor (GM-CSF)-containing supernatant from the cell line X63-GM-
CSF (kindly provided by Antonius Rolink, University of Basel, Basel,
Switzerland) or Flt3-L (R&D Systems, http://www.rndsystems.com/) at
20 ng/ml, respectively. Bone marrow–derived cDCs were further
puriﬁed using Optiprep density gradient centrifugation. Bone
marrow–derived pDCs were puriﬁed using the mouse pDC isolation
kit (Miltenyi Biotec, http://www.miltenyibiotec.com/) adapted for the
isolation of in vitro–derived pDCs by adding CD11b-biotin to the
negative selection cocktail. Antibodies used in this study were
purchased from BioLegend (http://www.biolegend.com/): CD11c-PE,
B220-APC, CD11b-FITC; or from Miltenyi Biotec: mPDCA-1-FITC
and CD11c-APC. Thioglycolate-elicited macrophages were collected
from the peritoneal cavity of mice and cultured at 4 3 105 cells per
well in DMEM (with 10% FCS, L-glutamine, and penicillin/strepto-
mycin) for 2 h at 37 8C. Non-adherent cells were removed by washing
with cold PBS.
Recombinant DNA and viruses. LCMV-WE strain, originally
obtained from F. Lehmann-Grube (Hamburg, Germany), was propa-
gated on L929 cells. MHV A59 was generated from a molecularly
cloned cDNA [24] based on the Albany strain of MHV A59.
Coronaviruses and recombinant vaccinia viruses were propagated,
titrated, and puriﬁed as described [24,50,51].
Mutant vaccinia viruses are based on the recombinant vaccina
virus vMHV-inf-1 (containing the full-length MHV-A59 cDNA) and
were generated using our reverse genetic system as described
previously [24]. Brieﬂy, the gene to be mutated was replaced by the
Escherichia coli guanine-phosphoribosyltransferase (GPT) gene
through vaccinia virus–mediated homologous recombination, and
GPT-positive clones were selected by three rounds of plaque
puriﬁcation on CV-1 cells in the presence of xanthine, hypoxanthine,
and mycophenolic acid (GPT-positive selection) [50]. In a second
round, the GPT gene was replaced by the mutated gene, and GPT-
negative clones, containing the mutated gene, were selected by three
rounds of plaque puriﬁcation on D980R cells in the presence of 6-
thioguanine (GPT-negative seletion) [50]. To construct the recombi-
nant vaccinia virus encoding the MHV-nsp1D99 cDNA, the 59 end of
the MHV-A59 cDNA in vMHV-inf-1 was replaced by GPT using the
plasmid pRec4. This plasmid is based on pGPT-1 [50], and the GPT
gene is ﬂanked to its left by 500 bp of vaccinia DNA and to its right by
an internal ribosomal entry sequence (IRES) followed by MHV-A59
nts 952-1315. The GPT-negative selection was carried out using the
plasmid pRec15. This plasmid contains 250 bp of vaccinia DNA
followed by the bacteriophage T7 RNA polymerase promoter, one G
nucleotide, and MHV nts 1–828 linked to MHV nts 928-1315. To
replace the MHV-A59 accessory gene 4 in vMHV-inf-1 and vMHV-
nsp1D99 by a gene encoding a fusion protein of EGFP and the LCMV-
derived CTL epitope KAVYNFATC (GP33-GFP) [29], the plasmid
pRec8 was used for recombination with vaccinia viruses vMHV-inf-1
and vMHV-nsp1D99 . This plasmid contains the GPT gene ﬂanked to
its left by MHV nts 27500–27967 and to its right by MHV nts 28265–
28700. GPT-negative selection was carried out using the plasmid
pRec9. This plasmid contains MHV bp 27500–27967, the GP33-GFP
gene, and MHV nts 28265–28700. Further cloning details, plasmid
maps, and sequences are available from the authors upon request.
Recombinant coronaviruses were rescued from cloned cDNA using
puriﬁed vaccinia virus DNA as template for the in vitro transcription
of recombinant MHV genomes as described [51].
The ﬁreﬂy luciferase (FF-Luc) plasmid for monitoring IFN-b
promoter activation (p125-Luc) was kindly provided by Takashi
Fujita, Tokyo Metropolitan Institute of Medical Science, Japan [52].
The FF-Luc reporter construct for monitoring ISRE activation (p(9–
27)4tkD(39)lucter) [53] was kindly provided by Stephen Goodbourn,
St. George’s Hospital Medical School, London, UK. The control
plasmid pRL-SV40 (Promega, http://www.promega.com/) encodes the
renilla luciferase (REN-Luc) gene under control of the constitutive
SV40 promoter. The negative control expression plasmid contained
the reading frame of the N-terminus of the human MxA protein. To
construct the coronavirus nsp1 expression plasmids, the MHV nts 1–
951 (pMHV-nsp1), MHV nts 1–902 (pMHV-D49), MHV nts 1–851
(pMHV-D100), HCoV-229E nts 293–625 (pHCoV-229E-nsp1), and
SARS-CoV nts 265–804 (pSARS-CoV-nsp1) were ampliﬁed by stand-
ard PCR techniques and cloned downstream of a CMV promoter
between the SmaI and XhoI sites of the eukaryotic high-level
expression plasmid pI.18 (kindly provided by Jim Robertson,
National Institute for Biological Standards and Control, Hertford-
shire, UK).
Transient transfections and reporter gene assays. Subconﬂuent
cell monolayers of 293 cells seeded in 12-well plates were transfected
with 250 ng p125-Luc reporter plasmid, 50 ng pRL-SV40, and 1 lg of
expression plasmid in 200 ll of OPTIMEM (Gibco-BRL) containing
3.9 ll of Fugene HD (Roche, http://www.roche.com). At 8 h post
transfection, cells were induced with either 0.2 lg of viral ssRNA
containing 59 triphosphates [54] (p125-Luc), 2.5 lg of poly(I:C)
(Sigma), or 500 U/ml IFN-a (p(9–27)4tkD(39)lucter), or left unin-
duced. After an incubation period of 16 h, cells were harvested and
lysed in 100 ll of Reporter Lysis Buffer (Promega). An aliquot of 10 ll
lysate was used to measure luciferase activity as decribed by the
manufacturer (Promega).
Virus infections, determination of virus titers, and liver enzyme
values. Mice were injected intraperitoneally or intracranially with
indicated pfu of MHV A59 or intravenously with the indicated pfu of
LCMV and sacriﬁced at the indicated time points. Organs were stored
at 70 8C until further analysis. Blood was incubated at RT to
coagulate, centrifuged, and serum was used for ALT measurements
using a Hitachi 747 autoanalyzer (http://www.hitachi.com/). Peritoneal
exudates cells (PECs) were isolated from the peritoneal cavity by
ﬂushing with 4 ml of ice-cold PBS. MHV titers were determined by
standard plaque assay using L929 cells. LCMV titers in the spleens
were determined 4 d after intravenous challenge in an LCMV
infectious focus assay as previously described [55].
Histology, IFN-a ELISA, IFN-a treatment. Organs were ﬁxed in 4%
formalin and embedded in parafﬁn. Sections were stained with
hematoxylin and eosin. Images were acquired using a Leica DMRA
microscope (Leica, http://www.leica.com/) with a 253/0.65 NA objec-
tive (total magniﬁcation, 3162). Images were processed using Adobe
Photoshop (Adobe Systems, http://www.adobe.com). Mouse IFN-a
concentration in cell culture supernatants was measured by ELISA
(PBL Biomedical Laboratories, http://www.interferonsource.com/)
according to the manufacturer’s instructions. IFN-a treatment of
cells prior to MHV infection was performed using universal type I
IFN (IFN-aA/D, Sigma).
Intracellular cytokine staining. Speciﬁc ex vivo production of IFN-
c was determined by intracellular cytokine staining. Organs were
removed at the indicated time points following infection with
recombinant MHV. For intracellular cytokine staining, single cell
suspensions of 13 106 splenocytes were incubated for 5 h at 37 8C in
96-well round-bottom plates in 200 ll of culture medium containing
25 U/ml IL-2 and 5 lg/ml Brefeldin A (Sigma). Cells were stimulated
with phorbolmyristateacetate (PMA, 50 ng/ml) and ionomycin (500
ng/ml) (both purchased from Sigma) as positive control or left
untreated as a negative control. For analysis of peptide-speciﬁc
responses, cells were stimulated with 106 M GP33 peptide or 104 M
MHV S598 peptide. The percentage of CD8þ T cells producing IFN-c
was determined using a FACSCalibur ﬂow cytometer (BD Bioscien-
ces). Both S598 (RCQIFANI) and GP33 (KAVYNFATC) peptides were
purchased from Neosystem (http://www.neomps.com/).
Statistical analysis. All statistical analyses were performed with
Prism 4.0 (GraphPad Software, http://www.graphpad.com/). Data were
analyzed with the paired Student’s t-test assuming that the values
followed a Gaussian distribution. A p-value of , 0.05 was considered
signiﬁcant.
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7 Unpublished data 
7.1 Introduction 
With genome sizes of about 30 kb coronaviruses have the largest genomes of all 
known RNA viruses. RNA viruses have high error rates, and the resulting 
quasispecies may aid survival of the virus population in the presence of selective 
pressure. Therefore, RNA viruses have been proposed to replicate and evolve at the 
maximum limit of genetic variability. The replication of RNA virus genomes occurs 
within limits, concurrently producing quasispecies diversity important for adaptation to 
changing environments, while simultaneously preventing population extinction due to 
excessive mutation (202, 270). This precarious balance is thought to be maintained 
by interplay between RNA polymerase fidelity and error repair by RNA recombination 
since proofreading activities have not been identified in RNA viruses. For MHV a 
mutation rate of 2.5 x 10-6 has been calculated, which is, in comparison to other RNA 
viruses very low (75). It has been proposed that coronaviruses may have acquired a 
proofreading activity, possibly associated with nsp14 exoribonuclease activity that 
may be critical for genome expansion up to 30 kb (94, 232). Indeed, it has been 
shown, that a mutation in a conserved site of MHV nsp14 leads to decreased fidelity 
in replication (75). The mechanism on how nsp14 leads to increased fidelity remains 
to be elucidated, however it is likely that ExoN activity may directly mediate 
hydrolysis of an incorrect nucleotide from the 3' end of the nascent RNA chain, 
similar to the role of DE-D-D ExoN proofreading domains or subunits of DNA 
polymerases (18, 184). Mutations in HCoV-229E even led to a lethal phenotype 
(181). It is unclear why infectious ExoN mutants were recovered for MHV but not for 
HCoV-229E but it may be that the defects exceed the threshold for recovery of 
recombinant HCoV-229E. Besides nsp14 an additional ribonuclease (nsp15; 
endoribonuclease NendoU) has been reported for coronaviruses (232), however 
knowledge is up to date very limited. It is known, that mutations in the catalytic pocket 
have little effect on kinetics in vitro (134). Besides the above mentioned ribonuclease 
activities, coronaviruses express a third RNA-processing protein encoded in ORF1b, 
termed nsp16. Nsp16 has been predicted to possess 2’-O-methyltransferase activity 
and very recently this activity has been demonstrated for the feline coronavirus 
nsp16. (63, 85, 232, 272). 
74
Unpublished Data
Although nsp14, nsp15, and nsp16 are part of the replicase complex, it has been 
shown at least for nsp14 and nsp15, that their ribonuclease activities are not strictly 
required for RNA synthesis. Therefore it is conceivable that these enzymes may play 
a role in host-pathogen interactions. To study the roles of nsp14-16 in virus 
replication we constructed MHV mutants bearing mutations in the respective 
conserved regions (75, 134, 222, 232, 237). 
7.2 Results 
7.2.1 The role of nsp14 in viral replication 
In order to study functions of nsp14 for viral replication in vitro and in vivo, we 
aimed to construct recombinant viruses bearing mutations in conserved regions of 
nsp14 (Fig. 4A). Both conserved regions targeted by homologous recombination 
could be mutated and progeny virus rescued. Nsp14-mut1 was designed to harbor a 
single nucleotide mutation (C to T) at base 19401 thereby causing a substitution of a 
tyrosine at position 6398 through a histidine. This mutation has previously been 
associated with a pronounced attenuation in vivo but does not affect virus growth in 
tissue culture (75, 237) (Fig. 4B). Nsp14-mut2 bears 4 point mutations (A18427C, 
T18428A, A18433C, and A18434T) leading to two aa substitutions (Asp to Ala, and 
Glu to Ala) at position 6072 and 6074, respectively. These aa substitutions abolish 
the exonuclease activity (75, 237) and growth of the recombinant virus termed nsp14-
mut2 was reduced in tissue culture (Fig. 4B). The differential growth kinetics of the 
two mutants suggest that nsp14 may actually possess two domains with distinctive 
functions. To further elucidate the important function(s) of nsp14 for virus replication 
and viral pathogenicity in vivo, 129Sv mice were infected intraperitoneally with 
different doses of wild-type MHV or MHV-nsp14-mut1. Both viruses replicated in the 
spleen, whereby MHV-nsp14-mut1 titers were consistently lower than wild-type virus 
titers (Figure 4C). Wild-type, but not mutant virus, was detectable in the liver at low 
and high dose (50 pfu and 5,000 pfu, respectively) (Figure 4C). The attenuation of 
the nsp14 mutant is also reflected in the low liver damage, measured as alanine 2-
oxoglutarate-aminotransferase (ALT) levels in serum. To investigate the potential 
influence of nsp14 on innate immune responses, we infected  type I IFN receptor-
deficient (IFNAR?/?) mice (186) with 5000 pfu of wild-type MHV or MHV-nsp14-mut1. 
Infection of IFNAR?/? mice with wild-type MHV led to high titers in all tested organs, 
indicating that signals transmitted via the IFNAR are crucial for preventing 
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uncontrolled spread of the virus (42). Replication of MHV-nsp14-mut1 in IFNAR?/?
mice was partially restored and peak titers of approximately 106 pfu/g tissue have 
been detected in spleen and liver (Fig. 4D). Surprisingly, the mutant virus could finally 
be controlled in IFNAR?/? mice, presumably by the onset of adaptive immune 
responses around day 5 post infection (17). 
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Fig. 4: Sequence alignment of nsp14 (A) and growth properties of recovered nsp14 
mutant viruses (B-D) (A) Sequence alignment of nsp14. Mutated regions are highlighted in 
yellow and aa substitutions are denoted with an arrow. The upper panel shows the mutations 
introduced in MHV-nsp14-mut1, the lower one shows mutations introduced into MHV-nsp14-
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mut2.  Figure adapted from Snijder et al. (231). (B) Single step kinetics of MHV-nsp14-mut1 
and MHV-nsp14-mut2, respectively in 17Cl1 cells. (C) 129Sv mice were infected with the 
indicated dose of MHV-nsp14-mut1 and viral titers in spleen and liver and ALT values were 
determined at the indicated time points p.i. (D) IFNAR-/- 129Sv mice were infected i.p. with 
5000 pfu of MHV-A59 or MHV-nsp14-mut1 and viral titers in spleens and livers and the 
survival of mice were determined. † denotes death of mice. 
 
7.2.2 The role of nsp15 in viral replication 
To investigate the role of nsp15 in virus replication, we decided to inactivate the 
nsp15-encoded endonuclease activity (134). A highly conserved histidine at position 
6781 was substituted by an alanine (Fig. 5A). As described before we found that the 
nsp15 mutant showed little defect in growth in tissue culture (Fig. 5B). We have 
commenced further experiments to elucidate if this mutation has an effect on viral 
pathogenicity.  
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Fig. 5: Sequence alignment of nsp15 (A) and growth properties of recovered virus 
(A) Sequence alignment of nsp15. Mutated regions are highlighted in yellow and aa 
substitutions are denoted with an arrow. Figure adapted from Snijder et al. (231). (B) Single 
step kinetics of MHV-nsp15 in 17Cl1 cells.
7.2.3 The role of nsp16 in viral replication 
The third RNA modifying enzyme encoded by the coronavirus genome is the 2’-O 
RNA methyltransferase nsp16. We were interested to investigate the role of this 
enzyme in viral replication and generated two mutants harboring aa substitutions at
position 6890 (proline to serine) or at position 7032 (leucine to proline) (Fig. 6A). 
These mutations have previously been associated with a temperature-sensitivity
displaying an RNA(-) phenotype, i.e. with no detectable RNA synthesis at the 
restrictive temperature (222). The reconstructed ts mutant viruses grew to 
comparable levels as wt-A59 in tissue culture at 33° C and 37° C. However,
replication is abolished at the restrictive temperature (Fig. 6B). Future studies are 
planned to elucidate if the observed ts phenotype is associated with the 2’-O 
methyltransferase activity of nsp16. 
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Fig. 6: Sequence alignment of nsp16 (A) and characterization of nsp16 temperature
sensitive mutants 
(A Sequence alignment of nsp16. Mutated regions are highlighted in yellow and aa 
substitutions are denoted with an arrow. The upper panel shows nsp16 mutant wüts18, 
whereas the lower panel shows nsp16 mutant wüts36 (B) Confluent L929 cells were infected
with the indicated virus, incubated for 3 h at 33° C, washed with PBS, overlayed with a 1:1
mixture of 2% Avicel and 2xDMEM and incubated 28 h (39° C) or 48 h (33° C and 37° C). 
The overlay was then removed and cells were stained with crystal violet.
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8 Discussion 
8.1 Summary of own findings 
The first article provides new insight into the genetic interaction between an 
essential pseudoknot in the MHV 3’ UTR, replicase gene products nsp8 and nsp9, 
and the extreme 3’ end of the genome. The analyses of a poorly replicating and 
genetically instable mutant virus (Alb391) containing a 6 nt insertion in loop 1 of the 
pseudoknot revealed a number of second site suppressor mutations that can 
compensate for the growth defect mediated by the initial 6 nt insertion. These second 
site mutations were found in nsp8 or nsp9, or at the penultimate nucleotide (A to G) 
at the extreme 3’-end of the MHV genome. Our data suggest, for the first time, an 
interaction of RNA-binding replicase gene products with cis-acting elements of the 
MHV 3’UTR.  A new model of the secondary structure of the 3’UTR and how it might 
function in the initiation of minus strand RNA synthesis has been proposed (300).
The second article describes the importance of type I IFNs on MHV replication in 
vitro. We could demonstrate that type I IFNs are absolutely essential to combat MHV 
infection and furthermore, that pDCs are the major source of IFN-? early after 
infection. pDC depletion diminished IFN-? expression, allowed MHV to rapidly spread 
to multiple organs and increased the severity of MHV-induced acute viral hepatitis.  
The third article provides evidence that nsp1 is an important pathogenicity factor.  
MHV encoding a truncated form of nsp1 was still able to replicate in tissue culture 
and in primary cells but was attenuated in the natural host. This attenuation was 
abolished in mice lacking the type I IFN receptor demonstrating that nsp1 interferes 
with host innate immune responses. Our finding, that the nsp1 mutant virus grew to 
high titers in vitro but was still able to replicate in secondary lymphoid organs and in 
professional antigen-presenting cells, such as macrophages and dendritic cells, led 
to the hypothesis that this mutant serves as an ideal attenuated vaccine candidate. 
Indeed, MHV-nsp1?99 encoding the immunodominant cytotoxic T lymphocyte (CTL) 
epitope (KAVYNFATC) of the lymphocytic choriomeningitis virus (LCMV) and the 
enhanced green fluorescent protein (GP33-GFP) fully protected against homologous 
MHV and partially against heterologous LCMV challenge (300). 
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The unpublished data show that nsp14 and nsp15 are dispensable on viral growth 
in vitro. We could confirm that MHV-nsp14-mut1 is greatly attenuated in vivo,
suggesting that nsp14 may play an important role in the natural host. Nsp16 seems 
to be essential for viral replication, since temperature sensitive mutants do not show 
any replication at the restrictive temperature (39°C). Further studies are in progress 
to assess if the growth defect is associated with impaired methyltransferase activity.  
8.2 Interactions of replicase gene products with 3’ UTR 
Initiation of coronavirus negative strand RNA synthesis occurs at the 3’ end of the 
genomic RNA. However, it was still elusive, which 3’-cis-acting elements and which 
replicase gene products play a role in this process. In the work presented in the 
thesis we analyzed revertants of a highly defective MHV mutant, Alb391, containing a 
particular insertion, AACAAG, in loop 1 of the MHV 3’UTR pseudoknot. Three types 
of revertants were repeatedly identified. First, so-called “true” revertants had deleted 
or altered the 6 nt insertion. Second, we also found two types of second-site 
revertants mapping to two distinct regions of the genome. One class was represented 
by a single nucleotide change at the penultimate nucleotide upstream the 3’-poly(A) 
tail (A to G) and the second class of second-site revertants encoded point mutations 
in nsp8 or nsp9. These findings corroborate recent reports, where it has been shown 
that nsp8 and nsp9 have RNA-binding activity (76, 246). In addition nsp8 has been 
shown to possess RdRp activity that mediates the ability to synthesize short RNAs 
(120). Therefore, nsp8 has been proposed to function as a primase for the canonical 
coronavirus RdRp (nsp12). Despite the demonstrated RNA-binding activity of nsp8 
and nsp9 it is currently not clear if RNA-binding is sequence specific. Our data 
strongly support the idea that MHV nsp8 and nsp9 interact with the pseudoknot of the 
3’ UTR. Based on our results we propose a new model for the initiation of negative 
strand synthesis that also includes the putative primase activity of nsp8 and a 
putative role for the molecular switch that has been previously proposed to consist of 
the 3’-UTR buldged stem loop and the adjacent pseudoknot structure (90, 120, 301).
In addition to the newly proposed model of RNA synthesis initiation we could 
demonstrate that only a very small part of the 3’ UTR is absolutely required for RNA 
synthesis. Based on m-fold structural predictions we could pin down the essential 
82
Discussion
regions to no more than 160 nt of the 3’ UTR, nearly discarding half of the 3’ UTR. 
Our predictions were further supported by a viable MHV mutant ?HVR3, where bases 
30 to 170 have been discarded. Interestingly, the deleted region encompasses in 
vitro binding sites for a number of cell proteins including PTB, hnRNP A1, and heat 
shock proteins, previously reported to be important for viral replication. Our results 
demand for reconsideration of conclusions obtained from a previous study that the 
last 45 to 55 nts of the genome are required (165).  Many mechanistic details of the 
initiation of negative-strand RNA remain to be elucidated. However, we hope this 
work will provide a starting point for further studies. 
8.3 Coronavirus interaction with the type I IFN system 
The innate immune response against coronavirus such as MHV has not yet been 
sufficiently characterized. Several studies could demonstrate that pretreatment with 
recombinant IFN-? or IFN-??can inhibit SARS-CoV replication (43, 238, 291) and 
diminish the severity of the disease (101, 167). However, neither peripheral-blood 
mono-nuclear cells, nor macrophages, nor monocyte-derived DCs respond to 
coronavirus infection with a significant IFN-? production (58, 130, 155, 212, 283, 
289). In the presented work (42) we could demonstrate that pDCs can respond to 
coronaviral infection with a swift IFN induction and that TLR7 acts as the sensor for 
coronavirus RNA. The importance of pDCs was shown since widespread replication 
in various nonlymphoid organs, and the associated organ damage, is efficiently kept 
in check through pDC-derived type I IFNs. A characteristic of pDCs is the 
constitutively high expression of IFN regulatory factor-7 (IRF7) (115, 125), which 
directly stimulates IFN-? expression, independently of an IFN-?-mediated feedback 
loop (11).
Several members of the Coronaviridae family, including SARS-CoV and MHV, have 
recently been shown to avoid recognition by cytoplasmic pattern recognition 
receptors (PRR) such as RigI, Mda5 and TLR3 (42, 269, 292). All these proteins 
have been demonstrated to recognize viral RNA (1, 116, 136, 269) and respond with 
a subsequent IFN induction. How coronavirus shields itself from the recognition 
through these PRRs remains to be determined.  We believe that coronavirus avoids 
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recognition through replication in a protected enviroment, the endoplasmatic 
reticulum-derived double membrane vesicles (97, 204).
8.4 The role of nsp1 in viral replication 
Nsp1 is the first protein to be expressed in the coronavirus life cycle of group I and 
group II coronaviruses and is therefore expected to play an important role in viral 
replication. Surprisingly, large parts of the C-terminal end can be deleted without 
effect on growth in vitro indicating a different role of this enzyme (32). Within the 
sequence encoding for the N-terminal region of nsp1 there are most likely essential 
cis-acting elements required for replication. For MHV and BCoV DI RNAs it has been 
shown that parts of the nsp1-coding region play a pivotal role as cis-acting elements 
in the replication (34). We could show that nsp1 plays a critical role in virus-host 
interactions. When nsp1 was expressed in vitro together with a reporter plasmid 
encoding the luciferase under the control of the IFN-?, ISRE or the constitutive active 
SV40 promoter, the expression of the reporter diminished significantly. This was not 
the case when a truncated form of MHV nsp1 was expressed. These results are in 
accordance with a report by Kamitani et al. (133). Their suggestion that SARS-CoV 
nsp1 may play a role in SARS-CoV pathogenesis by promoting host cell mRNA 
degradation received support through our analysis of an MHV nsp1 mutant in a 
murine model. How the SARS-CoV (and probably MHV) nsp1 promotes the 
degeneration only of host cell RNA without affecting viral RNA still remains to be 
investigated.
IFN-??? in addition to playing a key role in the innate control of virus replication, 
have been shown to potently enhance immune responses (156, 157, 206). Therefore 
virus have developed different strategies to evade the IFN activity, including 
sequestration of danger signals, targeting specific components of the IFN system 
such as members of the IFN regulatory factor (IRF) family or components of the JAK-
STAT signaling pathway. For coronavirus a protein fulfilling one of these functions 
has not been described. Our results clearly demonstrate that nsp1 mainly affects IFN 
signaling pathways or other downstream events rather than directly the induction of 
IFN-? expression. pDCs infected with MHV-nsp1?99 produced the same amount of 
IFN-? as did wild-type MHV-infected pDCs. Macrophages and cDCs did not express 
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significant amounts of IFN-? with wild-type MHV or MHV-nsp1?99. However, 
treatment of macrophages with IFN-? revealed a more efficient reduction of MHV-
nsp1?99 replication compared to wild-type MHV. This reduction could not be seen in 
pre-treated cDCs indicating that IFN has mainly a pivotal role on macrophages.  This 
observation received support in a recent work from our laboratory (Cervantes et al. 
JEM, in revision) where we showed that IFNAR expression on macrophages and 
cDCs is essential to combat MHV infection in mice, whereas mice lacking the IFNAR 
on B-cells or T-cells did not show such serious effects.
In vivo experiments demonstrated the pivotal role of nsp1 on viral pathogenicity. 
Wild type mice infected with MHV-nsp1?99 did not show any signs of disease and 
progeny virus in the liver could only be isolated when high doses of MHV-nsp1?99
were applied. Interestingly the mutant virus retained the potential to replicate in the 
spleen. Even when the mutant virus was applied intracranially the mice survived, 
although a severe demyelination could be observed. The strong attenuation of MHV-
nsp1?99 was abolished in mice lacking the IFNAR. IFNAR-/- mice were highly 
permissive for the mutant virus and organ titers almost reached those of wild type 
MHV infected IFNAR-/- mice. Nevertheless it should be noted that the mice infected 
with MHV-nsp1?99 survived longer than mice infected with wild-type MHV and the 
ALT values increased only late after infection. Therefore, further studies are required 
to precisely define the molecular targets and function(s) of coronavirus nsp1.
Nsp1 has been suggested as a group specific marker to differentiate group I 
coronaviruses from group II coronaviruses however our expression data denote a 
functional relationship between nsp1 molecules from both coronaviruses groups 
(232). Despite the apparent lack of any sequence homology (5, 232) nsp1 of HCoV-
229E, a group I member, may represent a functional correlate to the nsp1 of group 
IIa/IIb coronaviruses. It would be interesting to address this question in future studies 
and recent progress in the establishment of mouse models for HCoV-229E (153) will 
enable research on this topic.
The modification of a pathogenicity factor represents and attractive attenuation 
strategy for the rational design of live coronavirus vaccines. MHV-nsp1?99 grows to 
high titers in cell culture, thereby facilitating vaccine production. It generates a strong, 
long lasting immune response that mediates protection against viral challenge. 
Because of its pronounced tropism for professional antigen presenting cells and the 
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induction of strong cytotoxic T cell (CTL) responses coronaviruses might be 
promising vectors for the expression of heterologous antigens (80, 81). Indeed 
experiments performed in our laboratory demonstrate, that coronaviruses have a high 
cloning capacity allowing the expression of several antigens and additional cytokines 
which boost the immune response. MHV-based vectors containing deletions of all 
accessory genes and the deletion of the structural envelope protein E has resulted in 
propagation-deficient, replication-competent vectors. The combination of these 
deletions together with the herein described truncation of the nsp1 protein, would 
lead to a vector considered to be “recombination proof”, because the deletions are 
located at opposite genomic regions. We therefore suggest that such a vector would 
be particular safe with the potential to express multiple heterologous antigens. In 
future studies it will be important to transfer this knowledge to the generation of 
vaccines for humans. 
Taken together we describe a novel type of coronavirus vaccines based on 
impaired function of the replicase gene nsp1. We believe that our approach is 
applicable to most, if not all mammalian coronaviruses. This will enable the 
development of long-desired vaccines for important human and animal coronavirus-
induced diseases.  
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9 Future perspectives 
Reverse genetic systems have greatly facilitated the analysis of coronavirus 
replication at the molecular level.  Much progress has been made in understanding 
the role of particular replicase gene products and cis-acting elements in viral 
replication. For a number of replicase-encoded gene products enzymatic functions 
have been predicted by sequence comparison and/or demonstrated by biochemical 
studies. Reverse genetics, as well as classical “forward” genetics, are currently used 
to place these functions into distinct processes within the viral replication cycle.  
Interestingly, some replicase gene products have been shown to be dispensable for 
viral RNA synthesis, and therefore, several questions concerning the role of these 
replicase gene products have arisen: 
? To which extend do replicase gene products contribute to host cell tropism 
and viral pathogenicity?  
? Are replicase proteins specifically altering host cell gene expression, and 
how are specific cellular signaling pathways blocked or induced?
? Are replicase-encoded pathogenicity factors conserved amongst all 
coronaviruses or are some of them virus- and/or host specific?
To answer these questions it will be important to combine bioinformatic, 
biochemical and structural approaches with classical and reverse genetic techniques 
in order to produce and characterize informative virus mutants. Furthermore, these 
studies have to be expanded to the analysis of virus-host interactions on the cellular 
level, but also on the level of the host organism.  Therefore, we expect that MHV as a 
mouse pathogen will continue to provide an excellent model to study coronavirus 
replication and pathogenesis as both, the virus and the host can be genetically 
modified.
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